,exclusivity_code,exclusivity_code_desc,edition
0,NS,NEW STRENGTH,1985
1,NCE,NEW CHEMICAL ENTITY,1985
2,PP,PARENTERAL IN PLASTIC CONTAINER,1985
3,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1985
4,NR,NEW ROUTE,1985
5,I,"NEW INDICATION (SEE REFERENCE, BELOW)",1985
6,NDF,NEW DOSAGE FORM,1985
7,NC,NEW COMBINATION,1985
8,RTO,PRESCRIPTION TO OTC STATUS CHANGE,1985
9,D,"NEW DOSING SCHEDULE (SEE REFERENCE, BELOW)",1985
10,NP,NEW PRODUCT,1985
11,D-1,ONCE A DAY APPLICATION,1985
12,D-2,ONCE DAILY DOSING,1985
13,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1985
14,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1985
15,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1985
16,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1985
17,D-7,BID DOSING,1985
18,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1985
19,D-9,NARCOTIC OVERDOSE IN ADULTS,1985
20,D-10,NARCOTIC OVERDOSE IN CHILDREN,1985
21,D-11,POSTPOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1985
22,I-1,SEVERE HYPERTENSION IN PEDIATRICS AND NON-MALIGNANT HYPERTENSION,1985
23,I-2,DYSMENORRHEA,1985
24,I-3,TREATMENT OF TINEA VERSICOLOR,1985
25,I-4,SYMPTOMATIC GASTROESOPHAGEAL REFLUX,1985
26,I-5,NEPHROTOMOGRAPHY,1985
27,I-6,CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY,1985
28,I-7,VENOGRAPHY OF LOWER EXTREMITIES,1985
29,I-8,WHOLE-BODY COMPUTED TOMOGRAPHY,1985
30,I-9,GATED CARDIAC POOL IMAGING,1985
31,I-10,POST-MYOCARDIAL INFARCTION,1985
32,I-11,COLORECTAL SURGERY,1985
33,I-12,NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,1985
34,I-13,CISPLATIN INDUCED EMESIS,1985
35,I-14,DIABETIC GASTROPARESIS,1985
36,I-15,SHORT TERM TREATMENT OF GASTRIC ULCER DISEASE,1985
37,I-16,ACROMEGALY,1985
38,I-17,PITUITARY TUMORS,1985
39,I-18,POSTMENOPAUSAL OSTEOPOROSIS,1985
40,I-19,ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE,1985
41,I-20,CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE,1985
42,I-21,ACUTE OTITIS MEDIA,1985
43,I-22,EXERCISE INDUCED BRONCHOSPASMS,1985
44,I-23,MI OR STROKE,1985
45,I-24,COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL,1985
46,I-25,BLASTOMYCOSES DERMATITIDES,1985
47,I-26,PEDIATRIC SUBARACHNOID VASCULAR,1985
48,I-27,PETRIELLIDIUM BOYDII INFECTION,1985
49,I-28,HEREDITARY ANGIOEDEMA,1985
50,I-29,INTRACORONARY USE,1985
51,I-30,PEDIATRIC USE,1985
52,I-31,DIRECT ISOTOPIC CYSTOGRAPHY,1985
53,I-32,POSTPARTUM HEMORRHAGE,1985
54,I-33,USE IN METHODONE INDUCED RESPIRATORY DEPRESSION,1985
55,I-34,PROLACTIN SECRETING ADENOMAS,1985
56,NC,NEW COMBINATION,1987
57,PP,PARENTERAL IN PLASTIC CONTAINER,1987
58,NP,NEW PRODUCT,1987
59,RTO,PRESCRIPTION TO OTC STATUS CHANGE,1987
60,D,"NEW DOSING SHEDULE (SEE REFERENCE, BELOW)",1987
61,NS,NEW STRENGTH,1987
62,NR,NEW ROUTE,1987
63,NCE,NEW CHEMICAL ENTITY,1987
64,I,"NEW INDICATION (SEE REFERENCE, BELOW)",1987
65,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1987
66,NDF,NEW DOSAGE FORM,1987
67,ODE,ORPHAN DRUG EXCLUSIVITY,1987
68,D-1,ONCE A DAY APPLICATION,1987
69,D-2,ONCE DAILY DOSING,1987
70,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1987
71,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1987
72,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1987
73,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1987
74,D-7,BID DOSING,1987
75,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1987
76,D-9,NARCOTIC OVERDOSE IN ADULTS,1987
77,D-10,NARCOTIC OVERDOSE IN CHILDREN,1987
78,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1987
79,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT,1987
80,I-1,SEVERE HYPERTENSION IN PEDIATRICS AND NON-MALIGNANT HYPERTENSION,1987
81,I-2,DYSMENORRHEA,1987
82,I-3,TREATMENT OF TINEA VERSICOLOR,1987
83,I-4,SYMPTOMATIC GASTROESOPHAGEAL REFLUX,1987
84,I-5,NEPHROTOMOGRAPHY,1987
85,I-6,CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY,1987
86,I-7,VENOGRAPHY OF LOWER EXTREMITIES,1987
87,I-8,WHOLE-BODY COMPUTED TOMOGRAPHY,1987
88,I-9,GATED CARDIAC POOL IMAGING,1987
89,I-10,POST-MYOCARDIAL INFARCTION,1987
90,I-11,COLORECTAL SURGERY,1987
91,I-12,NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,1987
92,I-13,CISPLATIN INDUCED EMESIS,1987
93,I-14,DIABETIC GASTROPARESIS,1987
94,I-15,SHORT TERM TREATMENT OF GASTRIC ULCER DISEASE,1987
95,I-16,ACROMEGALY,1987
96,I-17,PITUITARY TUMORS,1987
97,I-18,POSTMENOPAUSAL OSTEOPOROSIS,1987
98,I-19,ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE,1987
99,I-20,CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE,1987
100,I-21,ACUTE OTITIS MEDIA,1987
101,I-22,EXERCISE INDUCED BRONCOSPASMS,1987
102,I-23,MYOCARDIAL INFARCTION OR STROKE,1987
103,I-24,COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL,1987
104,I-25,BLASTOMYCOSES DERMATITIDIS,1987
105,I-26,PEDIATRIC SUBARACHNOID VASCULAR,1987
106,I-27,PETRIELLIDIUM BOYDII INFECTION,1987
107,I-28,HEREDITARY ANGIOEDEMA,1987
108,I-29,INTRACORONARY USE,1987
109,I-30,PEDIATRIC USE,1987
110,I-31,DIRECT ISOTOPIC CYSTOGRAPHY,1987
111,I-32,POSTPARTUM HEMORRHAGE,1987
112,I-33,USE IN METHODONE INDUCED RESPIRATORY DEPRESSION,1987
113,I-34,PROLACTIN SECRETING ADENOMAS,1987
114,I-35,ANGINA PECTORIS DUE TO CORONARY ATHEROSCLEROSIS,1987
115,I-36,ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1987
116,I-37,SPINAL ANESTHESIA,1987
117,I-38,PATIENT PREOPERATIVE SKIN PREPARATION,1987
118,I-39,ADJUVANT WITH CHEMOTHERAPY FOR TREATMENT OF BREAST CANCER FOLLOWING MASTECTOMY,1987
119,I-40,ANTIDOTE FOR ACETAMINOPHEN OVERDOSE,1987
120,I-41,MANAGEMENT OF HYPOCALCEMIA AND RESULTANT METABOLIC BONE DISEASE IN RENAL DIALYSIS PATIENTS,1987
121,I-42,MAINTENANCE THERAPY AT REDUCED DOSE FOLLOWING HEALING OF ACUTE DUODENAL ULCER,1987
122,I-43,TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE,1987
123,I-44,TREATMENT OF SEVERE RECALCITRANT DERMATOPHYTE INFECTIONS,1987
124,I-45,ACCELERATE BARIUM TRANSIT THEREBY DECREASING TIME AND EXTENT OF RADIATION TO INTESTINAL TRACT,1987
125,I-46,TREATMENT OF SMALL CELL LUNG CANCER IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC DRUGS,1987
126,I-47,USE IN BALANCED ANESTHESIA,1987
127,I-48,MANAGEMENT OF FAMILIAL OR HEREDITARY ESSENTIAL TREMOR,1987
128,I-49,ADJUNCT TO COUMARIN ANTICOAGULANTS IN PREVENTION OF POSTOPERATIVE THROMBOEMBOLIC COMPLICATIONS OF CARDIAC VALVE REPLACEMENTS,1987
129,I-50,TREATMENT OF ARRHYTHMIAS,1987
130,I-51,MANAGEMENT OF ESSENTIAL HYPERTENSION,1987
131,I-52,CERVICAL MYELOGRAPHY,1987
132,I-53,USE AS SINGLE AGENT TO DELAY BREAST CANCER RECURRENCE FOLLOWING TOTAL MASTECTOMY AND AXILLARY DISSECTION IN POSTMENOPAUSAL WOMEN,1987
133,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1988
134,NCE,NEW CHEMICAL ENTITY,1988
135,NR,NEW ROUTE,1988
136,PC,PATENT CHALLENGE,1988
137,NS,NEW STRENGTH,1988
138,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1988
139,NDF,NEW DOSAGE FORM,1988
140,NC,NEW COMBINATION,1988
141,ODE,ORPHAN DRUG EXCLUSIVITY,1988
142,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1988
143,NP,NEW PRODUCT,1988
144,D-1,ONCE A DAY APPLICATION,1988
145,D-2,ONCE DAILY DOSING,1988
146,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1988
147,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1988
148,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1988
149,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1988
150,D-7,BID DOSING,1988
151,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1988
152,D-9,NARCOTIC OVERDOSE IN ADULTS,1988
153,D-10,NARCOTIC OVERDOSE IN CHILDREN,1988
154,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1988
155,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT,1988
156,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1988
157,I-1,SEVERE HYPERTENSION IN PEDIATRICS AND NONMALIGNANT HYPERTENSION,1988
158,I-2,DYSMENORRHEA,1988
159,I-3,TREATMENT OF TINEA VERSICOLOR,1988
160,I-4,SYMPTOMATIC GASTROESOPHAGEAL REFLUX,1988
161,I-5,NEPHROTOMOGRAPHY,1988
162,I-6,CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY,1988
163,I-7,VENOGRAPHY OF LOWER EXTREMITIES,1988
164,I-8,WHOLE-BODY COMPUTED TOMOGRAPHY,1988
165,I-9,GATED CARDIAC POOL IMAGING,1988
166,I-10,POST-MYOCARDIAL INFARCTION,1988
167,I-11,COLORECTAL SURGERY,1988
168,I-12,NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,1988
169,I-13,CISPLATIN-INDUCED EMESIS,1988
170,I-14,DIABETIC GASTROPARESIS,1988
171,I-15,SHORT-TERM TREATMENT OF GASTRIC ULCER DISEASE,1988
172,I-16,ACROMEGALY,1988
173,I-17,PITUITARY TUMORS,1988
174,I-18,POSTMENOPAUSAL OSTEOPOROSIS,1988
175,I-19,ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE,1988
176,I-20,CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE,1988
177,I-21,ACUTE OTITIS MEDIA,1988
178,I-22,EXERCISE-INDUCED BRONCHOSPASMS,1988
179,I-23,MYOCARDIAL INFARCTION OR STROKE,1988
180,I-24,COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL,1988
181,I-25,BLASTOMYCOSES DERMATITIDIS,1988
182,I-26,PEDIATRIC SUBARACHNOID VASCULAR,1988
183,I-27,PETRIELLIDIUM BOYDII INFECTION,1988
184,I-28,HEREDITARY ANGIOEDEMA,1988
185,I-29,INTRACORONARY USE,1988
186,I-30,PEDIATRIC USE,1988
187,I-31,DIRECT ISOTOPIC CYSTOGRAPHY,1988
188,I-32,POSTPARTUM HEMORRHAGE,1988
189,I-33,USE IN METHADONE-INDUCED RESPIRATORY DEPRESSION,1988
190,I-34,PROLACTIN SECRETING ADENOMAS,1988
191,I-35,ANGINA PECTORIS DUE TO CORONARY ATHEROSCLEROSIS,1988
192,I-36,ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1988
193,I-37,SPINAL ANESTHESIA,1988
194,I-38,PATIENT PREOPERATIVE SKIN PREPARATION,1988
195,I-39,ADJUVANT WITH CHEMOTHERAPY FOR TREATMENT OF BREAST CANCER FOLLOWING MASTECTOMY,1988
196,I-40,ANTIDOTE FOR ACETAMINOPHEN OVERDOSE,1988
197,I-41,MANAGEMENT OF HYPOCALCEMIA AND RESULTANT METABOLIC BONE DISEASE IN RENAL DIALYSIS PATIENTS,1988
198,I-42,MAINTENANCE THERAPY AT REDUCED DOSE FOLLOWING HEALING OF ACUTE DUODENAL ULCER,1988
199,I-43,TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE,1988
200,I-44,TREATMENT OF SEVERE RECALCITRANT DERMATOPHYTE INFECTIONS,1988
201,I-45,ACCELERATE BARIUM TRANSIT THEREBY DECREASING TIME AND EXTENT OF RADIATION TO INTESTINAL TRACT,1988
202,I-46,TREATMENT OF SMALL CELL LUNG CANCER IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC DRUGS,1988
203,I-47,USE IN BALANCED ANESTHESIA,1988
204,I-48,MANAGEMENT OF FAMILIAL OR HEREDITARY ESSENTIAL TREMOR,1988
205,I-49,ADJUNCT TO COUMARIN ANTICOAGULANTS IN PREVENTION OF POSTOPERATIVE THROMBOEMBOLIC COMPLICATIONS OF CARDIAC VALVE REPLACEMENTS,1988
206,I-50,TREATMENT OF ARRHYTHMIAS,1988
207,I-51,MANAGEMENT OF ESSENTIAL HYPERTENSION,1988
208,I-52,CERVICAL MYELOGRAPHY,1988
209,I-53,USE AS SINGLE AGENT TO DELAY BREAST CANCER RECURRENCE FOLLOWING TOTAL MASTECTOMY AND AXILLARY DISSECTION IN POSTMENOPAUSAL WOMEN,1988
210,I-54,CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC BODY IMAGING,1988
211,I-55,PEDIATRIC ANGIOCARDIOGRAPHY,1988
212,I-56,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1988
213,I-57,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1988
214,I-58,EXCRETORY UROGRAPHY,1988
215,I-59,ARTHROGRAPHY,1988
216,I-60,HYSTEROSALPINGOGRAPHY,1988
217,I-61,AORTOGRAPHY,1988
218,I-62,TREATMENT OF JUVENILE ARTHRITIS,1988
219,I-63,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1988
220,I-64,LONG-TERM TREATMENT OF ANGINA PECTORIS,1988
221,I-65,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1988
222,I-66,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1988
223,I-67,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1988
224,I-68,RELIEF OF MILD TO MODERATE PAIN,1988
225,I-69,TREATMENT OF CUTANEOUS CANDIDIASIS,1988
226,I-70,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTT^JN WOMEN WITH A HISTORY OF RECURRENT'UTI’S /,1988
227,I-71,SEBORRHEIC DERMATITIS,1988
228,NP,NEW PRODUCT,1989
229,PC,PATENT CHALLENGE,1989
230,NCE,NEW CHEMICAL ENTITY,1989
231,NC,NEW COMBINATION,1989
232,NDF,NEW DOSAGE FORM,1989
233,NR,NEW ROUTE,1989
234,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1989
235,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1989
236,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1989
237,ODE,ORPHAN DRUG EXCLUSIVITY,1989
238,NS,NEW STRENGTH,1989
239,D-1,ONCE A DAY APPLICATION,1989
240,D-2,ONCE DAILY DOSING,1989
241,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1989
242,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1989
243,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1989
244,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1989
245,D-7,BID DOSING,1989
246,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1989
247,D-9,NARCOTIC OVERDOSE IN ADULTS,1989
248,D-10,NARCOTIC OVERDOSE IN CHILDREN,1989
249,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1989
250,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,1989
251,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1989
252,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1989
253,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1989
254,I-1,SEVERE HYPERTENSION IN PEDIATRICS AND NONMALIGNANT HYPERTENSION,1989
255,I-2,DYSMENORRHEA,1989
256,I-3,TREATMENT OF TINEA VERSICOLOR,1989
257,I-4,SYMPTOMATIC GASTROESOPHAGEAL REFLUX,1989
258,I-5,NEPHROTOMOGRAPHY,1989
259,I-6,CONTRAST ENHANCEMENT IN CRANIAL COMPUTED TOMOGRAPHY,1989
260,I-7,VENOGRAPHY OF LOWER EXTREMITIES,1989
261,I-8,WHOLE-BODY COMPUTED TOMOGRAPHY,1989
262,I-9,GATED CARDIAC POOL IMAGING,1989
263,I-10,POST-MYOCARDIAL INFARCTION,1989
264,I-11,COLORECTAL SURGERY,1989
265,I-12,NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,1989
266,I-13,CISPLATIN-INDUCED EMESIS,1989
267,I-14,DIABETIC GASTROPARESIS,1989
268,I-15,SHORT-TERM TREATMENT OF GASTRIC ULCER DISEASE,1989
269,I-16,ACROMEGALY,1989
270,I-17,PITUITARY TUMORS,1989
271,I-18,POSTMENOPAUSAL OSTEOPOROSIS,1989
272,I-19,CHOLANGIOPANCREATOGRAPHY,1989
273,I-20,CONGESTIVE HEART FAILURE BID DOSAGE SCHEDULE,1989
274,I-21,ACUTE OTITIS MEDIA,1989
275,I-22,EXERCISE-INDUCED BRONCHOSPASMS,1989
276,I-23,MYOCARDIAL INFARCTION OR STROKE,1989
277,I-24,COMBINED USE WITH NICOTINIC ACID TO LOWER CHOLESTEROL LEVEL,1989
278,I-25,BLASTOMYCOSES DERMATITIDES,1989
279,I-26,PEDIATRIC SUBARACHNOID VASCULAR,1989
280,I-27,PETRIELLIDIUM BOYDII INFECTION,1989
281,I-28,HEREDITARY ANGIOEDEMA,1989
282,I-29,INTRACORONARY USE,1989
283,I-30,PEDIATRIC USE,1989
284,I-31,DIRECT ISOTOPIC CYSTOGRAPHY,1989
285,I-32,POSTPARTUM HEMORRHAGE,1989
286,I-33,USE IN METHADONE-INDUCED RESPIRATORY DEPRESSION,1989
287,I-34,PROLACTIN SECRETING ADENOMAS,1989
288,I-35,ANGINA PECTORIS DUE TO CORONARY ATHEROSCLEROSIS,1989
289,I-36,ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1989
290,I-37,SPINAL ANESTHESIA,1989
291,I-38,PATIENT PREOPERATIVE SKIN PREPARATION,1989
292,I-39,ADJUVANT WITH CHEMOTHERAPY FOR TREATMENT OF BREAST CANCER FOLLOWING MASTECTOMY,1989
293,I-40,ANTIDOTE FOR ACETAMINOPHEN OVERDOSE,1989
294,I-41,MANAGEMENT OF HYPOCALCEMIA AND RESULTANT METABOLIC BONE DISEASE IN RENAL DIALYSIS PATIENTS,1989
295,I-42,MAINTENANCE THERAPY AT REDUCED DOSE FOLLOWING HEALING OF ACUTE DUODENAL ULCER,1989
296,I-43,TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE,1989
297,I-44,TREATMENT OF SEVERE RECALCITRANT DERMATOPHYTE INFECTIONS,1989
298,I-45,ACCELERATE BARIUM TRANSIT THEREBY DECREASING TIME AND EXTENT OF RADIATION TO INTESTINAL TRACT,1989
299,I-46,TREATMENT OF SMALL CELL LUNG CANCER IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC DRUGS,1989
300,I-47,USE IN BALANCED ANESTHESIA,1989
301,I-48,MANAGEMENT OF FAMILIAL OR HEREDITARY ESSENTIAL TREMOR,1989
302,I-49,ADJUNCT TO COUMARIN ANTICOAGULANTS IN PREVENTION OF POSTOPERATIVE THROMBOEMBOLIC COMPLICATIONS OF CARDIAC VALVE REPLACEMENTS,1989
303,I-50,TREATMENT OF ARRHYTHMIAS,1989
304,I-51,MANAGEMENT OF ESSENTIAL HYPERTENSION,1989
305,I-52,CERVICAL MYELOGRAPHY,1989
306,I-53,USE AS SINGLE AGENT TO DELAY BREAST CANCER RECURRENCE FOLLOWING TOTAL MASTECTOMY AND AXILLARY DISSECTION IN POSTMENOPAUSAL WOMEN,1989
307,I-54,CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC BODY IMAGING,1989
308,I-55,PEDIATRIC ANGIOCARDIOGRAPHY,1989
309,I-56,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1989
310,I-57,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1989
311,I-58,EXCRETORY UROGRAPHY,1989
312,I-59,ARTHROGRAPHY,1989
313,I-60,HYSTEROSALPINGOGRAPHY,1989
314,I-61,AORTOGRAPHY,1989
315,I-62,TREATMENT OF JUVENILE ARTHRITIS,1989
316,I-63,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1989
317,I-64,LONG-TERM TREATMENT OF ANGINA PECTORIS,1989
318,I-65,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1989
319,I-66,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1989
320,I-67,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1989
321,I-68,RELIEF OF MILD TO MODERATE PAIN,1989
322,I-69,TREATMENT OF CUTANEOUS CANDIDIASIS,1989
323,I-70,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTIS,1989
324,I-71,SEBORRHEIC DERMATITIS,1989
325,I-72,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1989
326,I-73,FOLLICULAR STIMULATION IN IN VITRO FERTILIZATION,1989
327,I-74,MANAGEMENT OF CONGESTIVE HEART FAILURE,1989
328,I-75,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1989
329,I-76,HERNIOGRAPHY,1989
330,I-77,KNEE ARTHROGRAPHY,1989
331,I-78,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1989
332,I-79,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1989
333,I-80,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1989
334,I-81,TREATMENT OF RHEUMATOID ARTHRITIS,1989
335,I-82,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1989
336,I-83,TREATMENT OF LIVER FLUKES,1989
337,NCE,NEW CHEMICAL ENTITY,1990
338,NP,NEW PRODUCT,1990
339,NS,NEW STRENGTH,1990
340,PC,PATENT CHALLENGE,1990
341,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1990
342,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1990
343,ODE,ORPHAN DRUG EXCLUSIVITY,1990
344,NDF,NEW DOSAGE FORM,1990
345,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1990
346,NR,NEW ROUTE,1990
347,NC,NEW COMBINATION,1990
348,D-1,ONCE A DAY APPLICATION,1990
349,D-2,ONCE DAILY DOSING,1990
350,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1990
351,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1990
352,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1990
353,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1990
354,D-7,BID DOSING,1990
355,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1990
356,D-9,NARCOTIC OVERDOSE IN ADULTS,1990
357,D-10,NARCOTIC OVERDOSE IN CHILDREN,1990
358,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1990
359,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,1990
360,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1990
361,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1990
362,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1990
363,D-16,CONTINUOUS INTRAVENOUS INFUSION,1990
364,I-1,DYSMENORRHEA,1990
365,I-2,CHOLANGIOPANCREATOGRAPHY,1990
366,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1990
367,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1990
368,I-5,HYSTEROSALPINGOGRAPHY,1990
369,I-6,TREATMENT OF JUVENILE ARTHRITIS,1990
370,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1990
371,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1990
372,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1990
373,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1990
374,I-11,RELIEF OF MILD TO MODERATE PAIN,1990
375,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1990
376,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1990
377,I-14,SEBORRHEIC DERMATITIS,1990
378,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1990
379,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1990
380,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1990
381,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1990
382,I-19,HERNIOGRAPHY,1990
383,I-20,KNEE ARTHROGRAPHY,1990
384,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1990
385,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1990
386,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1990
387,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1990
388,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1990
389,I-26,TREATMENT OF LIVER FLUKES,1990
390,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1990
391,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1990
392,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ' ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1990
393,I-30,TREATMENT OF TINEA PEDIS,1990
394,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1990
395,I-32,PEDIATRIC MYELOGRAPHY,1990
396,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1990
397,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1990
398,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1990
399,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1990
400,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1990
401,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1990
402,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1990
403,I-40,PRIMARY NOCTURNAL ENURESIS,1990
404,NC,NEW COMBINATION,1991
405,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1991
406,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1991
407,NS,NEW STRENGTH,1991
408,NR,NEW ROUTE,1991
409,NDF,NEW DOSAGE FORM,1991
410,ODE,ORPHAN DRUG EXCLUSIVITY,1991
411,PC,PATENT CHALLENGE,1991
412,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1991
413,NCE,NEW CHEMICAL ENTITY,1991
414,NP,NEW PRODUCT,1991
415,D-1,ONCE A DAY APPLICATION,1991
416,D-2,ONCE DAILY DOSING,1991
417,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1991
418,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1991
419,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1991
420,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1991
421,D-7,BID DOSING,1991
422,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1991
423,D-9,NARCOTIC OVERDOSE IN ADULTS,1991
424,D-10,NARCOTIC OVERDOSE IN CHILDREN,1991
425,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1991
426,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,1991
427,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1991
428,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1991
429,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1991
430,D-16,CONTINUOUS INTRAVENOUS INFUSION,1991
431,I-1,DYSMENORRHEA,1991
432,I-2,CHOLANGIOPANCREATOGRAPHY,1991
433,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1991
434,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1991
435,I-5,HYSTEROSALPINGOGRAPHY,1991
436,I-6,TREATMENT OF JUVENILE ARTHRITIS,1991
437,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1991
438,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1991
439,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1991
440,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1991
441,I-11,RELIEF OF MILD TO MODERATE PAIN,1991
442,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1991
443,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1991
444,I-14,SEBORRHEIC DERMATITIS,1991
445,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1991
446,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1991
447,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1991
448,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1991
449,I-19,HERNIOGRAPHY,1991
450,I-20,KNEE ARTHROGRAPHY,1991
451,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1991
452,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1991
453,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1991
454,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1991
455,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1991
456,I-26,TREATMENT OF LIVER FLUKES,1991
457,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1991
458,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1991
459,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1991
460,I-30,TREATMENT OF TINEA PEDIS,1991
461,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1991
462,I-32,PEDIATRIC MYELOGRAPHY,1991
463,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1991
464,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1991
465,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1991
466,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1991
467,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1991
468,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1991
469,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1991
470,I-40,PRIMARY NOCTURNAL ENURESIS,1991
471,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1991
472,I-42,HERPES ZOSTER,1991
473,I-43,HERPES SIMPLEX ENCEPHALITIS,1991
474,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1991
475,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1991
476,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1991
477,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1991
478,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1991
479,I-49,TREATMENT OF TRAVELERS’ DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1991
480,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1991
481,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1991
482,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1991
483,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1991
484,I-54,RENAL CONCENTRATION CAPACITY TEST,1991
485,NC,NEW COMBINATION,1992
486,PC,PATENT CHALLENGE,1992
487,NDF,NEW DOSAGE FORM,1992
488,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1992
489,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1992
490,NP,NEW PRODUCT,1992
491,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1992
492,NR,NEW ROUTE,1992
493,NCE,NEW CHEMICAL ENTITY,1992
494,NS,NEW STRENGTH,1992
495,ODE,ORPHAN DRUG EXCLUSIVITY,1992
496,D-1,ONCE A DAY APPLICATION,1992
497,D-2,ONCE DAILY DOSING,1992
498,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1992
499,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1992
500,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1992
501,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1992
502,D-7,BID DOSING,1992
503,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1992
504,D-9,NARCOTIC OVERDOSE IN ADULTS,1992
505,D-10,NARCOTIC OVERDOSE IN CHILDREN,1992
506,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1992
507,D-12,BEDTIME DOSINS OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,1992
508,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1992
509,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1992
510,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1992
511,D-16,CONTINUOUS INTRAVENOUS INFUSION,1992
512,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1992
513,I-1,DYSMENORRHEA,1992
514,I-2,CHOLANGIOPANCREATOGRAPHY,1992
515,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1992
516,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1992
517,I-5,HYSTEROSALPINGOGRAPHY,1992
518,I-6,TREATMENT OF JUVENILE ARTHRITIS,1992
519,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1992
520,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1992
521,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1992
522,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1992
523,I-11,RELIEF OF MILD TO MODERATE PAIN,1992
524,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1992
525,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1992
526,I-14,SEBORRHEIC DERMATITIS,1992
527,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1992
528,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1992
529,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1992
530,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1992
531,I-19,HERNIOGRAPHY,1992
532,I-20,KNEE ARTHROGRAPHY,1992
533,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1992
534,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1992
535,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1992
536,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1992
537,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1992
538,I-26,TREATMENT OF LIVER FLUKES,1992
539,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1992
540,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1992
541,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1992
542,I-30,TREATMENT OF TINEA PEDIS,1992
543,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1992
544,I-32,PEDIATRIC MYELOGRAPHY,1992
545,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1992
546,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1992
547,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1992
548,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1992
549,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1992
550,I-38,CONTRAST ENHANCEMENT AGENT T0 FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1992
551,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1992
552,I-40,PRIMARY NOCTURNAL ENURESIS,1992
553,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1992
554,I-42,HERPES ZOSTER,1992
555,I-43,HERPES SIMPLEX ENCEPHALITIS,1992
556,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1992
557,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1992
558,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1992
559,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1992
560,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1992
561,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1992
562,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1992
563,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1992
564,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1992
565,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1992
566,I-54,RENAL CONCENTRATION CAPACITY TEST,1992
567,I-55,HYPERTENSION,1992
568,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1992
569,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1992
570,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1992
571,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS. INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1992
572,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1992
573,I-61,FEMALE ANOROGENETIC ALOPECIA,1992
574,I-62,PREVENTION OF TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1992
575,I-63,ONCE DAILY TREATMEMT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1992
576,I-64,PREVENTION OF SUPRAVENTRICULAR ARRHYTHMIAS,1992
577,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1992
578,I-66,UNCOMPLICATED GONORRHEA,1992
579,NS,NEW STRENGTH,1993
580,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1993
581,ODE,ORPHAN DRUG EXCLUSIVITY,1993
582,NC,NEW COMBINATION,1993
583,NCE,NEW CHEMICAL ENTITY,1993
584,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1993
585,NR,NEW ROUTE,1993
586,NP,NEW PRODUCT,1993
587,NDF,NEW DOSAGE FORM,1993
588,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1993
589,PC,PATENT CHALLENGE,1993
590,D-1,ONCE A DAY APPLICATION,1993
591,D-2,ONCE DAILY DOSING,1993
592,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1993
593,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1993
594,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1993
595,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1993
596,D-7,BID DOSING,1993
597,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1993
598,D-9,NARCOTIC OVERDOSE IN ADULTS,1993
599,D-10,NARCOTIC OVERDOSE IN CHILDREN,1993
600,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1993
601,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,1993
602,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1993
603,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1993
604,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1993
605,D-16,CONTINUOUS INTRAVENOUS INFUSION,1993
606,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1993
607,D-18,LOUER RECOMMENDED STARTING DOSE GUIDELINES,1993
608,D-19,BOLUS DOSING GUIDELINES,1993
609,I-1,DYSMENORRHEA,1993
610,I-2,CHOLANGIOPANCREATOGRAPHY,1993
611,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1993
612,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1993
613,I-5,HYSTEROSALPINGOGRAPHY,1993
614,I-6,TREATMENT OF JUVENILE ARTHRITIS,1993
615,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1993
616,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1993
617,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1993
618,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1993
619,I-11,RELIEF OF MILD TO MODERATE PAIN,1993
620,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1993
621,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1993
622,I-14,SEBORRHEIC DERMATITIS,1993
623,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1993
624,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1993
625,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1993
626,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1993
627,I-19,HERNIOGRAPHY,1993
628,I-20,KNEE ARTHROGRAPHY,1993
629,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1993
630,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1993
631,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1993
632,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1993
633,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1993
634,I-26,TREATMENT OF LIVER FLUKES,1993
635,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1993
636,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1993
637,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1993
638,I-30,TREATMENT OF TINEA PEDIS,1993
639,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1993
640,I-32,PEDIATRIC MYELOGRAPHY,1993
641,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1993
642,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1993
643,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1993
644,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1993
645,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1993
646,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1993
647,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1993
648,I-40,PRIMARY NOCTURNAL ENURESIS,1993
649,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1993
650,I-42,HERPES ZOSTER,1993
651,I-43,HERPES SIMPLEX ENCEPHALITIS,1993
652,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1993
653,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1993
654,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1993
655,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1993
656,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1993
657,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1993
658,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1993
659,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1993
660,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1993
661,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1993
662,I-54,RENAL CONCENTRATION CAPACITY TEST,1993
663,I-55,HYPERTENSION,1993
664,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1993
665,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1993
666,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1993
667,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1993
668,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1993
669,I-61,FEMALE ANDROGENETIC ALOPECIA,1993
670,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1993
671,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1993
672,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1993
673,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1993
674,I-66,UNCOMPLICATED GONORRHEA,1993
675,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1993
676,I-68,CENTRAL PRECOCIOUS PUBERTY,1993
677,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1993
678,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN,1993
679,I-71,THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER VARICELLA INFECTIONS (CHICKENPOX),1993
680,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR,1993
681,I-73,CMV DISEASE INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC),1993
682,I-74,SEDATION DURING DIAGNOSTIC PROCEDURES INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1993
683,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1993
684,I-76,PREVENTION OF OSTEOPOROSIS,1993
685,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1993
686,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY,1993
687,I-79,UROGRAPHY MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1993
688,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1993
689,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL,1993
690,I-82,CANDIDIASIS TREATMENT OF TRAVELERS' DIARRHEA,1993
691,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC",1993
692,I-84,"IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR",1993
693,I-85,HYPERTENSION TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS,1993
694,I-86,WITH AIDS TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1993
695,NS,NEW STRENGTH,1994
696,NC,NEW COMBINATION,1994
697,PC,PATENT CHALLENGE,1994
698,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1994
699,NDF,NEW DOSAGE FORM,1994
700,ODE,ORPHAN DRUG EXCLUSIVITY,1994
701,NR,NEW ROUTE,1994
702,NP,NEW PRODUCT,1994
703,NCE,NEW CHEMICAL ENTITY,1994
704,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1994
705,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1994
706,D-1,ONCE A DAY APPLICATION,1994
707,D-2,ONCE DAILY DOSING,1994
708,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1994
709,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1994
710,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1994
711,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1994
712,D-7,BID DOSING,1994
713,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1994
714,D-9,NARCOTIC OVERDOSE IN ADULTS,1994
715,D-10,NARCOTIC OVERDOSE IN CHILDREN,1994
716,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1994
717,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1994
718,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1994
719,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1994
720,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1994
721,D-16,CONTINUOUS INTRAVENOUS INFUSION,1994
722,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1994
723,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1994
724,D-19,BOLUS DOSING GUIDELINES,1994
725,D-20,SINGLE 32MG DOSE,1994
726,I-1,DYSMENORRHEA,1994
727,I-2,CHOLANGIOPANCREATOGRAPHY,1994
728,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1994
729,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1994
730,I-5,HYSTEROSALPINGOGRAPHY,1994
731,I-6,TREATMENT OF JUVENILE ARTHRITIS,1994
732,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1994
733,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1994
734,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1994
735,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1994
736,I-11,RELIEF OF MILD TO MODERATE PAIN,1994
737,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1994
738,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1994
739,I-14,SEBORRHEIC DERMATITIS,1994
740,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1994
741,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1994
742,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1994
743,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1994
744,I-19,HERNIOGRAPHY,1994
745,I-20,KNEE ARTHROGRAPHY,1994
746,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1994
747,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1994
748,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1994
749,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1994
750,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1994
751,I-26,TREATMENT OF LIVER FLUKES,1994
752,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1994
753,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1994
754,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1994
755,I-30,TREATMENT OF TINEA PEDIS,1994
756,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1994
757,I-32,PEDIATRIC MYELOGRAPHY,1994
758,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1994
759,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1994
760,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1994
761,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1994
762,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1994
763,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1994
764,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1994
765,I-40,PRIMARY NOCTURNAL ENURESIS,1994
766,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1994
767,I-42,HERPES ZOSTER,1994
768,I-43,HERPES SIMPLEX ENCEPHALITIS,1994
769,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1994
770,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1994
771,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1994
772,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1994
773,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1994
774,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1994
775,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1994
776,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1994
777,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1994
778,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1994
779,I-54,RENAL CONCENTRATION CAPACITY TEST,1994
780,I-55,HYPERTENSION,1994
781,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1994
782,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1994
783,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1994
784,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1994
785,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1994
786,I-61,FEMALE ANDROGENETIC ALOPECIA,1994
787,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1994
788,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1994
789,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1994
790,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1994
791,I-66,UNCOMPLICATED GONORRHEA,1994
792,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1994
793,I-68,CENTRAL PRECOCIOUS PUBERTY,1994
794,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1994
795,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1994
796,I-71,VARICELLA INFECTIONS (CHICKENPOX),1994
797,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1994
798,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1994
799,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1994
800,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1994
801,I-76,PREVENTION OF OSTEOPOROSIS,1994
802,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1994
803,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1994
804,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1994
805,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1994
806,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1994
807,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1994
808,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1994
809,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1994
810,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1994
811,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1994
812,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1994
813,I-88,MANAGEMENT OF ENDOMETRIOSIS,1994
814,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1994
815,I-90,INTENSIVE CARE UNIT SEDATION,1994
816,I-91,MONOTHERAPY USE FOR HYPERTENSION,1994
817,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1994
818,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1994
819,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],1994
820,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1994
821,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1994
822,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1994
823,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1994
824,ODE,ORPHAN DRUG EXCLUSIVITY,1995
825,NCE,NEW CHEMICAL ENTITY,1995
826,PC,PATENT CHALLENGE,1995
827,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1995
828,NC,NEW COMBINATION,1995
829,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1995
830,NP,NEW PRODUCT,1995
831,NDF,NEW DOSAGE FORM,1995
832,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1995
833,NS,NEW STRENGTH,1995
834,NR,NEW ROUTE,1995
835,D-1,ONCE A DAY APPLICATION,1995
836,D-2,ONCE DAILY DOSING,1995
837,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1995
838,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1995
839,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1995
840,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1995
841,D-7,BID DOSING,1995
842,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1995
843,D-9,NARCOTIC OVERDOSE IN ADULTS,1995
844,D-10,NARCOTIC OVERDOSE IN CHILDREN,1995
845,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1995
846,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1995
847,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1995
848,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1995
849,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1995
850,D-16,CONTINUOUS INTRAVENOUS INFUSION,1995
851,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1995
852,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1995
853,D-19,BOLUS DOSING GUIDELINES,1995
854,D-20,SINGLE 32MG DOSE,1995
855,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,1995
856,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,1995
857,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,1995
858,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,1995
859,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,1995
860,I-1,DYSMENORRHEA,1995
861,I-2,CHOLANGIOPANCREATOGRAPHY,1995
862,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1995
863,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1995
864,I-5,HYSTEROSALPINGOGRAPHY,1995
865,I-6,TREATMENT OF JUVENILE ARTHRITIS,1995
866,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1995
867,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1995
868,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1995
869,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1995
870,I-11,RELIEF OF MILD TO MODERATE PAIN,1995
871,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1995
872,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1995
873,I-14,SEBORRHEIC DERMATITIS,1995
874,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1995
875,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1995
876,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1995
877,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1995
878,I-19,HERNIOGRAPHY,1995
879,I-20,KNEE ARTHROGRAPHY,1995
880,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1995
881,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1995
882,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1995
883,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1995
884,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1995
885,I-26,TREATMENT OF LIVER FLUKES,1995
886,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1995
887,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1995
888,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1995
889,I-30,TREATMENT OF TINEA PEDIS,1995
890,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1995
891,I-32,PEDIATRIC MYELOGRAPHY,1995
892,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1995
893,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1995
894,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1995
895,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS.,1995
896,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1995
897,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1995
898,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1995
899,I-40,PRIMARY NOCTURNAL ENURESIS,1995
900,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1995
901,I-42,HERPES ZOSTER,1995
902,I-43,HERPES SIMPLEX ENCEPHALITIS,1995
903,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1995
904,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1995
905,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1995
906,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1995
907,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1995
908,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1995
909,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1995
910,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1995
911,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1995
912,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1995
913,I-54,RENAL CONCENTRATION CAPACITY TEST,1995
914,I-55,HYPERTENSION,1995
915,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1995
916,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1995
917,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1995
918,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1995
919,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1995
920,I-61,FEMALE ANDROGENETIC ALOPECIA,1995
921,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1995
922,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1995
923,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1995
924,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1995
925,I-66,UNCOMPLICATED GONORRHEA,1995
926,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1995
927,I-68,CENTRAL PRECOCIOUS PUBERTY,1995
928,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1995
929,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1995
930,I-71,VARICELLA INFECTIONS (CHICKENPOX),1995
931,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1995
932,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1995
933,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1995
934,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1995
935,I-76,PREVENTION OF OSTEOPOROSIS,1995
936,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1995
937,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1995
938,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1995
939,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1995
940,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1995
941,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1995
942,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1995
943,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1995
944,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1995
945,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1995
946,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1995
947,I-88,MANAGEMENT OF ENDOMETRIOSIS,1995
948,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1995
949,I-90,INTENSIVE CARE UNIT SEDATION,1995
950,I-91,MONOTHERAPY USE FOR HYPERTENSION,1995
951,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1995
952,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1995
953,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],1995
954,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1995
955,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1995
956,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1995
957,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1995
958,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,1995
959,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,1995
960,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1995
961,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,1995
962,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,1995
963,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,1995
964,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,1995
965,I-106,TREATMENT OF ACROMEGALY,1995
966,I-107,VAGINAL CANDIDIASIS,1995
967,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,1995
968,I-109,TYPHOID FEVER,1995
969,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,1995
970,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,1995
971,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,1995
972,I-113,TREATMENT OF PROSTATITIS,1995
973,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",1995
974,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,1995
975,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1995
976,NP,NEW PRODUCT,1996
977,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1996
978,ODE,ORPHAN DRUG EXCLUSIVITY,1996
979,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1996
980,NC,NEW COMBINATION,1996
981,NDF,NEW DOSAGE FORM,1996
982,NS,NEW STRENGTH,1996
983,PC,PATENT CHALLENGE,1996
984,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1996
985,NCE,NEW CHEMICAL ENTITY,1996
986,NR,NEW ROUTE,1996
987,D-1,ONCE A DAY APPLICATION,1996
988,D-2,ONCE DAILY DOSING,1996
989,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1996
990,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1996
991,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1996
992,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1996
993,D-7,BID DOSING,1996
994,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1996
995,D-9,NARCOTIC OVERDOSE IN ADULTS,1996
996,D-10,NARCOTIC OVERDOSE IN CHILDREN,1996
997,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1996
998,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1996
999,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1996
1000,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1996
1001,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1996
1002,D-16,CONTINUOUS INTRAVENOUS INFUSION,1996
1003,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1996
1004,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1996
1005,D-19,BOLUS DOSING GUIDELINES,1996
1006,D-20,SINGLE 32MG DOSE,1996
1007,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,1996
1008,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,1996
1009,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,1996
1010,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,1996
1011,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,1996
1012,D-26,ONCE WEEKLY APPLICATION,1996
1013,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,1996
1014,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,1996
1015,I-1,DYSMENORRHEA,1996
1016,I-2,CHOLANGIOPANCREATOGRAPHY,1996
1017,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1996
1018,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1996
1019,I-5,HYSTEROSALPINGOGRAPHY,1996
1020,I-6,TREATMENT OF JUVENILE ARTHRITIS,1996
1021,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1996
1022,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1996
1023,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1996
1024,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1996
1025,I-11,RELIEF OF MILD TO MODERATE PAIN,1996
1026,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1996
1027,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1996
1028,I-14,SEBORRHEIC DERMATITIS,1996
1029,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1996
1030,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1996
1031,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1996
1032,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1996
1033,I-19,HERNIOGRAPHY,1996
1034,I-20,KNEE ARTHROGRAPHY,1996
1035,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1996
1036,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1996
1037,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1996
1038,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1996
1039,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1996
1040,I-26,TREATMENT OF LIVER FLUKES,1996
1041,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1996
1042,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1996
1043,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1996
1044,I-30,TREATMENT OF TINEA PEDIS,1996
1045,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1996
1046,I-32,PEDIATRIC MYELOGRAPHY,1996
1047,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1996
1048,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1996
1049,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1996
1050,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1996
1051,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1996
1052,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1996
1053,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1996
1054,I-40,PRIMARY NOCTURNAL ENURESIS,1996
1055,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1996
1056,I-42,HERPES ZOSTER,1996
1057,I-43,HERPES SIMPLEX ENCEPHALITIS,1996
1058,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1996
1059,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1996
1060,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1996
1061,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1996
1062,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1996
1063,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1996
1064,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1996
1065,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1996
1066,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1996
1067,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1996
1068,I-54,RENAL CONCENTRATION CAPACITY TEST,1996
1069,I-55,HYPERTENSION,1996
1070,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1996
1071,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1996
1072,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1996
1073,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1996
1074,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1996
1075,I-61,FEMALE ANDROGENETIC ALOPECIA,1996
1076,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1996
1077,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1996
1078,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1996
1079,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1996
1080,I-66,UNCOMPLICATED GONORRHEA,1996
1081,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1996
1082,I-68,CENTRAL PRECOCIOUS PUBERTY,1996
1083,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1996
1084,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1996
1085,I-71,VARICELLA INFECTIONS (CHICKENPOX),1996
1086,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1996
1087,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1996
1088,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1996
1089,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1996
1090,I-76,PREVENTION OF OSTEOPOROSIS,1996
1091,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1996
1092,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1996
1093,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1996
1094,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1996
1095,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1996
1096,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1996
1097,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1996
1098,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1996
1099,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1996
1100,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1996
1101,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1996
1102,I-88,MANAGEMENT OF ENDOMETRIOSIS,1996
1103,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1996
1104,I-90,INTENSIVE CARE UNIT SEDATION,1996
1105,I-91,MONOTHERAPY USE FOR HYPERTENSION,1996
1106,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1996
1107,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1996
1108,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],1996
1109,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1996
1110,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1996
1111,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1996
1112,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1996
1113,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,1996
1114,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,1996
1115,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1996
1116,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,1996
1117,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,1996
1118,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,1996
1119,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,1996
1120,I-106,TREATMENT OF ACROMEGALY,1996
1121,I-107,VAGINAL CANDIDIASIS,1996
1122,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,1996
1123,I-109,TYPHOID FEVER,1996
1124,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,1996
1125,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,1996
1126,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,1996
1127,I-113,TREATMENT OF PROSTATITIS,1996
1128,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",1996
1129,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,1996
1130,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1996
1131,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,1996
1132,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",1996
1133,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,1996
1134,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,1996
1135,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,1996
1136,I-122,PSORIASIS OF THE SCALP,1996
1137,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,1996
1138,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,1996
1139,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,1996
1140,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,1996
1141,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,1996
1142,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),1996
1143,I-129,TREATMENT OF ALCOHOL DEPENDENCE,1996
1144,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1996
1145,I-131,PERIPHERAL ARTERIOGRAPHY,1996
1146,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,1996
1147,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,1996
1148,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,1996
1149,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,1996
1150,I-136,IDIOPATHIC CHRONIC URTICARIA,1996
1151,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",1996
1152,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,1996
1153,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,1996
1154,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,1996
1155,PC,PATENT CHALLENGE,1997
1156,NDF,NEW DOSAGE FORM,1997
1157,NP,NEW PRODUCT,1997
1158,NC,NEW COMBINATION,1997
1159,ODE,ORPHAN DRUG EXCLUSIVITY,1997
1160,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1997
1161,NCE,NEW CHEMICAL ENTITY,1997
1162,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1997
1163,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1997
1164,NS,NEW STRENGTH,1997
1165,NR,NEW ROUTE,1997
1166,D-1,ONCE A DAY APPLICATION,1997
1167,D-2,ONCE DAILY DOSING,1997
1168,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1997
1169,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1997
1170,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1997
1171,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1997
1172,D-7,BID DOSING,1997
1173,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1997
1174,D-9,NARCOTIC OVERDOSE IN ADULTS,1997
1175,D-10,NARCOTIC OVERDOSE IN CHILDREN,1997
1176,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1997
1177,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1997
1178,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1997
1179,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1997
1180,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1997
1181,D-16,CONTINUOUS INTRAVENOUS INFUSION,1997
1182,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1997
1183,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1997
1184,D-19,BOLUS DOSING GUIDELINES,1997
1185,D-20,SINGLE 32MG DOSE,1997
1186,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,1997
1187,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,1997
1188,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,1997
1189,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,1997
1190,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,1997
1191,D-26,ONCE WEEKLY APPLICATION,1997
1192,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,1997
1193,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-25O AND ISOVUE-300,1997
1194,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,1997
1195,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,1997
1196,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),1997
1197,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,1997
1198,I-1,DYSMENORRHEA,1997
1199,I-2,CHOLANGIOPANCREATOGRAPHY,1997
1200,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1997
1201,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1997
1202,I-5,HYSTEROSALPINGOGRAPHY,1997
1203,I-6,TREATMENT OF JUVENILE ARTHRITIS,1997
1204,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1997
1205,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1997
1206,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1997
1207,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1997
1208,I-11,RELIEF OF MILD TO MODERATE PAIN,1997
1209,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1997
1210,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1997
1211,I-14,SEBORRHEIC DERMATITIS,1997
1212,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1997
1213,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1997
1214,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1997
1215,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1997
1216,I-19,HERNIOGRAPHY,1997
1217,I-20,KNEE ARTHROGRAPHY,1997
1218,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1997
1219,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1997
1220,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1997
1221,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1997
1222,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1997
1223,I-26,TREATMENT OF LIVER FLUKES,1997
1224,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1997
1225,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1997
1226,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1997
1227,I-30,TREATMENT OF TINEA PEDIS,1997
1228,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1997
1229,I-32,PEDIATRIC MYELOGRAPHY,1997
1230,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1997
1231,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1997
1232,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1997
1233,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1997
1234,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1997
1235,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1997
1236,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1997
1237,I-40,PRIMARY NOCTURNAL ENURESIS,1997
1238,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1997
1239,I-42,HERPES ZOSTER,1997
1240,I-43,HERPES SIMPLEX ENCEPHALITIS,1997
1241,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1997
1242,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1997
1243,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1997
1244,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1997
1245,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1997
1246,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1997
1247,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1997
1248,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1997
1249,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1997
1250,I-53,"TREATMENT QF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1997
1251,I-54,RENAL CONCENTRATION CAPACITY TEST,1997
1252,I-55,HYPERTENSION,1997
1253,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1997
1254,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1997
1255,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1997
1256,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1997
1257,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1997
1258,I-61,FEMALE ANDROGENETIC ALOPECIA,1997
1259,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1997
1260,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1997
1261,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1997
1262,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1997
1263,I-66,UNCOMPLICATED GONORRHEA,1997
1264,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1997
1265,I-68,CENTRAL PRECOCIOUS PUBERTY,1997
1266,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1997
1267,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1997
1268,I-71,VARICELLA INFECTIONS (CHICKENPOX),1997
1269,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1997
1270,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1997
1271,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1997
1272,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1997
1273,I-76,PREVENTION OF OSTEOPOROSIS,1997
1274,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1997
1275,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1997
1276,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1997
1277,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1997
1278,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1997
1279,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1997
1280,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1997
1281,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1997
1282,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1997
1283,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1997
1284,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1997
1285,I-88,MANAGEMENT OF ENDOMETRIOSIS,1997
1286,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1997
1287,I-90,INTENSIVE CARE UNIT SEDATION,1997
1288,I-91,MONOTHERAPY USE FOR HYPERTENSION,1997
1289,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1997
1290,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1997
1291,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],1997
1292,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1997
1293,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1997
1294,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1997
1295,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1997
1296,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,1997
1297,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,1997
1298,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1997
1299,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,1997
1300,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,1997
1301,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,1997
1302,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,1997
1303,I-106,TREATMENT OF ACROMEGALY,1997
1304,I-107,VAGINAL CANDIDIASIS,1997
1305,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,1997
1306,I-109,TYPHOID FEVER,1997
1307,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,1997
1308,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,1997
1309,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,1997
1310,I-113,TREATMENT OF PROSTATITIS,1997
1311,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",1997
1312,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,1997
1313,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1997
1314,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,1997
1315,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",1997
1316,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,1997
1317,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,1997
1318,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,1997
1319,I-122,PSORIASIS OF THE SCALP,1997
1320,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,1997
1321,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,1997
1322,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,1997
1323,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,1997
1324,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,1997
1325,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),1997
1326,I-129,TREATMENT OF ALCOHOL DEPENDENCE,1997
1327,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1997
1328,I-131,PERIPHERAL ARTERIOGRAPHY,1997
1329,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,1997
1330,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,1997
1331,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,1997
1332,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,1997
1333,I-136,IDIOPATHIC CHRONIC URTICARIA,1997
1334,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",1997
1335,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,1997
1336,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,1997
1337,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,1997
1338,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,1997
1339,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,1997
1340,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,1997
1341,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,1997
1342,I-145,0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,1997
1343,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,1997
1344,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,1997
1345,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,1997
1346,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,1997
1347,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,1997
1348,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,1997
1349,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,1997
1350,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN],1997
1351,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,1997
1352,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,1997
1353,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,1997
1354,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,1997
1355,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,1997
1356,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",1997
1357,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,1997
1358,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,1997
1359,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,1997
1360,I-163,TREATMENT OF PHOTOPHOBIA,1997
1361,I-164,CHRONIC BACTERIAL PROSTATITIS,1997
1362,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",1997
1363,I-166,TREATMENT OF BULIMIA,1997
1364,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,1997
1365,I-168,MANAGEMENT OF LOCALLY CONFINED STATE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),1997
1366,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,1997
1367,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,1997
1368,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,1997
1369,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,1997
1370,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,1997
1371,I-174,PELVIC INFLAMMATORY DISEASE,1997
1372,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,1997
1373,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,1997
1374,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1998
1375,NS,NEW STRENGTH,1998
1376,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1998
1377,ODE,ORPHAN DRUG EXCLUSIVITY,1998
1378,NDF,NEW DOSAGE FORM,1998
1379,PC,PATENT CHALLENGE,1998
1380,NC,NEW COMBINATION,1998
1381,NP,NEW PRODUCT,1998
1382,NR,NEW ROUTE,1998
1383,NCE,NEW CHEMICAL ENTITY,1998
1384,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1998
1385,D-1,ONCE A DAY APPLICATION,1998
1386,D-2,ONCE DAILY DOSING,1998
1387,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1998
1388,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1998
1389,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1998
1390,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1998
1391,D-7,BID DOSING,1998
1392,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1998
1393,D-9,NARCOTIC OVERDOSE IN ADULTS,1998
1394,D-10,NARCOTIC OVERDOSE IN CHILDREN,1998
1395,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1998
1396,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1998
1397,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1998
1398,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1998
1399,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1998
1400,D-16,CONTINUOUS INTRAVENOUS INFUSION,1998
1401,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1998
1402,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1998
1403,D-19,BOLUS DOSING GUIDELINES,1998
1404,D-20,SINGLE 32MG DOSE,1998
1405,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,1998
1406,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,1998
1407,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,1998
1408,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,1998
1409,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,1998
1410,D-26,ONCE WEEKLY APPLICATION,1998
1411,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,1998
1412,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,1998
1413,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,1998
1414,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,1998
1415,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),1998
1416,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,1998
1417,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,1998
1418,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,1998
1419,D-35,FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS,1998
1420,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE IMG DOSE GIVE TWICE DAILY,1998
1421,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),1998
1422,I-1,DYSMENORRHEA,1998
1423,I-2,CHOLANGIOPANCREATOGRAPHY,1998
1424,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1998
1425,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1998
1426,I-5,HYSTEROSALPINGOGRAPHY,1998
1427,I-6,TREATMENT OF JUVENILE ARTHRITIS,1998
1428,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1998
1429,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1998
1430,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1998
1431,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1998
1432,I-11,RELIEF OF MILD TO MODERATE PAIN,1998
1433,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1998
1434,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECU RRENT UTI,1998
1435,I-14,SEBORRHEIC DERMATITIS,1998
1436,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1998
1437,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1998
1438,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1998
1439,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1998
1440,I-19,HERNIOGRAPHY,1998
1441,I-20,KNEE ARTHROGRAPHY,1998
1442,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1998
1443,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1998
1444,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1998
1445,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1998
1446,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1998
1447,I-26,TREATMENT OF LIVER FLUKES,1998
1448,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1998
1449,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1998
1450,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1998
1451,I-30,TREATMENT OF TINEA PEDIS,1998
1452,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1998
1453,I-32,PEDIATRIC MYELOGRAPHY,1998
1454,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1998
1455,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1998
1456,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1998
1457,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1998
1458,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1998
1459,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1998
1460,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1998
1461,I-40,PRIMARY NOCTURNAL ENURESIS,1998
1462,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1998
1463,I-42,HERPES ZOSTER,1998
1464,I-43,HERPES SIMPLEX ENCEPHALITIS,1998
1465,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1998
1466,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1998
1467,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1998
1468,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1998
1469,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1998
1470,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1998
1471,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1998
1472,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1998
1473,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1998
1474,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1998
1475,I-54,RENAL CONCENTRATION CAPACITY TEST,1998
1476,I-55,HYPERTENSION,1998
1477,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1998
1478,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL U LCER,1998
1479,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1998
1480,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1998
1481,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1998
1482,I-61,FEMALE ANDROGENETIC ALOPECIA,1998
1483,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1998
1484,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1998
1485,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1998
1486,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1998
1487,I-66,UNCOMPLICATED GONORRHEA,1998
1488,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1998
1489,I-68,CENTRAL PRECOCIOUS PUBERTY,1998
1490,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORTTERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1998
1491,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1998
1492,I-71,VARICELLA INFECTIONS (CHICKENPOX),1998
1493,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1998
1494,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1998
1495,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1998
1496,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1998
1497,I-76,PREVENTION OF OSTEOPOROSIS,1998
1498,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1998
1499,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1998
1500,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1998
1501,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1998
1502,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1998
1503,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1998
1504,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1998
1505,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1998
1506,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1998
1507,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1998
1508,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1998
1509,I-88,MANAG EMENT OF ENDOMETRIOSIS,1998
1510,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1998
1511,I-90,INTENSIVE CARE UNIT SEDATION,1998
1512,I-91,MONOTHERAPY USE FOR HYPERTENSION,1998
1513,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1998
1514,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1998
1515,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY (EXCLUDING THE HEART),1998
1516,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1998
1517,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1998
1518,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1998
1519,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1998
1520,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,1998
1521,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,1998
1522,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1998
1523,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,1998
1524,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,1998
1525,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,1998
1526,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,1998
1527,I-106,TREATMENT OF ACROMEGALY,1998
1528,I-107,VAGINAL CANDIDIASIS,1998
1529,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,1998
1530,I-109,TYPHOID FEVER,1998
1531,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,1998
1532,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,1998
1533,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,1998
1534,I-113,TREATMENT OF PROSTATITIS,1998
1535,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",1998
1536,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,1998
1537,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1998
1538,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,1998
1539,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",1998
1540,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,1998
1541,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,1998
1542,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,1998
1543,I-122,PSORIASIS OF THE SCALP,1998
1544,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,1998
1545,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,1998
1546,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,1998
1547,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,1998
1548,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,1998
1549,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES HA AND IIB),1998
1550,I-129,TREATMENT OF ALCOHOL DEPENDENCE,1998
1551,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1998
1552,I-131,PERIPHERAL ARTERIOGRAPHY,1998
1553,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,1998
1554,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,1998
1555,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,1998
1556,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,1998
1557,I-136,IDIOPATHIC CHRONIC URTICARIA,1998
1558,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",1998
1559,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,1998
1560,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,1998
1561,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,1998
1562,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,1998
1563,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,1998
1564,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,1998
1565,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,1998
1566,I-145,0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,1998
1567,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,1998
1568,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,1998
1569,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,1998
1570,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,1998
1571,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,1998
1572,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,1998
1573,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,1998
1574,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN],1998
1575,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,1998
1576,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,1998
1577,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,1998
1578,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,1998
1579,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,1998
1580,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",1998
1581,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,1998
1582,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,1998
1583,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,1998
1584,I-163,TREATMENT OF PHOTOPHOBIA,1998
1585,I-164,CHRONIC BACTERIAL PROSTATITIS,1998
1586,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",1998
1587,I-166,TREATMENT OF BULIMIA,1998
1588,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,1998
1589,I-168,MANAGEMENT OF LOCALLY CONFINED STATE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),1998
1590,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,1998
1591,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,1998
1592,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,1998
1593,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,1998
1594,I-173,PREOPERAT1VELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,1998
1595,I-174,PELVIC INFLAMMATORY DISEASE,1998
1596,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,1998
1597,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,1998
1598,I-177,"TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",1998
1599,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,1998
1600,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,1998
1601,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),1998
1602,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,1998
1603,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,1998
1604,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,1998
1605,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG),1998
1606,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,1998
1607,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),1998
1608,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1998
1609,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,1998
1610,I-189,TREATMENT OF ACUTE OTITIS M EDIA IN PEDIATRIC PATIENTS,1998
1611,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,1998
1612,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,1998
1613,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",1998
1614,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,1998
1615,I-194,CONGESTIVE HEART FAILURE,1998
1616,I-195,USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,1998
1617,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1998
1618,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,1998
1619,I-198,USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,1998
1620,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,1998
1621,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,1998
1622,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,1998
1623,I-202,SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA,1998
1624,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,1998
1625,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,1998
1626,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,1998
1627,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,1998
1628,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,1998
1629,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,1998
1630,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),1998
1631,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,1998
1632,I-211,FOR USE IN THE PEDIATRIC POPULATION,1998
1633,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,1999
1634,PED,PEDIATRIC EXCLUSIVITY,1999
1635,PC,PATENT CHALLENGE,1999
1636,NP,NEW PRODUCT,1999
1637,NCE,NEW CHEMICAL ENTITY,1999
1638,ODE,ORPHAN DRUG EXCLUSIVITY,1999
1639,NS,NEW STRENGTH,1999
1640,NC,NEW COMBINATION,1999
1641,NDF,NEW DOSAGE FORM,1999
1642,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",1999
1643,NR,NEW ROUTE,1999
1644,I,"NEW INDICATION (SEE REFERENCES, BELOW)",1999
1645,D-1,ONCE A DAY APPLICATION,1999
1646,D-2,ONCE DAILY DOSING,1999
1647,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,1999
1648,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,1999
1649,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,1999
1650,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,1999
1651,D-7,BID DOSING,1999
1652,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",1999
1653,D-9,NARCOTIC OVERDOSE IN ADULTS,1999
1654,D-10,NARCOTIC OVERDOSE IN CHILDREN,1999
1655,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,1999
1656,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,1999
1657,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,1999
1658,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1999
1659,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,1999
1660,D-16,CONTINUOUS INTRAVENOUS INFUSION,1999
1661,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,1999
1662,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,1999
1663,D-19,BOLUS DOSING GUIDELINES,1999
1664,D-20,SINGLE 32MG DOSE,1999
1665,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,1999
1666,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,1999
1667,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,1999
1668,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,1999
1669,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,1999
1670,D-26,ONCE WEEKLY APPLICATION,1999
1671,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,1999
1672,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,1999
1673,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,1999
1674,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,1999
1675,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),1999
1676,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,1999
1677,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,1999
1678,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,1999
1679,D-35,FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS,1999
1680,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE IMG DOSE GIVE TWICE DAILY,1999
1681,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),1999
1682,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,1999
1683,D-39,CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ” ...1/2-1 HOUR BEFORE EATING...” TO “...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING...”,1999
1684,D-40,ONCE-A-DAY DOSING REGIMEN,1999
1685,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,1999
1686,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",1999
1687,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,1999
1688,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",1999
1689,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,1999
1690,D-46,NEW DOSING REGIMEN OF 80MG DAILY,1999
1691,D-47,TAKE DRUG “15 MINUTES TO 1 HOUR” PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN,1999
1692,D-48,"ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL",1999
1693,D-49,PEDIATRIC DOSING GUIDELINES,1999
1694,I-1,DYSMENORRHEA,1999
1695,I-2,CHOLANGIOPANCREATOGRAPHY,1999
1696,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1999
1697,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),1999
1698,I-5,HYSTEROSALPINGOGRAPHY,1999
1699,I-6,TREATMENT OF JUVENILE ARTHRITIS,1999
1700,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,1999
1701,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,1999
1702,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,1999
1703,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,1999
1704,I-11,RELIEF OF MILD TO MODERATE PAIN,1999
1705,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,1999
1706,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,1999
1707,I-14,SEBORRHEIC DERMATITIS,1999
1708,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,1999
1709,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,1999
1710,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,1999
1711,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,1999
1712,I-19,HERNIOGRAPHY,1999
1713,I-20,KNEE ARTHROGRAPHY,1999
1714,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,1999
1715,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,1999
1716,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1999
1717,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,1999
1718,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",1999
1719,I-26,TREATMENT OF LIVER FLUKES,1999
1720,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,1999
1721,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,1999
1722,I-29,MET ASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,1999
1723,I-30,TREATMENT OF TINEA PEDIS,1999
1724,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,1999
1725,I-32,PEDIATRIC MYELOGRAPHY,1999
1726,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,1999
1727,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,1999
1728,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,1999
1729,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,1999
1730,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,1999
1731,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),1999
1732,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,1999
1733,I-40,PRIMARY NOCTURNAL ENURESIS,1999
1734,I-41,MIGRAINE HEADACHE PROPHYLAXIS,1999
1735,I-42,HERPES ZOSTER,1999
1736,I-43,HERPES SIMPLEX ENCEPHALITIS,1999
1737,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,1999
1738,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,1999
1739,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,1999
1740,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,1999
1741,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,1999
1742,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,1999
1743,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,1999
1744,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,1999
1745,I-52,PEDIATRIC EXCRETORY UROGRAPHY,1999
1746,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",1999
1747,I-54,RENAL CONCENTRATION CAPACITY TEST,1999
1748,I-55,HYPERTENSION,1999
1749,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,1999
1750,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,1999
1751,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,1999
1752,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",1999
1753,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,1999
1754,I-61,FEMALE ANDROGENETIC ALOPECIA,1999
1755,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1999
1756,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,1999
1757,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,1999
1758,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,1999
1759,I-66,UNCOMPLICATED GONORRHEA,1999
1760,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,1999
1761,I-68,CENTRAL PRECOCIOUS PUBERTY,1999
1762,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",1999
1763,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,1999
1764,I-71,VARICELLA INFECTIONS (CHICKENPOX),1999
1765,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,1999
1766,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,1999
1767,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,1999
1768,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,1999
1769,I-76,PREVENTION OF OSTEOPOROSIS,1999
1770,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",1999
1771,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,1999
1772,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,1999
1773,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,1999
1774,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,1999
1775,I-82,TREATMENT OF TRAVELERS' DIARRHEA,1999
1776,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",1999
1777,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,1999
1778,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,1999
1779,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,1999
1780,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,1999
1781,I-88,MANAGEMENT OF ENDOMETRIOSIS,1999
1782,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,1999
1783,I-90,INTENSIVE CARE UNIT SEDATION,1999
1784,I-91,MONOTHERAPY USE FOR HYPERTENSION,1999
1785,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,1999
1786,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,1999
1787,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY (EXCLUDING THE HEART],1999
1788,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,1999
1789,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1999
1790,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,1999
1791,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,1999
1792,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,1999
1793,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,1999
1794,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1999
1795,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,1999
1796,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,1999
1797,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,1999
1798,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,1999
1799,I-106,TREATMENT OF ACROMEGALY,1999
1800,I-107,VAGINAL CANDIDIASIS,1999
1801,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,1999
1802,I-109,TYPHOID FEVER,1999
1803,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,1999
1804,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,1999
1805,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,1999
1806,I-113,TREATMENT OF PROSTATITIS,1999
1807,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",1999
1808,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,1999
1809,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1999
1810,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,1999
1811,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",1999
1812,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,1999
1813,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,1999
1814,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,1999
1815,I-122,PSORIASIS OF THE SCALP,1999
1816,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,1999
1817,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,1999
1818,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,1999
1819,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,1999
1820,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,1999
1821,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),1999
1822,I-129,TREATMENT OF ALCOHOL DEPENDENCE,1999
1823,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,1999
1824,I-131,PERIPHERAL ARTERIOGRAPHY,1999
1825,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,1999
1826,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,1999
1827,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,1999
1828,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,1999
1829,I-136,IDIOPATHIC CHRONIC URTICARIA,1999
1830,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",1999
1831,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,1999
1832,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,1999
1833,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,1999
1834,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,1999
1835,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,1999
1836,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,1999
1837,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,1999
1838,I-145,0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,1999
1839,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,1999
1840,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,1999
1841,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,1999
1842,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,1999
1843,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,1999
1844,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,1999
1845,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,1999
1846,I-153,MANAGEMENT OF SEVERE SPASTICITY | ENCOMPASSES SPINAL AND CEREBRAL ORIGIN),1999
1847,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,1999
1848,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,1999
1849,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,1999
1850,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,1999
1851,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,1999
1852,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARD1OVASCULAR CAUSES",1999
1853,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,1999
1854,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,1999
1855,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,1999
1856,I-163,TREATMENT OF PHOTOPHOBIA,1999
1857,I-164,CHRONIC BACTERIAL PROSTATITIS,1999
1858,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",1999
1859,I-166,TREATMENT OF BULIMIA,1999
1860,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,1999
1861,I-168,MANAGEMENT OF LOCALLY CONFINED STATE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),1999
1862,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,1999
1863,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,1999
1864,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,1999
1865,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,1999
1866,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,1999
1867,I-174,PELVIC INFLAMMATORY DISEASE,1999
1868,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,1999
1869,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,1999
1870,I-177,"TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",1999
1871,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,1999
1872,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,1999
1873,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),1999
1874,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,1999
1875,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,1999
1876,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,1999
1877,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG),1999
1878,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,1999
1879,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),1999
1880,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,1999
1881,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,1999
1882,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,1999
1883,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,1999
1884,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,1999
1885,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",1999
1886,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,1999
1887,I-194,CONGESTIVE HEART FAILURE,1999
1888,I-195,USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,1999
1889,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,1999
1890,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,1999
1891,I-198,USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,1999
1892,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,1999
1893,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,1999
1894,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,1999
1895,I-202,SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA,1999
1896,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,1999
1897,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,1999
1898,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,1999
1899,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,1999
1900,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,1999
1901,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,1999
1902,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),1999
1903,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,1999
1904,I-211,FOR USE IN THE PEDIATRIC POPULATION,1999
1905,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN’S SYNDROME,1999
1906,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,1999
1907,I-214,TREATMENT OF OSTEOPOROSIS,1999
1908,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,1999
1909,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",1999
1910,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",1999
1911,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),1999
1912,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,1999
1913,I-220,"TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",1999
1914,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITFI AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",1999
1915,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",1999
1916,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,1999
1917,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,1999
1918,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",1999
1919,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,1999
1920,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD),1999
1921,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL,1999
1922,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",1999
1923,I-230,"IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",1999
1924,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,1999
1925,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,1999
1926,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,1999
1927,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,1999
1928,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,1999
1929,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,1999
1930,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,1999
1931,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,1999
1932,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,1999
1933,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML MIN) NOT YET ON DIALYSIS,1999
1934,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,1999
1935,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,1999
1936,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,1999
1937,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,1999
1938,I-245,TREATMENT OF ACUTE SINUSITIS,1999
1939,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,1999
1940,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,1999
1941,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM,1999
1942,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,1999
1943,NP*,NEW PRODUCT (MINT FLAVORED),2000
1944,ODE,ORPHAN DRUG EXCLUSIVITY,2000
1945,NC,NEW COMBINATION,2000
1946,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2000
1947,NCE,NEW CHEMICAL ENTITY,2000
1948,PC,PATENT CHALLENGE,2000
1949,I,"NEW INDICATION (SEE REFERENCES, BELOW)",2000
1950,NP,NEW PRODUCT,2000
1951,PED,PEDIATRIC EXCLUSIVITY,2000
1952,NR,NEW ROUTE,2000
1953,NS,NEW STRENGTH,2000
1954,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",2000
1955,NDF,NEW DOSAGE FORM,2000
1956,D-1,ONCE A DAY APPLICATION,2000
1957,D-2,ONCE DAILY DOSING,2000
1958,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2000
1959,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2000
1960,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2000
1961,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2000
1962,D-7,BID DOSING,2000
1963,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2000
1964,D-9,NARCOTIC OVERDOSE IN ADULTS,2000
1965,D-10,NARCOTIC OVERDOSE IN CHILDREN,2000
1966,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2000
1967,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,2000
1968,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2000
1969,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2000
1970,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2000
1971,D-16,CONTINUOUS INTRAVENOUS INFUSION,2000
1972,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2000
1973,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2000
1974,D-19,BOLUS DOSING GUIDELINES,2000
1975,D-20,SINGLE 32MG DOSE,2000
1976,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2000
1977,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2000
1978,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2000
1979,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,2000
1980,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,2000
1981,D-26,ONCE WEEKLY APPLICATION,2000
1982,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2000
1983,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2000
1984,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,2000
1985,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,2000
1986,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2000
1987,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2000
1988,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2000
1989,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2000
1990,D-35,FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS,2000
1991,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVE TWICE DAILY,2000
1992,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2000
1993,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2000
1994,D-39,CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ” ...1/2-1 HOUR BEFORE EATING...” TO “...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING...”,2000
1995,D-40,ONCE-A-DAY DOSING REGIMEN,2000
1996,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2000
1997,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2000
1998,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2000
1999,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2000
2000,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2000
2001,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2000
2002,D-47,"TAKE DRUG ""15 MINUTES TO 1 HOUR” PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN",2000
2003,D-48,"ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL",2000
2004,D-49,PEDIATRIC DOSING GUIDELINES,2000
2005,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2000
2006,D-51,TO BE DEFINED IN SUPPLEMENT,2000
2007,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2000
2008,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2000
2009,I-1,DYSMENORRHEA,2000
2010,I-2,CHOLANGIOPANCREATOGRAPHY,2000
2011,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2000
2012,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2000
2013,I-5,HYSTEROSALPINGOGRAPHY,2000
2014,I-6,TREATMENT OF JUVENILE ARTHRITIS,2000
2015,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2000
2016,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2000
2017,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2000
2018,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2000
2019,I-11,RELIEF OF MILD TO MODERATE PAIN,2000
2020,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2000
2021,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2000
2022,I-14,SEBORRHEIC DERMATITIS,2000
2023,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2000
2024,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2000
2025,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2000
2026,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2000
2027,I-19,HERNIOGRAPHY,2000
2028,I-20,KNEE ARTHROGRAPHY,2000
2029,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2000
2030,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2000
2031,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2000
2032,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2000
2033,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2000
2034,I-26,TREATMENT OF LIVER FLUKES,2000
2035,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2000
2036,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2000
2037,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2000
2038,I-30,TREATMENT OF TINEA PEDIS,2000
2039,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2000
2040,I-32,PEDIATRIC MYELOGRAPHY,2000
2041,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2000
2042,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2000
2043,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2000
2044,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2000
2045,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2000
2046,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2000
2047,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2000
2048,I-40,PRIMARY NOCTURNAL ENURESIS,2000
2049,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2000
2050,I-42,HERPES ZOSTER,2000
2051,I-43,HERPES SIMPLEX ENCEPHALITIS,2000
2052,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2000
2053,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2000
2054,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2000
2055,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2000
2056,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2000
2057,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2000
2058,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2000
2059,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2000
2060,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2000
2061,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2000
2062,I-54,RENAL CONCENTRATION CAPACITY TEST,2000
2063,I-55,HYPERTENSION,2000
2064,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2000
2065,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2000
2066,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2000
2067,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2000
2068,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2000
2069,I-61,FEMALE ANDROGENETIC ALOPECIA,2000
2070,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2000
2071,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2000
2072,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2000
2073,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2000
2074,I-66,UNCOMPLICATED GONORRHEA,2000
2075,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2000
2076,I-68,CENTRAL PRECOCIOUS PUBERTY,2000
2077,I-69,SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD); AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY,2000
2078,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2000
2079,I-71,VARICELLA INFECTIONS (CHICKENPOX),2000
2080,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2000
2081,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2000
2082,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2000
2083,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2000
2084,I-76,PREVENTION OF OSTEOPOROSIS,2000
2085,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2000
2086,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2000
2087,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2000
2088,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2000
2089,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2000
2090,I-82,TREATMENT OF TRAVELERS’ DIARRHEA,2000
2091,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2000
2092,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2000
2093,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2000
2094,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2000
2095,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2000
2096,I-88,MANAGEMENT OF ENDOMETRIOSIS,2000
2097,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2000
2098,I-90,INTENSIVE CARE UNIT SEDATION,2000
2099,I-91,MONOTHERAPY USE FOR HYPERTENSION,2000
2100,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2000
2101,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2000
2102,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY (EXCLUDING THE HEART],2000
2103,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2000
2104,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2000
2105,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2000
2106,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2000
2107,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2000
2108,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2000
2109,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 1 INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2000
2110,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2000
2111,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2000
2112,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2000
2113,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2000
2114,I-106,TREATMENT OF ACROMEGALY,2000
2115,I-107,VAGINAL CANDIDIASIS,2000
2116,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2000
2117,I-109,TYPHOID FEVER,2000
2118,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2000
2119,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2000
2120,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2000
2121,I-113,TREATMENT OF PROSTATITIS,2000
2122,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",2000
2123,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2000
2124,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2000
2125,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2000
2126,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",2000
2127,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2000
2128,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2000
2129,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,2000
2130,I-122,PSORIASIS OF THE SCALP,2000
2131,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2000
2132,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2000
2133,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2000
2134,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2000
2135,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2000
2136,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),2000
2137,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2000
2138,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2000
2139,I-131,PERIPHERAL ARTERIOGRAPHY,2000
2140,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2000
2141,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2000
2142,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2000
2143,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2000
2144,I-136,IDIOPATHIC CHRONIC URTICARIA,2000
2145,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2000
2146,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2000
2147,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,2000
2148,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2000
2149,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2000
2150,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2000
2151,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2000
2152,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2000
2153,I-145,0.1 MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2000
2154,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2000
2155,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2000
2156,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CAR1NI1 PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2000
2157,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2000
2158,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2000
2159,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2000
2160,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2000
2161,I-153,MANAGEMENT OF SEVERE SPASTICITY | ENCOMPASSES SPINAL AND CEREBRAL ORIGIN|,2000
2162,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2000
2163,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2000
2164,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2000
2165,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2000
2166,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2000
2167,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2000
2168,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2000
2169,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2000
2170,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2000
2171,I-163,TREATMENT OF PHOTOPHOBIA,2000
2172,I-164,CHRONIC BACTERIAL PROSTATITIS,2000
2173,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2000
2174,I-166,TREATMENT OF BULIMIA,2000
2175,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROB1C PATHOGENS,2000
2176,I-168,MANAGEMENT OF LOCALLY CONFINED STATE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2000
2177,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2000
2178,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2000
2179,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2000
2180,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2000
2181,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2000
2182,I-174,PELVIC INFLAMMATORY DISEASE,2000
2183,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2000
2184,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2000
2185,I-177,"TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2000
2186,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2000
2187,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2000
2188,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2000
2189,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2000
2190,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2000
2191,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2000
2192,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG),2000
2193,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2000
2194,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORB1CULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2000
2195,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENO PAUSAL OSTEOPOROSIS,2000
2196,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2000
2197,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2000
2198,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2000
2199,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2000
2200,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2000
2201,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2000
2202,I-194,CONGESTIVE HEART FAILURE,2000
2203,I-195,USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2000
2204,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2000
2205,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2000
2206,I-198,USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2000
2207,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2000
2208,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2000
2209,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2000
2210,I-202,SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA,2000
2211,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2000
2212,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2000
2213,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2000
2214,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2000
2215,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2000
2216,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2000
2217,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2000
2218,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2000
2219,I-211,FOR USE IN THE PEDIATRIC POPULATION,2000
2220,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN’S SYNDROME,2000
2221,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2000
2222,I-214,TREATMENT OF OSTEOPOROSIS,2000
2223,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2000
2224,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2000
2225,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2000
2226,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2000
2227,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2000
2228,I-220,"TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2000
2229,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2000
2230,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2000
2231,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2000
2232,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL S YMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2000
2233,I-225,"USE IN PATIENTS WITH PREVIOUS ML AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2000
2234,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2000
2235,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD),2000
2236,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL,2000
2237,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2000
2238,I-230,"IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2000
2239,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2000
2240,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2000
2241,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2000
2242,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR ILIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2000
2243,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2000
2244,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2000
2245,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2000
2246,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2000
2247,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2000
2248,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML MIN) NOT YET ON DIALYSIS,2000
2249,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2000
2250,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2000
2251,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2000
2252,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2000
2253,I-245,TREATMENT OF ACUTE SINUSITIS,2000
2254,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2000
2255,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2000
2256,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM,2000
2257,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2000
2258,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2000
2259,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2000
2260,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2000
2261,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2000
2262,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2000
2263,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2000
2264,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2000
2265,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION,2000
2266,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE,2000
2267,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2000
2268,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2000
2269,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2000
2270,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2000
2271,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2000
2272,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2000
2273,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2000
2274,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2000
2275,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2000
2276,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2000
2277,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2000
2278,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2000
2279,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2000
2280,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2000
2281,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2000
2282,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2000
2283,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2000
2284,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2000
2285,I-277,TREATMENT OF TYPE HI HYPERLIPOPROTEINEMIA,2000
2286,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2000
2287,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2000
2288,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2000
2289,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES ILA AND LIB),2000
2290,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2000
2291,I-283,TO BE DEFINED IN SUPPLEMENT,2000
2292,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2000
2293,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2000
2294,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2000
2295,NP*,NEW PRODUCT (MINT FLAVORED),2001
2296,NS,NEW STRENGTH,2001
2297,NDF,NEW DOSAGE FORM,2001
2298,ODE,ORPHAN DRUG EXCLUSIVITY,2001
2299,NCE,NEW CHEMICAL ENTITY,2001
2300,NPP,NEW PATIENT POPULATION,2001
2301,NR,NEW ROUTE,2001
2302,NC,NEW COMBINATION,2001
2303,PED,PEDIATRIC EXCLUSIVITY,2001
2304,I,"NEW INDICATION (SEE REFERENCES, BELOW)",2001
2305,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2001
2306,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",2001
2307,NP,NEW PRODUCT,2001
2308,PC,PATENT CHALLENGE,2001
2309,D-1,ONCE A DAY APPLICATION,2001
2310,D-2,ONCE DAILY DOSING,2001
2311,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2001
2312,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2001
2313,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2001
2314,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2001
2315,D-7,BID DOSING,2001
2316,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2001
2317,D-9,NARCOTIC OVERDOSE IN ADULTS,2001
2318,D-10,NARCOTIC OVERDOSE IN CHILDREN,2001
2319,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2001
2320,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,2001
2321,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2001
2322,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2001
2323,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2001
2324,D-16,CONTINUOUS INTRAVENOUS INFUSION,2001
2325,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2001
2326,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2001
2327,D-19,BOLUS DOSING GUIDELINES,2001
2328,D-20,SINGLE 32MG DOSE,2001
2329,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2001
2330,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2001
2331,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2001
2332,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,2001
2333,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,2001
2334,D-26,ONCE WEEKLY APPLICATION,2001
2335,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2001
2336,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2001
2337,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,2001
2338,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,2001
2339,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2001
2340,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2001
2341,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2001
2342,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2001
2343,D-35,FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS,2001
2344,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE IMG DOSE GIVE TWICE DAILY,2001
2345,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2001
2346,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2001
2347,D-39,CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ”... 1/2-1 HOUR BEFORE EATING..TO “...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING...”,2001
2348,D-40,ONCE-A-DAY DOSING REGIMEN,2001
2349,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2001
2350,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2001
2351,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2001
2352,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2001
2353,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2001
2354,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2001
2355,D-47,TAKE DRUG “15 MINUTES TO 1 HOUR” PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN,2001
2356,D-48,"ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL",2001
2357,D-49,PEDIATRIC DOSING GUIDELINES,2001
2358,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2001
2359,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2001
2360,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2001
2361,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2001
2362,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2001
2363,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2001
2364,D-56,ADDITION OF POSTPRANDIAL DOSING,2001
2365,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2001
2366,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2001
2367,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2001
2368,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2001
2369,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2370,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2371,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2001
2372,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2001
2373,I-1,DYSMENORRHEA,2001
2374,I-2,CHOLANGIOPANCREATOGRAPHY,2001
2375,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2001
2376,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2001
2377,I-5,HYSTEROSALPINGOGRAPHY,2001
2378,I-6,TREATMENT OF JUVENILE ARTHRITIS,2001
2379,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2001
2380,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2001
2381,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2001
2382,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2001
2383,I-11,RELIEF OF MILD TO MODERATE PAIN,2001
2384,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2001
2385,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2001
2386,I-14,SEBORRHEIC DERMATITIS,2001
2387,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2001
2388,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2001
2389,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2001
2390,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2001
2391,I-19,HERNIOGRAPHY,2001
2392,I-20,KNEE ARTHROGRAPHY,2001
2393,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2001
2394,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2001
2395,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2001
2396,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2001
2397,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2001
2398,I-26,TREATMENT OF LIVER FLUKES,2001
2399,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2001
2400,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2001
2401,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2001
2402,I-30,TREATMENT OF TINEA PEDIS,2001
2403,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2001
2404,I-32,PEDIATRIC MYELOGRAPHY,2001
2405,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2001
2406,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2001
2407,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2001
2408,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2001
2409,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2001
2410,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2001
2411,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2001
2412,I-40,PRIMARY NOCTURNAL ENURESIS,2001
2413,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2001
2414,I-42,HERPES ZOSTER,2001
2415,I-43,HERPES SIMPLEX ENCEPHALITIS,2001
2416,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2001
2417,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2001
2418,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2001
2419,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2001
2420,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2001
2421,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2001
2422,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2001
2423,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2001
2424,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2001
2425,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2001
2426,I-54,RENAL CONCENTRATION CAPACITY TEST,2001
2427,I-55,HYPERTENSION,2001
2428,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2001
2429,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2001
2430,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2001
2431,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2001
2432,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2001
2433,I-61,FEMALE ANDROGENETIC ALOPECIA,2001
2434,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2435,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2001
2436,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2001
2437,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2001
2438,I-66,UNCOMPLICATED GONORRHEA,2001
2439,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2001
2440,I-68,CENTRAL PRECOCIOUS PUBERTY,2001
2441,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2001
2442,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2001
2443,I-71,VARICELLA INFECTIONS (CHICKENPOX),2001
2444,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2001
2445,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2001
2446,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2001
2447,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2001
2448,I-76,PREVENTION OF OSTEOPOROSIS,2001
2449,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2001
2450,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2001
2451,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2001
2452,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2001
2453,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2001
2454,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2001
2455,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2001
2456,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2001
2457,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2001
2458,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2001
2459,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2001
2460,I-88,MANAGEMENT OF ENDOMETRIOSIS,2001
2461,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2001
2462,I-90,INTENSIVE CARE UNIT SEDATION,2001
2463,I-91,MONOTHERAPY USE FOR HYPERTENSION,2001
2464,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2001
2465,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2001
2466,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2001
2467,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2001
2468,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2001
2469,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2001
2470,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2001
2471,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2001
2472,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2001
2473,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2001
2474,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE,2001
2475,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2001
2476,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2001
2477,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2001
2478,I-106,TREATMENT OF ACROMEGALY,2001
2479,I-107,VAGINAL CANDIDIASIS,2001
2480,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2001
2481,I-109,TYPHOID FEVER,2001
2482,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2001
2483,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2001
2484,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2001
2485,I-113,TREATMENT OF PROSTATITIS,2001
2486,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",2001
2487,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2001
2488,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2001
2489,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2001
2490,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",2001
2491,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2001
2492,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2001
2493,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,2001
2494,I-122,PSORIASIS OF THE SCALP,2001
2495,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2001
2496,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2001
2497,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2001
2498,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2001
2499,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2001
2500,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),2001
2501,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2001
2502,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2001
2503,I-131,PERIPHERAL ARTERIOGRAPHY,2001
2504,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2001
2505,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2001
2506,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2001
2507,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2001
2508,I-136,IDIOPATHIC CHRONIC URTICARIA,2001
2509,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2001
2510,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2001
2511,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,2001
2512,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMVDISEASE,2001
2513,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2001
2514,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2001
2515,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2001
2516,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2001
2517,I-145,O.IMMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2001
2518,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2001
2519,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2001
2520,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2001
2521,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2001
2522,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2001
2523,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2001
2524,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2001
2525,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN],2001
2526,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2001
2527,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2001
2528,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2001
2529,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2001
2530,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2001
2531,I-159,"FOR HYPERCHOLESTEROLEMIC PATI ENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2001
2532,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2001
2533,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2001
2534,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2001
2535,I-163,TREATMENT OF PHOTOPHOBIA,2001
2536,I-164,CHRONIC BACTERIAL PROSTATITIS,2001
2537,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2001
2538,I-166,TREATMENT OF BULIMIA,2001
2539,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2001
2540,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2001
2541,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2001
2542,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2001
2543,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2001
2544,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2001
2545,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2001
2546,I-174,PELVIC INFLAMMATORY DISEASE,2001
2547,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2001
2548,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2001
2549,I-177,"TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2001
2550,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2001
2551,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2001
2552,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2001
2553,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2001
2554,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2001
2555,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2001
2556,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG),2001
2557,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2001
2558,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2001
2559,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2560,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2001
2561,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2001
2562,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2001
2563,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2001
2564,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN. 40MG ONCE DAILY, FOR THIS INDICATION",2001
2565,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2001
2566,I-194,CONGESTIVE HEART FAILURE,2001
2567,I-195,USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2001
2568,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2001
2569,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2001
2570,I-198,USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2001
2571,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2001
2572,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2001
2573,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2001
2574,I-202,SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2001
2575,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2001
2576,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2001
2577,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2001
2578,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2001
2579,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2001
2580,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2001
2581,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2001
2582,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2001
2583,I-211,FOR USE IN THE PEDIATRIC POPULATION,2001
2584,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2001
2585,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2001
2586,I-214,TREATMENT OF OSTEOPOROSIS,2001
2587,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2001
2588,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2001
2589,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2001
2590,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2001
2591,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2001
2592,I-220,"TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2001
2593,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2001
2594,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2001
2595,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2001
2596,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2001
2597,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2001
2598,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2001
2599,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD),2001
2600,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL,2001
2601,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H, PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2001
2602,I-230,"IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2001
2603,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2001
2604,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2001
2605,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2001
2606,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2001
2607,I-235,PREVENTION OF EXERCISE-INDUCED BRONCFIOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2001
2608,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2001
2609,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2001
2610,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2001
2611,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2001
2612,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML MIN) NOT YET ON DIALYSIS,2001
2613,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2001
2614,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2001
2615,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2001
2616,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2001
2617,I-245,TREATMENT OF ACUTE SINUSITIS,2001
2618,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2001
2619,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2001
2620,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM,2001
2621,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2001
2622,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2001
2623,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2001
2624,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2001
2625,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2001
2626,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2001
2627,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2001
2628,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2001
2629,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION,2001
2630,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE,2001
2631,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2001
2632,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2001
2633,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2001
2634,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2001
2635,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2001
2636,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2001
2637,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2001
2638,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2001
2639,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2001
2640,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2001
2641,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2001
2642,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2001
2643,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2001
2644,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2001
2645,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2001
2646,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2001
2647,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2001
2648,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2001
2649,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2001
2650,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2001
2651,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2001
2652,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2001
2653,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2001
2654,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2001
2655,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2001
2656,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2001
2657,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2001
2658,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2001
2659,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2001
2660,I-288,CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2001
2661,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2001
2662,I-290,TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS,2001
2663,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2664,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2001
2665,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2001
2666,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2001
2667,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2001
2668,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2001
2669,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2001
2670,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2001
2671,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2001
2672,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2001
2673,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2001
2674,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2001
2675,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2001
2676,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2001
2677,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2001
2678,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY IIYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2001
2679,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2001
2680,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2001
2681,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2001
2682,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2001
2683,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS.,2001
2684,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2001
2685,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2001
2686,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2001
2687,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2001
2688,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2001
2689,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2001
2690,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2001
2691,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2001
2692,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2001
2693,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2001
2694,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2001
2695,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2001
2696,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2001
2697,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2001
2698,ODE,ORPHAN DRUG EXCLUSIVITY,2002
2699,NR,NEW ROUTE,2002
2700,NP,NEW PRODUCT,2002
2701,NDF,NEW DOSAGE FORM,2002
2702,PC,PATENT CHALLENGE,2002
2703,NCE,NEW CHEMICAL ENTITY,2002
2704,NC,NEW COMBINATION,2002
2705,D,"NEW DOSING SCHEDULE (SEE REFERENCES, BELOW)",2002
2706,NP*,NEW PRODUCT (MINT FLAVORED),2002
2707,PED,PEDIATRIC EXCLUSIVITY,2002
2708,NS,NEW STRENGTH,2002
2709,NPP,NEW PATIENT POPULATION,2002
2710,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2002
2711,I,"NEW INDICATION (SEE REFERENCES, BELOW)",2002
2712,D-1,ONCE A DAY APPLICATION,2002
2713,D-2,ONCE DAILY DOSING,2002
2714,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2002
2715,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2002
2716,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2002
2717,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2002
2718,D-7,BID DOSING,2002
2719,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2002
2720,D-9,NARCOTIC OVERDOSE IN ADULTS,2002
2721,D-10,NARCOTIC OVERDOSE IN CHILDREN,2002
2722,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2002
2723,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,2002
2724,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2002
2725,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2002
2726,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2002
2727,D-16,CONTINUOUS INTRAVENOUS INFUSION,2002
2728,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2002
2729,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2002
2730,D-19,BOLUS DOSING GUIDELINES,2002
2731,D-20,SINGLE 32MG DOSE,2002
2732,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2002
2733,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2002
2734,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2002
2735,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 OVER THREE HOURS EVERY THREE WEEKS,2002
2736,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,2002
2737,D-26,ONCE WEEKLY APPLICATION,2002
2738,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2002
2739,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2002
2740,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS,2002
2741,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,2002
2742,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2002
2743,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2002
2744,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2002
2745,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2002
2746,D-35,FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS,2002
2747,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE IMG DOSE GIVE TWICE DAILY,2002
2748,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2002
2749,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2002
2750,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ” ...1/2-1 HOUR BEFORE EATING..."" TO “...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING...”",2002
2751,D-40,ONCE-A-DAY DOSING REGIMEN,2002
2752,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2002
2753,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2002
2754,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2002
2755,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2002
2756,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2002
2757,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2002
2758,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT NCLUDING, HOUR PRIOR TO A PROVOCATIVE MEAL",2002
2759,D-48,"ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL",2002
2760,D-49,PEDIATRIC DOSING GUIDELINES,2002
2761,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2002
2762,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2002
2763,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2002
2764,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2002
2765,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2002
2766,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2002
2767,D-56,ADDITION OF POSTPRANDIAL DOSING,2002
2768,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2002
2769,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2002
2770,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2002
2771,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2002
2772,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2002
2773,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2002
2774,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2002
2775,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2002
2776,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2002
2777,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2002
2778,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2002
2779,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2002
2780,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2002
2781,D-70,80MG ONCE DAILY DOSING REGIMEN,2002
2782,I-1,DYSMENORRHEA,2002
2783,I-2,CHOLANGIOPANCREATOGRAPHY,2002
2784,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2002
2785,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2002
2786,I-5,HYSTEROSALPINGOGRAPHY,2002
2787,I-6,TREATMENT OF JUVENILE ARTHRITIS,2002
2788,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2002
2789,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2002
2790,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2002
2791,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP,2002
2792,I-11,REPLACEMENT SURGERY RELIEF OF MILD TO MODERATE PAIN,2002
2793,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2002
2794,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2002
2795,I-14,SEBORRHEIC DERMATITIS,2002
2796,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL,2002
2797,I-16,LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING,2002
2798,I-17,IN AN IN VITRO FERTILIZATION PROGRAM MANAGEMENT OF CONGESTIVE HEART FAILURE,2002
2799,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2002
2800,I-19,HERNIOGRAPHY,2002
2801,I-20,KNEE ARTHROGRAPHY,2002
2802,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC,2002
2803,I-22,AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2002
2804,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2002
2805,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2002
2806,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL",2002
2807,I-26,AND PERIPHERAL VESSELS TREATMENT OF LIVER FLUKES,2002
2808,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2002
2809,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2002
2810,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR,2002
2811,I-30,OVARIAN IRRADIATION TREATMENT OF TINEA PEDIS,2002
2812,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED,2002
2813,I-32,TISSUES PEDIATRIC MYELOGRAPHY,2002
2814,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED,2002
2815,I-34,TOMOGRAPHY OF THE ABDOMEN ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2002
2816,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2002
2817,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2002
2818,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2002
2819,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS,2002
2820,I-39,SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER) TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2002
2821,I-40,PRIMARY NOCTURNAL ENURESIS,2002
2822,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2002
2823,I-42,HERPES ZOSTER,2002
2824,I-43,HERPES SIMPLEX ENCEPHALITIS,2002
2825,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2002
2826,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2002
2827,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2002
2828,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2002
2829,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2002
2830,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2002
2831,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2002
2832,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2002
2833,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2002
2834,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2002
2835,I-54,RENAL CONCENTRATION CAPACITY TEST,2002
2836,I-55,HYPERTENSION,2002
2837,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2002
2838,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2002
2839,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2002
2840,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2002
2841,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2002
2842,I-61,FEMALE ANDROGENETIC ALOPECIA,2002
2843,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2002
2844,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2002
2845,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2002
2846,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2002
2847,I-66,UNCOMPLICATED GONORRHEA,2002
2848,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2002
2849,I-68,CENTRAL PRECOCIOUS PUBERTY,2002
2850,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2002
2851,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2002
2852,I-71,VARICELLA INFECTIONS (CHICKENPOX),2002
2853,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2002
2854,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2002
2855,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2002
2856,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2002
2857,I-76,PREVENTION OF OSTEOPOROSIS,2002
2858,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2002
2859,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2002
2860,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2002
2861,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2002
2862,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2002
2863,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2002
2864,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2002
2865,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2002
2866,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2002
2867,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2002
2868,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2002
2869,I-88,MANAGEMENT OF ENDOMETRIOSIS,2002
2870,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2002
2871,I-90,INTENSIVE CARE UNIT SEDATION,2002
2872,I-91,MONOTHERAPY USE FOR HYPERTENSION,2002
2873,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2002
2874,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2002
2875,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2002
2876,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2002
2877,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2002
2878,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2002
2879,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2002
2880,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2002
2881,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2002
2882,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2002
2883,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE,2002
2884,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2002
2885,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2002
2886,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2002
2887,I-106,TREATMENT OF ACROMEGALY,2002
2888,I-107,VAGINAL CANDIDIASIS,2002
2889,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2002
2890,I-109,TYPHOID FEVER,2002
2891,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2002
2892,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2002
2893,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2002
2894,I-113,TREATMENT OF PROSTATITIS,2002
2895,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE",2002
2896,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2002
2897,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2002
2898,I-117,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2002
2899,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY",2002
2900,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2002
2901,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2002
2902,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,2002
2903,I-122,PSORIASIS OF THE SCALP,2002
2904,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2002
2905,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2002
2906,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2002
2907,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2002
2908,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2002
2909,I-128,IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB),2002
2910,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2002
2911,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2002
2912,I-131,PERIPHERAL ARTERIOGRAPHY,2002
2913,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2002
2914,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2002
2915,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2002
2916,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2002
2917,I-136,IDIOPATHIC CHRONIC URTICARIA,2002
2918,I-137,"PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2002
2919,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2002
2920,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,2002
2921,I-140,"PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR , DEVELOPING CMV DISEASE",2002
2922,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2002
2923,I-142,LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION',2002
2924,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2002
2925,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2002
2926,I-145,0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2002
2927,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2002
2928,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2002
2929,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2002
2930,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2002
2931,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2002
2932,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2002
2933,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2002
2934,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN],2002
2935,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2002
2936,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2002
2937,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2002
2938,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2002
2939,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2002
2940,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2002
2941,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2002
2942,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2002
2943,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2002
2944,I-163,TREATMENT OF PHOTOPHOBIA,2002
2945,I-164,CHRONIC BACTERIAL PROSTATITIS,2002
2946,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2002
2947,I-166,TREATMENT OF BULIMIA,2002
2948,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2002
2949,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2002
2950,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2002
2951,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2002
2952,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2002
2953,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2002
2954,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2002
2955,I-174,PELVIC INFLAMMATORY DISEASE,2002
2956,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2002
2957,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2002
2958,I-177,"TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2002
2959,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2002
2960,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2002
2961,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2002
2962,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2002
2963,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2002
2964,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2002
2965,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG),2002
2966,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2002
2967,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2002
2968,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2002
2969,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2002
2970,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2002
2971,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2002
2972,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2002
2973,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2002
2974,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2002
2975,I-194,CONGESTIVE HEART FAILURE,2002
2976,I-195,USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2002
2977,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2002
2978,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2002
2979,I-198,USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2002
2980,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE 11 DIABETES,2002
2981,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2002
2982,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2002
2983,I-202,SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA,2002
2984,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2002
2985,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2002
2986,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2002
2987,I-206,TREATMENTOFEDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2002
2988,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2002
2989,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2002
2990,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2002
2991,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2002
2992,I-211,FOR USE IN THE PEDIATRIC POPULATION,2002
2993,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN’S SYNDROME,2002
2994,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2002
2995,I-214,TREATMENT OF OSTEOPOROSIS,2002
2996,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2002
2997,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2002
2998,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2002
2999,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2002
3000,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2002
3001,I-220,"TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2002
3002,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2002
3003,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2002
3004,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2002
3005,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2002
3006,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2002
3007,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2002
3008,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD),2002
3009,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL,2002
3010,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2002
3011,I-230,"IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2002
3012,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2002
3013,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2002
3014,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2002
3015,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2002
3016,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2002
3017,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2002
3018,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2002
3019,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2002
3020,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2002
3021,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML MIN) NOT YET ON DIALYSIS,2002
3022,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2002
3023,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2002
3024,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2002
3025,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2002
3026,I-245,TREATMENT OF ACUTE SINUSITIS,2002
3027,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2002
3028,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2002
3029,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM,2002
3030,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2002
3031,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2002
3032,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2002
3033,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2002
3034,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2002
3035,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2002
3036,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2002
3037,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2002
3038,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION,2002
3039,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE,2002
3040,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS . UNDERGOING HIP REPLACEMENT SURGERY",2002
3041,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2002
3042,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2002
3043,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2002
3044,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2002
3045,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2002
3046,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2002
3047,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2002
3048,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2002
3049,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2002
3050,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2002
3051,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2002
3052,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2002
3053,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2002
3054,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2002
3055,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2002
3056,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2002
3057,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2002
3058,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2002
3059,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2002
3060,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2002
3061,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2002
3062,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2002
3063,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2002
3064,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2002
3065,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2002
3066,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2002
3067,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2002
3068,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2002
3069,I-288,CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2002
3070,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2002
3071,I-290,TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS,2002
3072,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2002
3073,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2002
3074,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2002
3075,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2002
3076,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2002
3077,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2002
3078,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2002
3079,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2002
3080,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2002
3081,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2002
3082,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2002
3083,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2002
3084,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2002
3085,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2002
3086,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2002
3087,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2002
3088,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2002
3089,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2002
3090,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2002
3091,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2002
3092,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS.,2002
3093,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2002
3094,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2002
3095,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2002
3096,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2002
3097,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2002
3098,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2002
3099,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2002
3100,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2002
3101,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2002
3102,I-321,JUVENILE RHEUMATOID ARTHRITIS,2002
3103,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2002
3104,I-323,COLORECTAL CANCER,2002
3105,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2002
3106,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2002
3107,I-326,GENERALIZED ANXIETY DISORDER,2002
3108,I-327,SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2002
3109,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2002
3110,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2002
3111,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2002
3112,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2002
3113,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN),2002
3114,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2002
3115,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2002
3116,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2002
3117,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2002
3118,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2002
3119,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2002
3120,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2002
3121,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2002
3122,I-341,BREAST CANCER COMBINATION THERAPY,2002
3123,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2002
3124,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2002
3125,I-344,ACNE VULGARIS,2002
3126,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2002
3127,I-346,TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD),2002
3128,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2002
3129,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2002
3130,M-2,APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2002
3131,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2002
3132,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2002
3133,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2002
3134,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN,2002
3135,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2002
3136,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2002
3137,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2002
3138,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2002
3139,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2002
3140,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2002
3141,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2002
3142,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2002
3143,NS,NEW STRENGTH,2003
3144,NDF,NEW DOSAGE FORM,2003
3145,PED,PEDIATRIC EXCLUSIVITY,2003
3146,NP,NEW PRODUCT,2003
3147,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2003
3148,ODE,ORPHAN DRUG EXCLUSIVITY,2003
3149,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2003
3150,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2003
3151,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE ANNUAL EDITION SECTION 1.8 WAIVED EXCLUSIVITY,2003
3152,NPP,NEW PATIENT POPULATION,2003
3153,NR,NEW ROUTE,2003
3154,NP*,NEW PRODUCT (MINT FLAVORED),2003
3155,NCE,NEW CHEMICAL ENTITY,2003
3156,NC,NEW COMBINATION,2003
3157,PC,PATENT CHALLENGE,2003
3158,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2003
3159,D-1,ONCE A DAY APPLICATION,2003
3160,D-2,ONCE DAILY DOSING,2003
3161,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2003
3162,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2003
3163,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2003
3164,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2003
3165,D-7,BID DOSING,2003
3166,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2003
3167,D-9,NARCOTIC OVERDOSE IN ADULTS,2003
3168,D-10,NARCOTIC OVERDOSE IN CHILDREN,2003
3169,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2003
3170,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,2003
3171,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2003
3172,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2003
3173,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2003
3174,D-16,CONTINUOUS INTRAVENOUS INFUSION,2003
3175,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2003
3176,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2003
3177,D-19,BOLUS DOSING GUIDELINES,2003
3178,D-20,SINGLE 32MG DOSE,2003
3179,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2003
3180,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2003
3181,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2003
3182,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 OVER THREE HOURS EVERY THREE WEEKS,2003
3183,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,2003
3184,D-26,ONCE WEEKLY APPLICATION,2003
3185,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2003
3186,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2003
3187,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2003
3188,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,2003
3189,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2003
3190,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2003
3191,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2003
3192,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2003
3193,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2003
3194,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2003
3195,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2003
3196,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2003
3197,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1 /2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2003
3198,D-40,ONCE-A-DAY DOSING REGIMEN,2003
3199,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2003
3200,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2003
3201,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2003
3202,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2003
3203,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2003
3204,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2003
3205,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2003
3206,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2003
3207,D-49,PEDIATRIC DOSING GUIDELINES,2003
3208,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2003
3209,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2003
3210,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2003
3211,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2003
3212,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2003
3213,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2003
3214,D-56,ADDITION OF POSTPRANDIAL DOSING,2003
3215,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2003
3216,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2003
3217,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2003
3218,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2003
3219,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3220,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3221,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2003
3222,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2003
3223,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2003
3224,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2003
3225,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2003
3226,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2003
3227,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2003
3228,D-70,80MG ONCE DAILY DOSING REGIMEN,2003
3229,D-71,EIGHT WEEK DOSING REGIMEN,2003
3230,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2003
3231,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3232,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3233,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2003
3234,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2003
3235,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2003
3236,I-1,DYSMENORRHEA,2003
3237,I-2,CHOLANGIOPANCREATOGRAPHY,2003
3238,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2003
3239,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2003
3240,I-5,HYSTEROSALPINGOCRAPHY,2003
3241,I-6,TREATMENT OF JUVENILE ARTHRITIS,2003
3242,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2003
3243,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2003
3244,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2003
3245,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2003
3246,I-11,RELIEF OF MILD TO MODERATE PAIN,2003
3247,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2003
3248,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2003
3249,I-14,SEBORRHEIC DERMATITIS,2003
3250,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2003
3251,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2003
3252,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2003
3253,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2003
3254,I-19,HERNIOCRAPHY,2003
3255,I-20,KNEE ARTHROGRAPHY,2003
3256,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2003
3257,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2003
3258,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2003
3259,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2003
3260,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2003
3261,I-26,TREATMENT OF LIVER FLUKES,2003
3262,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2003
3263,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2003
3264,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2003
3265,I-30,TREATMENT OF TINEA PEDIS,2003
3266,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2003
3267,I-32,PEDIATRIC MYELOGRAPHY,2003
3268,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2003
3269,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2003
3270,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2003
3271,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2003
3272,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2003
3273,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2003
3274,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2003
3275,I-40,PRIMARY NOCTURNAL ENURESIS,2003
3276,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2003
3277,I-42,HERPES ZOSTER,2003
3278,I-43,HERPES SIMPLEX ENCEPHALITIS,2003
3279,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2003
3280,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2003
3281,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2003
3282,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2003
3283,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2003
3284,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2003
3285,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2003
3286,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2003
3287,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2003
3288,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2003
3289,I-54,RENAL CONCENTRATION CAPACITY TEST,2003
3290,I-55,HYPERTENSION,2003
3291,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2003
3292,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2003
3293,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2003
3294,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2003
3295,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2003
3296,I-61,FEMALE ANDROGENETIC ALOPECIA,2003
3297,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3298,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2003
3299,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2003
3300,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2003
3301,I-66,UNCOMPLICATED GONORRHEA,2003
3302,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2003
3303,I-68,CENTRAL PRECOCIOUS PUBERTY,2003
3304,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2003
3305,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2003
3306,I-71,VARICELLA INFECTIONS (CHICKENPOX),2003
3307,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2003
3308,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2003
3309,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2003
3310,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2003
3311,I-76,PREVENTION OF OSTEOPOROSIS,2003
3312,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2003
3313,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2003
3314,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2003
3315,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2003
3316,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2003
3317,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2003
3318,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2003
3319,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2003
3320,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2003
3321,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2003
3322,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2003
3323,I-88,MANAGEMENT OF ENDOMETRIOSIS,2003
3324,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2003
3325,I-90,INTENSIVE CARE UNIT SEDATION,2003
3326,I-91,MONOTHERAPY USE FOR HYPERTENSION,2003
3327,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2003
3328,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN ACES 4-11 YEARS,2003
3329,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2003
3330,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2003
3331,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2003
3332,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2003
3333,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2003
3334,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2003
3335,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2003
3336,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 1 INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2003
3337,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2003
3338,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2003
3339,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2003
3340,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2003
3341,I-106,TREATMENT OF ACROMEGALY,2003
3342,I-107,VAGINAL CANDIDIASIS,2003
3343,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2003
3344,I-109,TYPHOID FEVER,2003
3345,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2003
3346,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2003
3347,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2003
3348,I-113,TREATMENT OF PROSTATITIS,2003
3349,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2003
3350,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2003
3351,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2003
3352,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2003
3353,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2003
3354,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2003
3355,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2003
3356,I-121,EXPANDED PATIENT POPULATION — USE IN ICU PATIENTS,2003
3357,I-122,PSORIASIS OF THE SCALP,2003
3358,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2003
3359,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2003
3360,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2003
3361,I-126,ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2003
3362,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2003
3363,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL ML; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2003
3364,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2003
3365,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2003
3366,I-131,PERIPHERAL ARTERIOGRAPHY,2003
3367,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2003
3368,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2003
3369,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2003
3370,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2003
3371,I-136,IDIOPATHIC CHRONIC URTICARIA,2003
3372,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2003
3373,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2003
3374,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,2003
3375,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2003
3376,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2003
3377,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2003
3378,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2003
3379,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2003
3380,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2003
3381,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2003
3382,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2003
3383,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2003
3384,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2003
3385,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2003
3386,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2003
3387,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2003
3388,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2003
3389,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2003
3390,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2003
3391,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2003
3392,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2003
3393,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2003
3394,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2003
3395,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2003
3396,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2003
3397,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2003
3398,I-163,TREATMENT OF PHOTOPHOBIA,2003
3399,I-164,CHRONIC BACTERIAL PROSTATITIS,2003
3400,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2003
3401,I-166,TREATMENT OF BULIMIA,2003
3402,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2003
3403,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2003
3404,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2003
3405,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2003
3406,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2003
3407,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2003
3408,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2003
3409,I-174,PELVIC INFLAMMATORY DISEASE,2003
3410,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2003
3411,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2003
3412,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2003
3413,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2003
3414,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2003
3415,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2003
3416,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2003
3417,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2003
3418,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2003
3419,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2003
3420,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2003
3421,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2003
3422,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3423,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2003
3424,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2003
3425,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2003
3426,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2003
3427,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2003
3428,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2003
3429,I-194,CONGESTIVE HEART FAILURE,2003
3430,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2003
3431,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2003
3432,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2003
3433,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2003
3434,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2003
3435,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2003
3436,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2003
3437,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2003
3438,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2003
3439,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE ACES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2003
3440,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2003
3441,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2003
3442,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2003
3443,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2003
3444,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2003
3445,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2003
3446,I-211,FOR USE IN PEDIATRIC POPULATION,2003
3447,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2003
3448,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2003
3449,I-214,TREATMENT OF OSTEOPOROSIS,2003
3450,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2003
3451,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2003
3452,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2003
3453,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2003
3454,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2003
3455,I-220,"TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2003
3456,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2003
3457,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2003
3458,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2003
3459,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2003
3460,I-225,"USE IN PATIENTS WITH PREVIOUS ML AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT ML, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2003
3461,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2003
3462,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2003
3463,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2003
3464,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2003
3465,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2003
3466,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2003
3467,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2003
3468,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2003
3469,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2003
3470,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2003
3471,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2003
3472,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2003
3473,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2003
3474,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2003
3475,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2003
3476,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2003
3477,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2003
3478,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN ACE 5 TO 11 YEARS,2003
3479,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2003
3480,I-245,TREATMENT OF ACUTE SINUSITIS,2003
3481,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2003
3482,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2003
3483,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2003
3484,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2003
3485,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2003
3486,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2003
3487,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2003
3488,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2003
3489,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2003
3490,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2003
3491,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2003
3492,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2003
3493,I-258,FOR PERENNIAL NONALLERCIC RHINITIS FOR ACES 4 AND ABOVE,2003
3494,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2003
3495,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL ACE OF 37 WEEKS OR GREATER),2003
3496,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2003
3497,I-262,TREATMENT OF PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN ACES 4-12,2003
3498,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2003
3499,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2003
3500,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2003
3501,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS ACES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2003
3502,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2003
3503,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF ACE,2003
3504,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2003
3505,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2003
3506,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2003
3507,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2003
3508,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2003
3509,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2003
3510,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2003
3511,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2003
3512,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2003
3513,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2003
3514,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2003
3515,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2003
3516,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2003
3517,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2003
3518,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POSTOPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2003
3519,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2003
3520,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF ACE AND OLDER,2003
3521,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2003
3522,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2003
3523,I-288,CHANCES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2003
3524,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2003
3525,I-290,TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS,2003
3526,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3527,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2003
3528,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2003
3529,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2003
3530,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2003
3531,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2003
3532,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2003
3533,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2003
3534,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2003
3535,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF ACE,2003
3536,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2003
3537,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2003
3538,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2003
3539,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2003
3540,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2003
3541,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOCONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2003
3542,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2003
3543,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2003
3544,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2003
3545,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2003
3546,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2003
3547,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2003
3548,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2003
3549,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2003
3550,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2003
3551,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2003
3552,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2003
3553,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2003
3554,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2003
3555,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2003
3556,I-321,JUVENILE RHEUMATOID ARTHRITIS,2003
3557,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2003
3558,I-323,COLORECTAL CANCER,2003
3559,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2003
3560,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2003
3561,I-326,GENERALIZED ANXIETY DISORDER,2003
3562,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2003
3563,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2003
3564,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2003
3565,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2003
3566,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2003
3567,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2003
3568,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2003
3569,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2003
3570,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2003
3571,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2003
3572,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2003
3573,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2003
3574,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2003
3575,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2003
3576,I-341,BREAST CANCER COMBINATION THERAPY,2003
3577,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2003
3578,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2003
3579,I-344,ACNE VULGARIS,2003
3580,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2003
3581,I-346,TREATMENT OF SYMPTOMATIC CASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2003
3582,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF ACE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2003
3583,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2003
3584,I-349,ACUTE CORONARY SYNDROME,2003
3585,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2003
3586,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2003
3587,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2003
3588,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2003
3589,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2003
3590,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2003
3591,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2003
3592,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2003
3593,I-358,TREATMENT OF PANIC DISORDER,2003
3594,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2003
3595,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN ACES TWO UP TO ACE THREE,2003
3596,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2003
3597,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2003
3598,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2003
3599,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2003
3600,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2003
3601,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2003
3602,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2003
3603,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2003
3604,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2003
3605,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, ACES 8-1 3 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2003
3606,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2003
3607,I-372,NOSOCOMIAL PNEUMONIA,2003
3608,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2003
3609,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2003
3610,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANCLE GLAUCOMA OR OCULAR HYPERTENSION,2003
3611,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2003
3612,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2003
3613,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2003
3614,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2003
3615,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2003
3616,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2003
3617,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2003
3618,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2003
3619,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2003
3620,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2003
3621,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2003
3622,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2003
3623,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2003
3624,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2003
3625,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2003
3626,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2003
3627,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2003
3628,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2003
3629,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2003
3630,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2003
3631,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2003
3632,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2003
3633,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2003
3634,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2003
3635,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2003
3636,M-22,CHANGE IN TIME TO ONSET OF ACTION,2003
3637,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE ANNUAL EDITION SECTION 1.8 WAIVED EXCLUSIVITY,2004
3638,RTO,RX TO OTC SWITCH OR OTC USE,2004
3639,PC,PATENT CHALLENGE,2004
3640,NDF,NEW DOSAGE FORM,2004
3641,ODE,ORPHAN DRUG EXCLUSIVITY,2004
3642,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2004
3643,NP*,NEW PRODUCT (MINT FLAVORED),2004
3644,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2004
3645,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2004
3646,NCE,NEW CHEMICAL ENTITY,2004
3647,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2004
3648,NR,NEW ROUTE,2004
3649,NC,NEW COMBINATION,2004
3650,NPP,NEW PATIENT POPULATION,2004
3651,NP,NEW PRODUCT,2004
3652,PED,PEDIATRIC EXCLUSIVITY,2004
3653,NS,NEW STRENGTH,2004
3654,D-1,ONCE A DAY APPLICATION,2004
3655,D-2,ONCE DAILY DOSING,2004
3656,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2004
3657,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2004
3658,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2004
3659,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2004
3660,D-7,BID DOSING,2004
3661,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2004
3662,D-9,NARCOTIC OVERDOSE IN ADULTS,2004
3663,D-10,NARCOTIC OVERDOSE IN CHILDREN,2004
3664,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2004
3665,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT FOR TREATMENT OF ACTIVE DUODENAL ULCER,2004
3666,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2004
3667,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2004
3668,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2004
3669,D-16,CONTINUOUS INTRAVENOUS INFUSION,2004
3670,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2004
3671,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2004
3672,D-19,BOLUS DOSING GUIDELINES,2004
3673,D-20,SINGLE 32MG DOSE,2004
3674,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2004
3675,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2004
3676,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2004
3677,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 OVER THREE HOURS EVERY THREE WEEKS,2004
3678,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN,2004
3679,D-26,ONCE WEEKLY APPLICATION,2004
3680,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2004
3681,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2004
3682,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2004
3683,D-30,5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS,2004
3684,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2004
3685,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2004
3686,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2004
3687,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2004
3688,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2004
3689,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2004
3690,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2004
3691,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2004
3692,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2004
3693,D-40,ONCE-A-DAY DOSING REGIMEN,2004
3694,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2004
3695,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2004
3696,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2004
3697,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2004
3698,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2004
3699,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2004
3700,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2004
3701,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2004
3702,D-49,PEDIATRIC DOSING GUIDELINES,2004
3703,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2004
3704,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2004
3705,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2004
3706,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2004
3707,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2004
3708,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2004
3709,D-56,ADDITION OF POSTPRANDIAL DOSING,2004
3710,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2004
3711,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2004
3712,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2004
3713,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2004
3714,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3715,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3716,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2004
3717,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2004
3718,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2004
3719,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2004
3720,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2004
3721,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2004
3722,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2004
3723,D-70,80MG ONCE DAILY DOSING REGIMEN,2004
3724,D-71,EIGHT WEEK DOSING REGIMEN,2004
3725,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2004
3726,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3727,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3728,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2004
3729,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2004
3730,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2004
3731,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2004
3732,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2004
3733,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2004
3734,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2004
3735,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3736,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2004
3737,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P AERUGINOSA AND S.AUREUS",2004
3738,I-1,DYSMENORRHEA,2004
3739,I-2,CHOLANGIOPANCREATOGRAPHY,2004
3740,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2004
3741,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2004
3742,I-5,HYSTEROSALPINGOGRAPHY,2004
3743,I-6,TREATMENT OF JUVENILE ARTHRITIS,2004
3744,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2004
3745,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2004
3746,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2004
3747,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2004
3748,I-11,RELIEF OF MILD TO MODERATE PAIN,2004
3749,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2004
3750,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2004
3751,I-14,SEBORRHEIC DERMATITIS,2004
3752,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2004
3753,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2004
3754,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2004
3755,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2004
3756,I-19,HERNIOGRAPHY,2004
3757,I-20,KNEE ARTHROGRAPHY,2004
3758,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2004
3759,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2004
3760,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2004
3761,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2004
3762,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2004
3763,I-26,TREATMENT OF LIVER FLUKES,2004
3764,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2004
3765,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2004
3766,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2004
3767,I-30,TREATMENT OF TINEA PEDIS,2004
3768,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2004
3769,I-32,PEDIATRIC MYELOGRAPHY,2004
3770,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2004
3771,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2004
3772,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2004
3773,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2004
3774,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2004
3775,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2004
3776,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2004
3777,I-40,PRIMARY NOCTURNAL ENURESIS,2004
3778,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2004
3779,I-42,HERPES ZOSTER,2004
3780,I-43,HERPES SIMPLEX ENCEPHALITIS,2004
3781,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2004
3782,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2004
3783,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2004
3784,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2004
3785,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2004
3786,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2004
3787,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2004
3788,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2004
3789,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2004
3790,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2004
3791,I-54,RENAL CONCENTRATION CAPACITY TEST,2004
3792,I-55,HYPERTENSION,2004
3793,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2004
3794,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2004
3795,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2004
3796,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2004
3797,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2004
3798,I-61,FEMALE ANDROGENETIC ALOPECIA,2004
3799,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3800,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2004
3801,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2004
3802,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2004
3803,I-66,UNCOMPLICATED GONORRHEA,2004
3804,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2004
3805,I-68,CENTRAL PRECOCIOUS PUBERTY,2004
3806,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2004
3807,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2004
3808,I-71,VARICELLA INFECTIONS (CHICKENPOX),2004
3809,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2004
3810,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2004
3811,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2004
3812,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2004
3813,I-76,PREVENTION OF OSTEOPOROSIS,2004
3814,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2004
3815,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2004
3816,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2004
3817,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2004
3818,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2004
3819,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2004
3820,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2004
3821,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2004
3822,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2004
3823,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2004
3824,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2004
3825,I-88,MANAGEMENT OF ENDOMETRIOSIS,2004
3826,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2004
3827,I-90,INTENSIVE CARE UNIT SEDATION,2004
3828,I-91,MONOTHERAPY USE FOR HYPERTENSION,2004
3829,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2004
3830,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2004
3831,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2004
3832,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2004
3833,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2004
3834,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2004
3835,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2004
3836,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2004
3837,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2004
3838,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2004
3839,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2004
3840,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2004
3841,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2004
3842,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2004
3843,I-106,TREATMENT OF ACROMEGALY,2004
3844,I-107,VAGINAL CANDIDIASIS,2004
3845,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2004
3846,I-109,TYPHOID FEVER,2004
3847,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2004
3848,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2004
3849,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2004
3850,I-113,TREATMENT OF PROSTATITIS,2004
3851,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2004
3852,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2004
3853,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2004
3854,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2004
3855,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2004
3856,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2004
3857,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2004
3858,I-121,EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS,2004
3859,I-122,PSORIASIS OF THE SCALP,2004
3860,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2004
3861,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2004
3862,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2004
3863,I-126,ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2004
3864,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2004
3865,I-128,IN PT W/CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL ML; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2004
3866,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2004
3867,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2004
3868,I-131,PERIPHERAL ARTERIOGRAPHY,2004
3869,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2004
3870,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2004
3871,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2004
3872,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2004
3873,I-136,IDIOPATHIC CHRONIC URTICARIA,2004
3874,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2004
3875,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2004
3876,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN,2004
3877,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2004
3878,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2004
3879,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2004
3880,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULT,2004
3881,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2004
3882,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2004
3883,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2004
3884,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2004
3885,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2004
3886,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2004
3887,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2004
3888,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2004
3889,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2004
3890,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2004
3891,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2004
3892,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2004
3893,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2004
3894,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2004
3895,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2004
3896,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2004
3897,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2004
3898,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2004
3899,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2004
3900,I-163,TREATMENT OF PHOTOPHOBIA,2004
3901,I-164,CHRONIC BACTERIAL PROSTATITIS,2004
3902,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2004
3903,I-166,TREATMENT OF BULIMIA,2004
3904,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2004
3905,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2004
3906,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2004
3907,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2004
3908,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2004
3909,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2004
3910,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2004
3911,I-174,PELVIC INFLAMMATORY DISEASE,2004
3912,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2004
3913,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2004
3914,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2004
3915,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2004
3916,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2004
3917,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2004
3918,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2004
3919,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2004
3920,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2004
3921,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2004
3922,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2004
3923,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2004
3924,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2004
3925,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2004
3926,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2004
3927,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2004
3928,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2004
3929,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2004
3930,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2004
3931,I-194,CONGESTIVE HEART FAILURE,2004
3932,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2004
3933,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2004
3934,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2004
3935,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2004
3936,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2004
3937,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2004
3938,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2004
3939,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2004
3940,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2004
3941,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2004
3942,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2004
3943,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2004
3944,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2004
3945,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2004
3946,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2004
3947,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2004
3948,I-211,FOR USE IN PEDIATRIC POPULATION,2004
3949,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN’S SYNDROME,2004
3950,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2004
3951,I-214,TREATMENT OF OSTEOPOROSIS,2004
3952,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2004
3953,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2004
3954,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2004
3955,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2004
3956,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2004
3957,I-220,"TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2004
3958,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2004
3959,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2004
3960,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2004
3961,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2004
3962,I-225,"USE IN PATIENTS WITH PREVIOUS ML AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT ML, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2004
3963,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2004
3964,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2004
3965,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2004
3966,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2004
3967,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2004
3968,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2004
3969,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2004
3970,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2004
3971,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2004
3972,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2004
3973,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2004
3974,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2004
3975,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2004
3976,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2004
3977,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2004
3978,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2004
3979,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2004
3980,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2004
3981,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2004
3982,I-245,TREATMENT OF ACUTE SINUSITIS,2004
3983,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2004
3984,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2004
3985,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2004
3986,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2004
3987,I-250,"PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C,AND LDL-C AND BELOW AVERAGE HDL-C",2004
3988,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2004
3989,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2004
3990,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2004
3991,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2004
3992,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2004
3993,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2004
3994,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2004
3995,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2004
3996,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2004
3997,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2004
3998,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2004
3999,I-262,TREATMENT OF PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 412,2004
4000,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2004
4001,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2004
4002,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2004
4003,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2004
4004,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2004
4005,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2004
4006,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2004
4007,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2004
4008,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2004
4009,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2004
4010,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2004
4011,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2004
4012,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2004
4013,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2004
4014,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2004
4015,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2004
4016,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2004
4017,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2004
4018,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2004
4019,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2004
4020,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2004
4021,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2004
4022,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2004
4023,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2004
4024,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2004
4025,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2004
4026,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2004
4027,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2004
4028,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2004
4029,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2004
4030,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2004
4031,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2004
4032,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2004
4033,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2004
4034,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2004
4035,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND I IB HYPERLIPOPROTEINEMIA,2004
4036,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2004
4037,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2004
4038,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2004
4039,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2004
4040,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2004
4041,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2004
4042,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2004
4043,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2004
4044,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2004
4045,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2004
4046,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2004
4047,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2004
4048,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2004
4049,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2004
4050,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2004
4051,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2004
4052,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2004
4053,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2004
4054,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2004
4055,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2004
4056,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2004
4057,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2004
4058,I-321,JUVENILE RHEUMATOID ARTHRITIS,2004
4059,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2004
4060,I-323,COLORECTAL CANCER,2004
4061,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2004
4062,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2004
4063,I-326,GENERALIZED ANXIETY DISORDER,2004
4064,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2004
4065,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2004
4066,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2004
4067,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2004
4068,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2004
4069,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2004
4070,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2004
4071,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2004
4072,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2004
4073,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2004
4074,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2004
4075,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2004
4076,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2004
4077,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2004
4078,I-341,BREAST CANCER COMBINATION THERAPY,2004
4079,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2004
4080,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2004
4081,I-344,ACNE VULGARIS,2004
4082,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2004
4083,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2004
4084,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2004
4085,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2004
4086,I-349,ACUTE CORONARY SYNDROME,2004
4087,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2004
4088,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2004
4089,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2004
4090,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2004
4091,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2004
4092,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2004
4093,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2004
4094,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2004
4095,I-358,TREATMENT OF PANIC DISORDER,2004
4096,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2004
4097,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2004
4098,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2004
4099,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2004
4100,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2004
4101,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2004
4102,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2004
4103,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2004
4104,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES",2004
4105,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2004
4106,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2004
4107,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2004
4108,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2004
4109,I-372,NOSOCOMIAL PNEUMONIA,2004
4110,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2004
4111,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2004
4112,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2004
4113,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2004
4114,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2004
4115,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2004
4116,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2004
4117,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2004
4118,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2004
4119,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2004
4120,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2004
4121,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2004
4122,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2004
4123,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2004
4124,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2004
4125,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2004
4126,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2004
4127,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL ML & STROKE",2004
4128,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2004
4129,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2004
4130,I-393,CHRONIC BACTERIAL PROSTATITIS,2004
4131,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2004
4132,I-395,TO IMPROVE PHYSICAL FUNCTION,2004
4133,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2004
4134,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2004
4135,I-398,IDIOPATHIC SHORT STATURE,2004
4136,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2004
4137,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2004
4138,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2004
4139,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2004
4140,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2004
4141,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2004
4142,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2004
4143,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2004
4144,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2004
4145,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP),2004
4146,I-409,ESOPHAGEAL CANDIDIASIS,2004
4147,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2004
4148,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2004
4149,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2004
4150,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2004
4151,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2004
4152,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2004
4153,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2004
4154,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2004
4155,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2004
4156,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2004
4157,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2004
4158,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2004
4159,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2004
4160,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2004
4161,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2004
4162,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2004
4163,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2004
4164,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2004
4165,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2004
4166,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2004
4167,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2004
4168,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2004
4169,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2004
4170,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2004
4171,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2004
4172,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2004
4173,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2004
4174,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2004
4175,M-22,CHANGE IN TIME TO ONSET OF ACTION,2004
4176,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2004
4177,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2004
4178,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2004
4179,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2004
4180,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2004
4181,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2004
4182,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS PATENT USE,2004
4183,NDF,NEW DOSAGE FORM,2005
4184,NPP,NEW PATIENT POPULATION,2005
4185,NC,NEW COMBINATION,2005
4186,ODE,ORPHAN DRUG EXCLUSIVITY,2005
4187,NS,NEW STRENGTH,2005
4188,PC,PATENT CHALLENGE,2005
4189,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2005
4190,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2005
4191,NCE,NEW CHEMICAL ENTITY,2005
4192,PED,PEDIATRIC EXCLUSIVITY,2005
4193,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2005
4194,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2005
4195,NP,NEW PRODUCT,2005
4196,NP*,NEW PRODUCT (MINT FLAVORED),2005
4197,RTO,RX TO OTC SWITCH OR OTC USE,2005
4198,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2005
4199,NR,NEW ROUTE,2005
4200,D-1,ONCE A DAY APPLICATION,2005
4201,D-2,ONCE DAILY DOSING,2005
4202,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2005
4203,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2005
4204,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2005
4205,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2005
4206,D-7,BID DOSING,2005
4207,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2005
4208,D-9,NARCOTIC OVERDOSE IN ADULTS,2005
4209,D-10,NARCOTIC OVERDOSE IN CHILDREN,2005
4210,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2005
4211,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2005
4212,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2005
4213,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2005
4214,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2005
4215,D-16,CONTINUOUS INTRAVENOUS INFUSION,2005
4216,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2005
4217,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2005
4218,D-19,BOLUS DOSING GUIDELINES,2005
4219,D-20,SINGLE 32MG DOSE,2005
4220,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2005
4221,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2005
4222,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2005
4223,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2005
4224,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2005
4225,D-26,ONCE WEEKLY APPLICATION,2005
4226,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2005
4227,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2005
4228,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2005
4229,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2005
4230,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2005
4231,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2005
4232,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2005
4233,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2005
4234,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2005
4235,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2005
4236,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2005
4237,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2005
4238,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2005
4239,D-40,ONCE-A-DAY DOSING REGIMEN,2005
4240,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2005
4241,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2005
4242,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2005
4243,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2005
4244,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2005
4245,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2005
4246,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2005
4247,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2005
4248,D-49,PEDIATRIC DOSING GUIDELINES,2005
4249,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2005
4250,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2005
4251,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2005
4252,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2005
4253,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2005
4254,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2005
4255,D-56,ADDITION OF POSTPRANDIAL DOSING,2005
4256,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2005
4257,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2005
4258,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2005
4259,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2005
4260,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4261,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4262,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2005
4263,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2005
4264,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2005
4265,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2005
4266,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2005
4267,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2005
4268,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2005
4269,D-70,80MG ONCE DAILY DOSING REGIMEN,2005
4270,D-71,EIGHT WEEK DOSING REGIMEN,2005
4271,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2005
4272,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4273,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4274,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2005
4275,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2005
4276,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2005
4277,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2005
4278,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2005
4279,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2005
4280,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2005
4281,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4282,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2005
4283,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2005
4284,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2005
4285,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2005
4286,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2005
4287,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2005
4288,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2005
4289,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2005
4290,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2005
4291,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2005
4292,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2005
4293,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2005
4294,I-1,DYSMENORRHEA,2005
4295,I-2,CHOLANGIOPANCREATOGRAPHY,2005
4296,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2005
4297,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2005
4298,I-5,HYSTEROSALPINGOGRAPHY,2005
4299,I-6,TREATMENT OF JUVENILE ARTHRITIS,2005
4300,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2005
4301,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2005
4302,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2005
4303,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2005
4304,I-11,RELIEF OF MILD TO MODERATE PAIN,2005
4305,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2005
4306,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2005
4307,I-14,SEBORRHEIC DERMATITIS,2005
4308,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2005
4309,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2005
4310,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2005
4311,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2005
4312,I-19,HERNIOGRAPHY,2005
4313,I-20,KNEE ARTHROGRAPHY,2005
4314,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2005
4315,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2005
4316,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2005
4317,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2005
4318,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2005
4319,I-26,TREATMENT OF LIVER FLUKES,2005
4320,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2005
4321,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2005
4322,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2005
4323,I-30,TREATMENT OF TINEA PEDIS,2005
4324,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2005
4325,I-32,PEDIATRIC MYELOGRAPHY,2005
4326,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2005
4327,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2005
4328,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2005
4329,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2005
4330,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2005
4331,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2005
4332,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2005
4333,I-40,PRIMARY NOCTURNAL ENURESIS,2005
4334,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2005
4335,I-42,HERPES ZOSTER,2005
4336,I-43,HERPES SIMPLEX ENCEPHALITIS,2005
4337,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2005
4338,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2005
4339,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2005
4340,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2005
4341,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2005
4342,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2005
4343,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2005
4344,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2005
4345,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2005
4346,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2005
4347,I-54,RENAL CONCENTRATION CAPACITY TEST,2005
4348,I-55,HYPERTENSION,2005
4349,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2005
4350,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2005
4351,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2005
4352,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2005
4353,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2005
4354,I-61,FEMALE ANDROGENETIC ALOPECIA,2005
4355,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4356,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2005
4357,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2005
4358,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2005
4359,I-66,UNCOMPLICATED GONORRHEA,2005
4360,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2005
4361,I-68,CENTRAL PRECOCIOUS PUBERTY,2005
4362,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2005
4363,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2005
4364,I-71,VARICELLA INFECTIONS (CHICKENPOX),2005
4365,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2005
4366,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2005
4367,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2005
4368,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2005
4369,I-76,PREVENTION OF OSTEOPOROSIS,2005
4370,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2005
4371,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2005
4372,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2005
4373,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2005
4374,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2005
4375,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2005
4376,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2005
4377,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2005
4378,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2005
4379,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2005
4380,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2005
4381,I-88,MANAGEMENT OF ENDOMETRIOSIS,2005
4382,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2005
4383,I-90,INTENSIVE CARE UNIT SEDATION,2005
4384,I-91,MONOTHERAPY USE FOR HYPERTENSION,2005
4385,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2005
4386,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2005
4387,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2005
4388,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2005
4389,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2005
4390,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2005
4391,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2005
4392,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2005
4393,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2005
4394,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2005
4395,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2005
4396,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2005
4397,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2005
4398,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2005
4399,I-106,TREATMENT OF ACROMEGALY,2005
4400,I-107,VAGINAL CANDIDIASIS,2005
4401,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2005
4402,I-109,TYPHOID FEVER,2005
4403,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2005
4404,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2005
4405,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2005
4406,I-113,TREATMENT OF PROSTATITIS,2005
4407,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2005
4408,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2005
4409,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2005
4410,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2005
4411,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2005
4412,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2005
4413,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2005
4414,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2005
4415,I-122,PSORIASIS OF THE SCALP,2005
4416,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2005
4417,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2005
4418,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2005
4419,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2005
4420,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2005
4421,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2005
4422,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2005
4423,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2005
4424,I-131,PERIPHERAL ARTERIOGRAPHY,2005
4425,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2005
4426,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2005
4427,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2005
4428,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2005
4429,I-136,IDIOPATHIC CHRONIC URTICARIA,2005
4430,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2005
4431,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2005
4432,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2005
4433,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2005
4434,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2005
4435,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTIONï¿½,2005
4436,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTSï¿½,2005
4437,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2005
4438,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2005
4439,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2005
4440,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2005
4441,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2005
4442,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2005
4443,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2005
4444,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2005
4445,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2005
4446,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2005
4447,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2005
4448,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2005
4449,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2005
4450,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2005
4451,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2005
4452,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2005
4453,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2005
4454,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2005
4455,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2005
4456,I-163,TREATMENT OF PHOTOPHOBIA,2005
4457,I-164,CHRONIC BACTERIAL PROSTATITIS,2005
4458,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2005
4459,I-166,TREATMENT OF BULIMIA,2005
4460,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2005
4461,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2005
4462,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2005
4463,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2005
4464,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2005
4465,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2005
4466,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2005
4467,I-174,PELVIC INFLAMMATORY DISEASE,2005
4468,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2005
4469,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2005
4470,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2005
4471,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2005
4472,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2005
4473,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2005
4474,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2005
4475,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2005
4476,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2005
4477,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2005
4478,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2005
4479,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2005
4480,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4481,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2005
4482,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2005
4483,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2005
4484,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2005
4485,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2005
4486,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2005
4487,I-194,CONGESTIVE HEART FAILURE,2005
4488,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2005
4489,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2005
4490,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2005
4491,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2005
4492,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2005
4493,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2005
4494,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2005
4495,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2005
4496,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2005
4497,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2005
4498,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2005
4499,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2005
4500,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2005
4501,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2005
4502,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2005
4503,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2005
4504,I-211,FOR USE IN PEDIATRIC POPULATION,2005
4505,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2005
4506,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2005
4507,I-214,TREATMENT OF OSTEOPOROSIS,2005
4508,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2005
4509,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2005
4510,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2005
4511,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2005
4512,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2005
4513,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2005
4514,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2005
4515,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2005
4516,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2005
4517,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2005
4518,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2005
4519,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2005
4520,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2005
4521,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2005
4522,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2005
4523,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2005
4524,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2005
4525,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2005
4526,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2005
4527,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2005
4528,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2005
4529,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2005
4530,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2005
4531,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2005
4532,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2005
4533,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2005
4534,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2005
4535,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2005
4536,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2005
4537,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2005
4538,I-245,TREATMENT OF ACUTE SINUSITIS,2005
4539,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2005
4540,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2005
4541,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2005
4542,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2005
4543,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2005
4544,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2005
4545,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2005
4546,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2005
4547,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2005
4548,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2005
4549,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2005
4550,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2005
4551,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2005
4552,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2005
4553,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2005
4554,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2005
4555,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2005
4556,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2005
4557,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2005
4558,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2005
4559,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2005
4560,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2005
4561,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2005
4562,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2005
4563,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2005
4564,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2005
4565,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2005
4566,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2005
4567,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2005
4568,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2005
4569,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2005
4570,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2005
4571,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2005
4572,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2005
4573,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2005
4574,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2005
4575,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2005
4576,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2005
4577,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2005
4578,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2005
4579,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2005
4580,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2005
4581,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2005
4582,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2005
4583,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2005
4584,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4585,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2005
4586,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2005
4587,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2005
4588,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2005
4589,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2005
4590,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2005
4591,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2005
4592,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2005
4593,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2005
4594,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2005
4595,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2005
4596,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2005
4597,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2005
4598,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2005
4599,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2005
4600,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2005
4601,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2005
4602,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2005
4603,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2005
4604,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2005
4605,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2005
4606,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2005
4607,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2005
4608,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2005
4609,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2005
4610,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2005
4611,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2005
4612,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2005
4613,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2005
4614,I-321,JUVENILE RHEUMATOID ARTHRITIS,2005
4615,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2005
4616,I-323,COLORECTAL CANCER,2005
4617,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2005
4618,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2005
4619,I-326,GENERALIZED ANXIETY DISORDER,2005
4620,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2005
4621,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2005
4622,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2005
4623,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2005
4624,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2005
4625,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2005
4626,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2005
4627,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2005
4628,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2005
4629,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2005
4630,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2005
4631,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2005
4632,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2005
4633,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2005
4634,I-341,BREAST CANCER COMBINATION THERAPY,2005
4635,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2005
4636,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2005
4637,I-344,ACNE VULGARIS,2005
4638,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2005
4639,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2005
4640,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2005
4641,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2005
4642,I-349,ACUTE CORONARY SYNDROME,2005
4643,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2005
4644,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2005
4645,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2005
4646,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2005
4647,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2005
4648,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2005
4649,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2005
4650,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2005
4651,I-358,TREATMENT OF PANIC DISORDER,2005
4652,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2005
4653,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2005
4654,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2005
4655,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2005
4656,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2005
4657,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2005
4658,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2005
4659,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2005
4660,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2005
4661,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2005
4662,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2005
4663,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2005
4664,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2005
4665,I-372,NOSOCOMIAL PNEUMONIA,2005
4666,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2005
4667,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2005
4668,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2005
4669,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2005
4670,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2005
4671,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2005
4672,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2005
4673,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2005
4674,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2005
4675,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2005
4676,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2005
4677,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2005
4678,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2005
4679,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2005
4680,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2005
4681,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2005
4682,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2005
4683,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2005
4684,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2005
4685,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2005
4686,I-393,CHRONIC BACTERIAL PROSTATITIS,2005
4687,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2005
4688,I-395,TO IMPROVE PHYSICAL FUNCTION,2005
4689,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2005
4690,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2005
4691,I-398,IDIOPATHIC SHORT STATURE,2005
4692,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2005
4693,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2005
4694,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2005
4695,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2005
4696,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2005
4697,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2005
4698,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2005
4699,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2005
4700,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2005
4701,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2005
4702,I-409,ESOPHAGEAL CANDIDIASIS,2005
4703,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2005
4704,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2005
4705,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2005
4706,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2005
4707,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2005
4708,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2005
4709,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2005
4710,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2005
4711,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2005
4712,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2005
4713,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2005
4714,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2005
4715,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2005
4716,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2005
4717,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2005
4718,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2005
4719,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2005
4720,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2005
4721,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2005
4722,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2005
4723,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2005
4724,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2005
4725,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2005
4726,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2005
4727,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2005
4728,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2005
4729,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2005
4730,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2005
4731,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2005
4732,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2005
4733,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2005
4734,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2005
4735,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2005
4736,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2005
4737,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2005
4738,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2005
4739,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2005
4740,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2005
4741,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2005
4742,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2005
4743,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2005
4744,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2005
4745,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2005
4746,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2005
4747,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2005
4748,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2005
4749,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2005
4750,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2005
4751,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2005
4752,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2005
4753,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2005
4754,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2005
4755,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2005
4756,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2005
4757,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2005
4758,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2005
4759,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2005
4760,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2005
4761,M-22,CHANGE IN TIME TO ONSET OF ACTION,2005
4762,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2005
4763,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2005
4764,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2005
4765,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2005
4766,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2005
4767,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2005
4768,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2005
4769,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2005
4770,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2005
4771,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2005
4772,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2005
4773,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2005
4774,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2005
4775,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2005
4776,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2005
4777,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2005
4778,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2005
4779,NCE,NEW CHEMICAL ENTITY,2006
4780,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2006
4781,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2006
4782,ODE,ORPHAN DRUG EXCLUSIVITY,2006
4783,NPP,NEW PATIENT POPULATION,2006
4784,NS,NEW STRENGTH,2006
4785,NDF,NEW DOSAGE FORM,2006
4786,NP,NEW PRODUCT,2006
4787,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2006
4788,NP*,NEW PRODUCT (MINT FLAVORED),2006
4789,PED,PEDIATRIC EXCLUSIVITY,2006
4790,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2006
4791,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2006
4792,NC,NEW COMBINATION,2006
4793,RTO,RX TO OTC SWITCH OR OTC USE,2006
4794,NR,NEW ROUTE,2006
4795,PC,PATENT CHALLENGE,2006
4796,D-1,ONCE A DAY APPLICATION,2006
4797,D-2,ONCE DAILY DOSING,2006
4798,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2006
4799,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2006
4800,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2006
4801,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2006
4802,D-7,BID DOSING,2006
4803,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2006
4804,D-9,NARCOTIC OVERDOSE IN ADULTS,2006
4805,D-10,NARCOTIC OVERDOSE IN CHILDREN,2006
4806,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2006
4807,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2006
4808,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2006
4809,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2006
4810,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2006
4811,D-16,CONTINUOUS INTRAVENOUS INFUSION,2006
4812,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2006
4813,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2006
4814,D-19,BOLUS DOSING GUIDELINES,2006
4815,D-20,SINGLE 32MG DOSE,2006
4816,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2006
4817,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2006
4818,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2006
4819,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2006
4820,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2006
4821,D-26,ONCE WEEKLY APPLICATION,2006
4822,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2006
4823,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2006
4824,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2006
4825,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2006
4826,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2006
4827,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2006
4828,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2006
4829,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2006
4830,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2006
4831,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2006
4832,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2006
4833,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2006
4834,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2006
4835,D-40,ONCE-A-DAY DOSING REGIMEN,2006
4836,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2006
4837,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2006
4838,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2006
4839,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2006
4840,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2006
4841,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2006
4842,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2006
4843,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2006
4844,D-49,PEDIATRIC DOSING GUIDELINES,2006
4845,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2006
4846,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2006
4847,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2006
4848,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2006
4849,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2006
4850,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2006
4851,D-56,ADDITION OF POSTPRANDIAL DOSING,2006
4852,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2006
4853,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2006
4854,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2006
4855,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2006
4856,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4857,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4858,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2006
4859,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2006
4860,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2006
4861,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2006
4862,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2006
4863,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2006
4864,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2006
4865,D-70,80MG ONCE DAILY DOSING REGIMEN,2006
4866,D-71,EIGHT WEEK DOSING REGIMEN,2006
4867,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2006
4868,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4869,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4870,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2006
4871,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2006
4872,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2006
4873,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2006
4874,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2006
4875,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2006
4876,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2006
4877,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4878,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2006
4879,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2006
4880,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2006
4881,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2006
4882,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2006
4883,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2006
4884,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2006
4885,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2006
4886,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2006
4887,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2006
4888,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2006
4889,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2006
4890,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2006
4891,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2006
4892,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2006
4893,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2006
4894,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2006
4895,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2006
4896,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2006
4897,I-1,DYSMENORRHEA,2006
4898,I-2,CHOLANGIOPANCREATOGRAPHY,2006
4899,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2006
4900,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2006
4901,I-5,HYSTEROSALPINGOGRAPHY,2006
4902,I-6,TREATMENT OF JUVENILE ARTHRITIS,2006
4903,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2006
4904,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2006
4905,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2006
4906,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2006
4907,I-11,RELIEF OF MILD TO MODERATE PAIN,2006
4908,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2006
4909,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2006
4910,I-14,SEBORRHEIC DERMATITIS,2006
4911,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2006
4912,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2006
4913,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2006
4914,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2006
4915,I-19,HERNIOGRAPHY,2006
4916,I-20,KNEE ARTHROGRAPHY,2006
4917,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2006
4918,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2006
4919,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2006
4920,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2006
4921,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2006
4922,I-26,TREATMENT OF LIVER FLUKES,2006
4923,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2006
4924,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2006
4925,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2006
4926,I-30,TREATMENT OF TINEA PEDIS,2006
4927,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2006
4928,I-32,PEDIATRIC MYELOGRAPHY,2006
4929,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2006
4930,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2006
4931,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2006
4932,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2006
4933,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2006
4934,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2006
4935,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2006
4936,I-40,PRIMARY NOCTURNAL ENURESIS,2006
4937,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2006
4938,I-42,HERPES ZOSTER,2006
4939,I-43,HERPES SIMPLEX ENCEPHALITIS,2006
4940,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2006
4941,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2006
4942,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2006
4943,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2006
4944,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2006
4945,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2006
4946,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2006
4947,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2006
4948,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2006
4949,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2006
4950,I-54,RENAL CONCENTRATION CAPACITY TEST,2006
4951,I-55,HYPERTENSION,2006
4952,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2006
4953,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2006
4954,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2006
4955,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2006
4956,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2006
4957,I-61,FEMALE ANDROGENETIC ALOPECIA,2006
4958,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4959,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2006
4960,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2006
4961,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2006
4962,I-66,UNCOMPLICATED GONORRHEA,2006
4963,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2006
4964,I-68,CENTRAL PRECOCIOUS PUBERTY,2006
4965,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2006
4966,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2006
4967,I-71,VARICELLA INFECTIONS (CHICKENPOX),2006
4968,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2006
4969,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2006
4970,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2006
4971,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2006
4972,I-76,PREVENTION OF OSTEOPOROSIS,2006
4973,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2006
4974,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2006
4975,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2006
4976,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2006
4977,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2006
4978,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2006
4979,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2006
4980,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2006
4981,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2006
4982,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2006
4983,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2006
4984,I-88,MANAGEMENT OF ENDOMETRIOSIS,2006
4985,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2006
4986,I-90,INTENSIVE CARE UNIT SEDATION,2006
4987,I-91,MONOTHERAPY USE FOR HYPERTENSION,2006
4988,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2006
4989,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2006
4990,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2006
4991,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2006
4992,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2006
4993,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2006
4994,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2006
4995,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2006
4996,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2006
4997,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2006
4998,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2006
4999,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2006
5000,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2006
5001,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2006
5002,I-106,TREATMENT OF ACROMEGALY,2006
5003,I-107,VAGINAL CANDIDIASIS,2006
5004,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2006
5005,I-109,TYPHOID FEVER,2006
5006,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2006
5007,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2006
5008,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2006
5009,I-113,TREATMENT OF PROSTATITIS,2006
5010,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2006
5011,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2006
5012,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2006
5013,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2006
5014,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2006
5015,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2006
5016,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2006
5017,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2006
5018,I-122,PSORIASIS OF THE SCALP,2006
5019,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2006
5020,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2006
5021,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2006
5022,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2006
5023,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2006
5024,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2006
5025,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2006
5026,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2006
5027,I-131,PERIPHERAL ARTERIOGRAPHY,2006
5028,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2006
5029,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2006
5030,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2006
5031,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2006
5032,I-136,IDIOPATHIC CHRONIC URTICARIA,2006
5033,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2006
5034,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2006
5035,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2006
5036,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2006
5037,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2006
5038,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTIONï¿½,2006
5039,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTSï¿½,2006
5040,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2006
5041,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2006
5042,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2006
5043,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2006
5044,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2006
5045,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2006
5046,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2006
5047,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2006
5048,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2006
5049,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2006
5050,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2006
5051,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2006
5052,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2006
5053,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2006
5054,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2006
5055,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2006
5056,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2006
5057,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2006
5058,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2006
5059,I-163,TREATMENT OF PHOTOPHOBIA,2006
5060,I-164,CHRONIC BACTERIAL PROSTATITIS,2006
5061,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2006
5062,I-166,TREATMENT OF BULIMIA,2006
5063,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2006
5064,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2006
5065,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2006
5066,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2006
5067,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2006
5068,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2006
5069,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2006
5070,I-174,PELVIC INFLAMMATORY DISEASE,2006
5071,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2006
5072,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2006
5073,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2006
5074,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2006
5075,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2006
5076,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2006
5077,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2006
5078,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2006
5079,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2006
5080,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2006
5081,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2006
5082,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2006
5083,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2006
5084,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2006
5085,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2006
5086,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2006
5087,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2006
5088,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2006
5089,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2006
5090,I-194,CONGESTIVE HEART FAILURE,2006
5091,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2006
5092,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2006
5093,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2006
5094,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2006
5095,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2006
5096,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2006
5097,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2006
5098,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2006
5099,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2006
5100,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2006
5101,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2006
5102,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2006
5103,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2006
5104,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2006
5105,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2006
5106,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2006
5107,I-211,FOR USE IN PEDIATRIC POPULATION,2006
5108,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2006
5109,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2006
5110,I-214,TREATMENT OF OSTEOPOROSIS,2006
5111,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2006
5112,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2006
5113,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2006
5114,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2006
5115,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2006
5116,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2006
5117,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2006
5118,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2006
5119,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2006
5120,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2006
5121,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2006
5122,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2006
5123,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2006
5124,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2006
5125,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2006
5126,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2006
5127,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2006
5128,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2006
5129,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2006
5130,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2006
5131,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2006
5132,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2006
5133,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2006
5134,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2006
5135,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2006
5136,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2006
5137,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2006
5138,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2006
5139,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2006
5140,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2006
5141,I-245,TREATMENT OF ACUTE SINUSITIS,2006
5142,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2006
5143,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2006
5144,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2006
5145,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2006
5146,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2006
5147,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2006
5148,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2006
5149,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2006
5150,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2006
5151,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2006
5152,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2006
5153,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2006
5154,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2006
5155,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2006
5156,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2006
5157,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2006
5158,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2006
5159,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2006
5160,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2006
5161,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2006
5162,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2006
5163,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2006
5164,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2006
5165,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2006
5166,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2006
5167,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2006
5168,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2006
5169,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2006
5170,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2006
5171,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2006
5172,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2006
5173,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2006
5174,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2006
5175,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2006
5176,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2006
5177,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2006
5178,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2006
5179,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2006
5180,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2006
5181,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2006
5182,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2006
5183,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2006
5184,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2006
5185,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2006
5186,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2006
5187,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
5188,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2006
5189,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2006
5190,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2006
5191,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2006
5192,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2006
5193,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2006
5194,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2006
5195,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2006
5196,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2006
5197,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2006
5198,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2006
5199,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2006
5200,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2006
5201,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2006
5202,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2006
5203,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2006
5204,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2006
5205,I-309,INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2006
5206,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2006
5207,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2006
5208,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2006
5209,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2006
5210,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2006
5211,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2006
5212,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2006
5213,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2006
5214,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2006
5215,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2006
5216,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2006
5217,I-321,JUVENILE RHEUMATOID ARTHRITIS,2006
5218,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2006
5219,I-323,COLORECTAL CANCER,2006
5220,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2006
5221,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2006
5222,I-326,GENERALIZED ANXIETY DISORDER,2006
5223,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2006
5224,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2006
5225,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2006
5226,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2006
5227,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2006
5228,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2006
5229,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2006
5230,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2006
5231,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2006
5232,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2006
5233,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2006
5234,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2006
5235,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2006
5236,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2006
5237,I-341,BREAST CANCER COMBINATION THERAPY,2006
5238,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2006
5239,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2006
5240,I-344,ACNE VULGARIS,2006
5241,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2006
5242,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2006
5243,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2006
5244,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2006
5245,I-349,ACUTE CORONARY SYNDROME,2006
5246,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2006
5247,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2006
5248,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2006
5249,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2006
5250,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2006
5251,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2006
5252,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2006
5253,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2006
5254,I-358,TREATMENT OF PANIC DISORDER,2006
5255,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2006
5256,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2006
5257,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2006
5258,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2006
5259,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2006
5260,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2006
5261,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2006
5262,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2006
5263,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2006
5264,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2006
5265,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2006
5266,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2006
5267,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2006
5268,I-372,NOSOCOMIAL PNEUMONIA,2006
5269,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2006
5270,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2006
5271,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2006
5272,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2006
5273,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2006
5274,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2006
5275,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2006
5276,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2006
5277,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2006
5278,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2006
5279,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2006
5280,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2006
5281,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2006
5282,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2006
5283,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2006
5284,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2006
5285,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2006
5286,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2006
5287,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2006
5288,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2006
5289,I-393,CHRONIC BACTERIAL PROSTATITIS,2006
5290,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2006
5291,I-395,TO IMPROVE PHYSICAL FUNCTION,2006
5292,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2006
5293,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2006
5294,I-398,IDIOPATHIC SHORT STATURE,2006
5295,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2006
5296,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2006
5297,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2006
5298,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2006
5299,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2006
5300,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2006
5301,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2006
5302,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2006
5303,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2006
5304,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2006
5305,I-409,ESOPHAGEAL CANDIDIASIS,2006
5306,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2006
5307,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2006
5308,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2006
5309,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2006
5310,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2006
5311,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2006
5312,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2006
5313,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2006
5314,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2006
5315,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2006
5316,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2006
5317,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2006
5318,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2006
5319,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2006
5320,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2006
5321,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2006
5322,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2006
5323,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2006
5324,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2006
5325,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2006
5326,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2006
5327,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2006
5328,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2006
5329,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2006
5330,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2006
5331,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2006
5332,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2006
5333,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2006
5334,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2006
5335,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2006
5336,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2006
5337,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2006
5338,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2006
5339,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2006
5340,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2006
5341,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2006
5342,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2006
5343,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2006
5344,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2006
5345,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2006
5346,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2006
5347,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2006
5348,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2006
5349,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2006
5350,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2006
5351,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2006
5352,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2006
5353,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2006
5354,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2006
5355,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2006
5356,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2006
5357,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2006
5358,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2006
5359,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2006
5360,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2006
5361,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2006
5362,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2006
5363,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2006
5364,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2006
5365,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRISTIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2006
5366,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2006
5367,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2006
5368,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2006
5369,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2006
5370,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2006
5371,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2006
5372,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2006
5373,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2006
5374,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2006
5375,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2006
5376,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2006
5377,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2006
5378,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2006
5379,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
5380,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2006
5381,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2006
5382,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2006
5383,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2006
5384,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2006
5385,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2006
5386,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2006
5387,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2006
5388,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2006
5389,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2006
5390,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2006
5391,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2006
5392,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2006
5393,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2006
5394,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2006
5395,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2006
5396,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2006
5397,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2006
5398,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2006
5399,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2006
5400,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2006
5401,M-22,CHANGE IN TIME TO ONSET OF ACTION,2006
5402,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2006
5403,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2006
5404,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2006
5405,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2006
5406,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2006
5407,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2006
5408,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2006
5409,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2006
5410,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2006
5411,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2006
5412,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2006
5413,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2006
5414,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2006
5415,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2006
5416,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2006
5417,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2006
5418,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2006
5419,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2006
5420,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2006
5421,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2006
5422,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2006
5423,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2006
5424,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2006
5425,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2006
5426,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2006
5427,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2006
5428,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2006
5429,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2006
5430,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2006
5431,NPP,NEW PATIENT POPULATION,2007
5432,NS,NEW STRENGTH,2007
5433,PC,PATENT CHALLENGE,2007
5434,NP*,NEW PRODUCT (MINT FLAVORED),2007
5435,NC,NEW COMBINATION,2007
5436,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2007
5437,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2007
5438,NP,NEW PRODUCT,2007
5439,NDF,NEW DOSAGE FORM,2007
5440,ODE,ORPHAN DRUG EXCLUSIVITY,2007
5441,PED,PEDIATRIC EXCLUSIVITY,2007
5442,NCE,NEW CHEMICAL ENTITY,2007
5443,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2007
5444,RTO,RX TO OTC SWITCH OR OTC USE,2007
5445,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2007
5446,NR,NEW ROUTE,2007
5447,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2007
5448,D-1,ONCE A DAY APPLICATION,2007
5449,D-2,ONCE DAILY DOSING,2007
5450,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2007
5451,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2007
5452,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2007
5453,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2007
5454,D-7,BID DOSING,2007
5455,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2007
5456,D-9,NARCOTIC OVERDOSE IN ADULTS,2007
5457,D-10,NARCOTIC OVERDOSE IN CHILDREN,2007
5458,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2007
5459,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2007
5460,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2007
5461,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2007
5462,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2007
5463,D-16,CONTINUOUS INTRAVENOUS INFUSION,2007
5464,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2007
5465,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2007
5466,D-19,BOLUS DOSING GUIDELINES,2007
5467,D-20,SINGLE 32MG DOSE,2007
5468,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2007
5469,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2007
5470,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2007
5471,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2007
5472,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2007
5473,D-26,ONCE WEEKLY APPLICATION,2007
5474,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2007
5475,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2007
5476,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2007
5477,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2007
5478,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2007
5479,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2007
5480,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2007
5481,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2007
5482,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2007
5483,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2007
5484,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2007
5485,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2007
5486,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2007
5487,D-40,ONCE-A-DAY DOSING REGIMEN,2007
5488,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2007
5489,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2007
5490,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2007
5491,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2007
5492,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2007
5493,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2007
5494,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2007
5495,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2007
5496,D-49,PEDIATRIC DOSING GUIDELINES,2007
5497,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2007
5498,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2007
5499,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2007
5500,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2007
5501,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2007
5502,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2007
5503,D-56,ADDITION OF POSTPRANDIAL DOSING,2007
5504,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2007
5505,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2007
5506,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2007
5507,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2007
5508,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5509,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5510,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2007
5511,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2007
5512,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2007
5513,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2007
5514,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2007
5515,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2007
5516,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2007
5517,D-70,80MG ONCE DAILY DOSING REGIMEN,2007
5518,D-71,EIGHT WEEK DOSING REGIMEN,2007
5519,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2007
5520,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5521,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5522,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2007
5523,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2007
5524,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2007
5525,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2007
5526,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2007
5527,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2007
5528,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2007
5529,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5530,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2007
5531,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2007
5532,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2007
5533,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2007
5534,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2007
5535,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2007
5536,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2007
5537,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2007
5538,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2007
5539,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2007
5540,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2007
5541,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2007
5542,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2007
5543,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2007
5544,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2007
5545,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2007
5546,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2007
5547,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2007
5548,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2007
5549,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2007
5550,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2007
5551,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2007
5552,I-1,DYSMENORRHEA,2007
5553,I-2,CHOLANGIOPANCREATOGRAPHY,2007
5554,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2007
5555,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2007
5556,I-5,HYSTEROSALPINGOGRAPHY,2007
5557,I-6,TREATMENT OF JUVENILE ARTHRITIS,2007
5558,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2007
5559,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2007
5560,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2007
5561,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2007
5562,I-11,RELIEF OF MILD TO MODERATE PAIN,2007
5563,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2007
5564,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2007
5565,I-14,SEBORRHEIC DERMATITIS,2007
5566,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2007
5567,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2007
5568,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2007
5569,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2007
5570,I-19,HERNIOGRAPHY,2007
5571,I-20,KNEE ARTHROGRAPHY,2007
5572,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2007
5573,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2007
5574,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2007
5575,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2007
5576,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2007
5577,I-26,TREATMENT OF LIVER FLUKES,2007
5578,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2007
5579,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2007
5580,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2007
5581,I-30,TREATMENT OF TINEA PEDIS,2007
5582,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2007
5583,I-32,PEDIATRIC MYELOGRAPHY,2007
5584,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2007
5585,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2007
5586,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2007
5587,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2007
5588,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2007
5589,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2007
5590,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2007
5591,I-40,PRIMARY NOCTURNAL ENURESIS,2007
5592,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2007
5593,I-42,HERPES ZOSTER,2007
5594,I-43,HERPES SIMPLEX ENCEPHALITIS,2007
5595,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2007
5596,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2007
5597,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2007
5598,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2007
5599,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2007
5600,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2007
5601,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2007
5602,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2007
5603,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2007
5604,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2007
5605,I-54,RENAL CONCENTRATION CAPACITY TEST,2007
5606,I-55,HYPERTENSION,2007
5607,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2007
5608,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2007
5609,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2007
5610,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2007
5611,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2007
5612,I-61,FEMALE ANDROGENETIC ALOPECIA,2007
5613,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5614,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2007
5615,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2007
5616,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2007
5617,I-66,UNCOMPLICATED GONORRHEA,2007
5618,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2007
5619,I-68,CENTRAL PRECOCIOUS PUBERTY,2007
5620,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2007
5621,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2007
5622,I-71,VARICELLA INFECTIONS (CHICKENPOX),2007
5623,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2007
5624,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2007
5625,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2007
5626,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2007
5627,I-76,PREVENTION OF OSTEOPOROSIS,2007
5628,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2007
5629,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2007
5630,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2007
5631,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2007
5632,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2007
5633,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2007
5634,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2007
5635,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2007
5636,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2007
5637,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2007
5638,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2007
5639,I-88,MANAGEMENT OF ENDOMETRIOSIS,2007
5640,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2007
5641,I-90,INTENSIVE CARE UNIT SEDATION,2007
5642,I-91,MONOTHERAPY USE FOR HYPERTENSION,2007
5643,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2007
5644,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2007
5645,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2007
5646,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2007
5647,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2007
5648,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2007
5649,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2007
5650,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2007
5651,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2007
5652,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2007
5653,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2007
5654,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2007
5655,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2007
5656,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2007
5657,I-106,TREATMENT OF ACROMEGALY,2007
5658,I-107,VAGINAL CANDIDIASIS,2007
5659,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2007
5660,I-109,TYPHOID FEVER,2007
5661,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2007
5662,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2007
5663,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2007
5664,I-113,TREATMENT OF PROSTATITIS,2007
5665,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2007
5666,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2007
5667,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2007
5668,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2007
5669,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2007
5670,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2007
5671,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2007
5672,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2007
5673,I-122,PSORIASIS OF THE SCALP,2007
5674,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2007
5675,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2007
5676,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2007
5677,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2007
5678,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2007
5679,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2007
5680,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2007
5681,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2007
5682,I-131,PERIPHERAL ARTERIOGRAPHY,2007
5683,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2007
5684,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2007
5685,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2007
5686,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2007
5687,I-136,IDIOPATHIC CHRONIC URTICARIA,2007
5688,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2007
5689,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2007
5690,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2007
5691,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2007
5692,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2007
5693,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTIONï¿½,2007
5694,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTSï¿½,2007
5695,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2007
5696,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2007
5697,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2007
5698,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2007
5699,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2007
5700,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2007
5701,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2007
5702,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2007
5703,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2007
5704,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2007
5705,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2007
5706,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2007
5707,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2007
5708,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2007
5709,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2007
5710,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2007
5711,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2007
5712,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2007
5713,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2007
5714,I-163,TREATMENT OF PHOTOPHOBIA,2007
5715,I-164,CHRONIC BACTERIAL PROSTATITIS,2007
5716,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2007
5717,I-166,TREATMENT OF BULIMIA,2007
5718,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2007
5719,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2007
5720,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2007
5721,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2007
5722,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2007
5723,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2007
5724,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2007
5725,I-174,PELVIC INFLAMMATORY DISEASE,2007
5726,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2007
5727,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2007
5728,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2007
5729,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2007
5730,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2007
5731,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2007
5732,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2007
5733,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2007
5734,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2007
5735,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2007
5736,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5737,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2007
5738,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5739,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2007
5740,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2007
5741,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2007
5742,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2007
5743,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2007
5744,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2007
5745,I-194,CONGESTIVE HEART FAILURE,2007
5746,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2007
5747,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2007
5748,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2007
5749,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2007
5750,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2007
5751,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2007
5752,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2007
5753,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2007
5754,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2007
5755,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2007
5756,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2007
5757,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2007
5758,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2007
5759,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2007
5760,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2007
5761,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2007
5762,I-211,FOR USE IN PEDIATRIC POPULATION,2007
5763,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2007
5764,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2007
5765,I-214,TREATMENT OF OSTEOPOROSIS,2007
5766,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2007
5767,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2007
5768,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2007
5769,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2007
5770,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2007
5771,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2007
5772,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2007
5773,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2007
5774,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2007
5775,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2007
5776,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2007
5777,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2007
5778,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2007
5779,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2007
5780,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2007
5781,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2007
5782,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2007
5783,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2007
5784,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2007
5785,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2007
5786,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2007
5787,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2007
5788,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2007
5789,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2007
5790,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2007
5791,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2007
5792,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2007
5793,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2007
5794,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2007
5795,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2007
5796,I-245,TREATMENT OF ACUTE SINUSITIS,2007
5797,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2007
5798,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2007
5799,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2007
5800,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2007
5801,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2007
5802,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2007
5803,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2007
5804,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2007
5805,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2007
5806,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2007
5807,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2007
5808,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2007
5809,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2007
5810,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2007
5811,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2007
5812,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2007
5813,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2007
5814,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2007
5815,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2007
5816,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2007
5817,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2007
5818,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2007
5819,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2007
5820,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2007
5821,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2007
5822,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5823,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2007
5824,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2007
5825,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2007
5826,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2007
5827,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2007
5828,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2007
5829,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2007
5830,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2007
5831,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2007
5832,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2007
5833,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2007
5834,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2007
5835,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2007
5836,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2007
5837,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2007
5838,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2007
5839,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2007
5840,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2007
5841,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2007
5842,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5843,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5844,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2007
5845,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2007
5846,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2007
5847,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2007
5848,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2007
5849,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2007
5850,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2007
5851,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2007
5852,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2007
5853,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2007
5854,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2007
5855,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2007
5856,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2007
5857,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2007
5858,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2007
5859,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2007
5860,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2007
5861,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2007
5862,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2007
5863,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2007
5864,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2007
5865,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2007
5866,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2007
5867,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2007
5868,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2007
5869,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2007
5870,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2007
5871,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2007
5872,I-321,JUVENILE RHEUMATOID ARTHRITIS,2007
5873,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2007
5874,I-323,COLORECTAL CANCER,2007
5875,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2007
5876,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2007
5877,I-326,GENERALIZED ANXIETY DISORDER,2007
5878,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2007
5879,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2007
5880,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2007
5881,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2007
5882,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2007
5883,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2007
5884,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2007
5885,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2007
5886,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME,2007
5887,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2007
5888,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2007
5889,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2007
5890,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2007
5891,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2007
5892,I-341,BREAST CANCER COMBINATION THERAPY,2007
5893,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2007
5894,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2007
5895,I-344,ACNE VULGARIS,2007
5896,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2007
5897,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2007
5898,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2007
5899,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2007
5900,I-349,ACUTE CORONARY SYNDROME,2007
5901,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2007
5902,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2007
5903,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2007
5904,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2007
5905,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2007
5906,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2007
5907,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2007
5908,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2007
5909,I-358,TREATMENT OF PANIC DISORDER,2007
5910,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2007
5911,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2007
5912,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2007
5913,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2007
5914,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2007
5915,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2007
5916,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2007
5917,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2007
5918,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2007
5919,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2007
5920,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2007
5921,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2007
5922,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2007
5923,I-372,NOSOCOMIAL PNEUMONIA,2007
5924,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2007
5925,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2007
5926,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2007
5927,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2007
5928,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2007
5929,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2007
5930,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2007
5931,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2007
5932,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2007
5933,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2007
5934,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2007
5935,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2007
5936,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2007
5937,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2007
5938,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2007
5939,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2007
5940,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2007
5941,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2007
5942,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2007
5943,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2007
5944,I-393,CHRONIC BACTERIAL PROSTATITIS,2007
5945,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2007
5946,I-395,TO IMPROVE PHYSICAL FUNCTION,2007
5947,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2007
5948,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2007
5949,I-398,IDIOPATHIC SHORT STATURE,2007
5950,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2007
5951,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2007
5952,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2007
5953,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2007
5954,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2007
5955,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2007
5956,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2007
5957,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2007
5958,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2007
5959,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2007
5960,I-409,ESOPHAGEAL CANDIDIASIS,2007
5961,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2007
5962,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2007
5963,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2007
5964,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2007
5965,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2007
5966,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2007
5967,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2007
5968,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2007
5969,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2007
5970,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2007
5971,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2007
5972,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2007
5973,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2007
5974,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2007
5975,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2007
5976,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2007
5977,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2007
5978,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2007
5979,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2007
5980,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2007
5981,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2007
5982,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2007
5983,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2007
5984,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2007
5985,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2007
5986,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2007
5987,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2007
5988,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2007
5989,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2007
5990,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2007
5991,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2007
5992,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2007
5993,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2007
5994,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2007
5995,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2007
5996,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2007
5997,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2007
5998,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2007
5999,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2007
6000,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2007
6001,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2007
6002,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2007
6003,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2007
6004,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2007
6005,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2007
6006,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2007
6007,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2007
6008,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2007
6009,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2007
6010,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2007
6011,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2007
6012,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2007
6013,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2007
6014,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2007
6015,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2007
6016,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2007
6017,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2007
6018,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2007
6019,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2007
6020,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2007
6021,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2007
6022,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2007
6023,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2007
6024,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2007
6025,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2007
6026,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2007
6027,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2007
6028,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2007
6029,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2007
6030,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2007
6031,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2007
6032,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2007
6033,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2007
6034,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
6035,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2007
6036,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2007
6037,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2007
6038,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2007
6039,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2007
6040,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2007
6041,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2007
6042,I-491,INFLUENZA PROPHYLAXIS,2007
6043,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2007
6044,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2007
6045,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2007
6046,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2007
6047,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2007
6048,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2007
6049,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2007
6050,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM BASED THERAPY,2007
6051,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2007
6052,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2007
6053,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2007
6054,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2007
6055,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2007
6056,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2007
6057,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2007
6058,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2007
6059,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2007
6060,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2007
6061,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2007
6062,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2007
6063,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2007
6064,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2007
6065,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2007
6066,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2007
6067,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2007
6068,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2007
6069,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2007
6070,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2007
6071,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2007
6072,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2007
6073,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2007
6074,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2007
6075,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2007
6076,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2007
6077,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2007
6078,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2007
6079,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2007
6080,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2007
6081,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2007
6082,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2007
6083,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2007
6084,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2007
6085,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2007
6086,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2007
6087,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2007
6088,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2007
6089,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2007
6090,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2007
6091,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2007
6092,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2007
6093,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2007
6094,M-22,CHANGE IN TIME TO ONSET OF ACTION,2007
6095,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2007
6096,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2007
6097,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2007
6098,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2007
6099,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2007
6100,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2007
6101,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2007
6102,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2007
6103,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2007
6104,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2007
6105,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2007
6106,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2007
6107,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2007
6108,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2007
6109,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2007
6110,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2007
6111,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2007
6112,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2007
6113,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2007
6114,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2007
6115,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2007
6116,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2007
6117,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2007
6118,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2007
6119,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2007
6120,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2007
6121,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2007
6122,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2007
6123,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2007
6124,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
6125,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2007
6126,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2007
6127,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2007
6128,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2007
6129,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2007
6130,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2007
6131,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2007
6132,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2007
6133,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2008
6134,NC,NEW COMBINATION,2008
6135,NPP,NEW PATIENT POPULATION,2008
6136,PC,PATENT CHALLENGE,2008
6137,NR,NEW ROUTE,2008
6138,NP,NEW PRODUCT,2008
6139,PED,PEDIATRIC EXCLUSIVITY,2008
6140,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2008
6141,RTO,RX TO OTC SWITCH OR OTC USE,2008
6142,NS,NEW STRENGTH,2008
6143,NCE,NEW CHEMICAL ENTITY,2008
6144,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2008
6145,NP*,NEW PRODUCT (MINT FLAVORED),2008
6146,NDF,NEW DOSAGE FORM,2008
6147,ODE,ORPHAN DRUG EXCLUSIVITY,2008
6148,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2008
6149,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2008
6150,D-1,ONCE A DAY APPLICATION,2008
6151,D-2,ONCE DAILY DOSING,2008
6152,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2008
6153,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2008
6154,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2008
6155,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2008
6156,D-7,BID DOSING,2008
6157,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2008
6158,D-9,NARCOTIC OVERDOSE IN ADULTS,2008
6159,D-10,NARCOTIC OVERDOSE IN CHILDREN,2008
6160,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2008
6161,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2008
6162,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2008
6163,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2008
6164,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2008
6165,D-16,CONTINUOUS INTRAVENOUS INFUSION,2008
6166,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2008
6167,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2008
6168,D-19,BOLUS DOSING GUIDELINES,2008
6169,D-20,SINGLE 32MG DOSE,2008
6170,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2008
6171,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2008
6172,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2008
6173,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2008
6174,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2008
6175,D-26,ONCE WEEKLY APPLICATION,2008
6176,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2008
6177,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2008
6178,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2008
6179,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2008
6180,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2008
6181,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2008
6182,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2008
6183,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2008
6184,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2008
6185,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2008
6186,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2008
6187,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2008
6188,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2008
6189,D-40,ONCE-A-DAY DOSING REGIMEN,2008
6190,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2008
6191,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2008
6192,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2008
6193,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2008
6194,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2008
6195,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2008
6196,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2008
6197,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2008
6198,D-49,PEDIATRIC DOSING GUIDELINES,2008
6199,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2008
6200,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2008
6201,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2008
6202,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2008
6203,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2008
6204,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2008
6205,D-56,ADDITION OF POSTPRANDIAL DOSING,2008
6206,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2008
6207,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2008
6208,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2008
6209,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2008
6210,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6211,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6212,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2008
6213,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2008
6214,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2008
6215,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2008
6216,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2008
6217,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2008
6218,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2008
6219,D-70,80MG ONCE DAILY DOSING REGIMEN,2008
6220,D-71,EIGHT WEEK DOSING REGIMEN,2008
6221,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2008
6222,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6223,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6224,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2008
6225,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2008
6226,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2008
6227,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2008
6228,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2008
6229,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2008
6230,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2008
6231,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6232,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2008
6233,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2008
6234,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2008
6235,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2008
6236,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2008
6237,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2008
6238,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2008
6239,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2008
6240,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2008
6241,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2008
6242,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2008
6243,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2008
6244,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2008
6245,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2008
6246,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2008
6247,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2008
6248,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2008
6249,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2008
6250,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2008
6251,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2008
6252,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2008
6253,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2008
6254,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6255,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY ACQUIRED PNEUMONIA",2008
6256,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2008
6257,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2008
6258,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2008
6259,I-1,DYSMENORRHEA,2008
6260,I-2,CHOLANGIOPANCREATOGRAPHY,2008
6261,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2008
6262,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2008
6263,I-5,HYSTEROSALPINGOGRAPHY,2008
6264,I-6,TREATMENT OF JUVENILE ARTHRITIS,2008
6265,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2008
6266,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2008
6267,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2008
6268,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2008
6269,I-11,RELIEF OF MILD TO MODERATE PAIN,2008
6270,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2008
6271,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2008
6272,I-14,SEBORRHEIC DERMATITIS,2008
6273,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2008
6274,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2008
6275,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2008
6276,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2008
6277,I-19,HERNIOGRAPHY,2008
6278,I-20,KNEE ARTHROGRAPHY,2008
6279,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2008
6280,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2008
6281,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2008
6282,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2008
6283,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2008
6284,I-26,TREATMENT OF LIVER FLUKES,2008
6285,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2008
6286,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2008
6287,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2008
6288,I-30,TREATMENT OF TINEA PEDIS,2008
6289,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2008
6290,I-32,PEDIATRIC MYELOGRAPHY,2008
6291,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2008
6292,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2008
6293,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2008
6294,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2008
6295,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2008
6296,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2008
6297,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2008
6298,I-40,PRIMARY NOCTURNAL ENURESIS,2008
6299,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2008
6300,I-42,HERPES ZOSTER,2008
6301,I-43,HERPES SIMPLEX ENCEPHALITIS,2008
6302,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2008
6303,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2008
6304,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2008
6305,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2008
6306,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2008
6307,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2008
6308,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2008
6309,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2008
6310,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2008
6311,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2008
6312,I-54,RENAL CONCENTRATION CAPACITY TEST,2008
6313,I-55,HYPERTENSION,2008
6314,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2008
6315,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2008
6316,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2008
6317,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2008
6318,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2008
6319,I-61,FEMALE ANDROGENETIC ALOPECIA,2008
6320,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6321,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2008
6322,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2008
6323,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2008
6324,I-66,UNCOMPLICATED GONORRHEA,2008
6325,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2008
6326,I-68,CENTRAL PRECOCIOUS PUBERTY,2008
6327,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2008
6328,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2008
6329,I-71,VARICELLA INFECTIONS (CHICKENPOX),2008
6330,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2008
6331,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2008
6332,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2008
6333,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2008
6334,I-76,PREVENTION OF OSTEOPOROSIS,2008
6335,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2008
6336,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2008
6337,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2008
6338,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2008
6339,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2008
6340,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2008
6341,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2008
6342,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2008
6343,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2008
6344,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2008
6345,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2008
6346,I-88,MANAGEMENT OF ENDOMETRIOSIS,2008
6347,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2008
6348,I-90,INTENSIVE CARE UNIT SEDATION,2008
6349,I-91,MONOTHERAPY USE FOR HYPERTENSION,2008
6350,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2008
6351,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2008
6352,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2008
6353,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2008
6354,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2008
6355,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2008
6356,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2008
6357,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2008
6358,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2008
6359,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2008
6360,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2008
6361,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2008
6362,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2008
6363,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2008
6364,I-106,TREATMENT OF ACROMEGALY,2008
6365,I-107,VAGINAL CANDIDIASIS,2008
6366,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2008
6367,I-109,TYPHOID FEVER,2008
6368,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2008
6369,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2008
6370,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2008
6371,I-113,TREATMENT OF PROSTATITIS,2008
6372,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2008
6373,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2008
6374,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2008
6375,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2008
6376,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2008
6377,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2008
6378,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2008
6379,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2008
6380,I-122,PSORIASIS OF THE SCALP,2008
6381,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2008
6382,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2008
6383,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2008
6384,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2008
6385,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2008
6386,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2008
6387,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2008
6388,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2008
6389,I-131,PERIPHERAL ARTERIOGRAPHY,2008
6390,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2008
6391,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2008
6392,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2008
6393,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2008
6394,I-136,IDIOPATHIC CHRONIC URTICARIA,2008
6395,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2008
6396,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2008
6397,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2008
6398,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2008
6399,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2008
6400,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTIONï¿½,2008
6401,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTSï¿½,2008
6402,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2008
6403,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2008
6404,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2008
6405,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2008
6406,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2008
6407,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2008
6408,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2008
6409,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2008
6410,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2008
6411,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2008
6412,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2008
6413,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2008
6414,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2008
6415,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2008
6416,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2008
6417,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2008
6418,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2008
6419,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2008
6420,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2008
6421,I-163,TREATMENT OF PHOTOPHOBIA,2008
6422,I-164,CHRONIC BACTERIAL PROSTATITIS,2008
6423,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2008
6424,I-166,TREATMENT OF BULIMIA,2008
6425,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2008
6426,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2008
6427,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2008
6428,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2008
6429,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2008
6430,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2008
6431,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2008
6432,I-174,PELVIC INFLAMMATORY DISEASE,2008
6433,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2008
6434,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2008
6435,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2008
6436,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2008
6437,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2008
6438,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2008
6439,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2008
6440,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2008
6441,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2008
6442,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2008
6443,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6444,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2008
6445,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6446,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2008
6447,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2008
6448,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2008
6449,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2008
6450,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2008
6451,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2008
6452,I-194,CONGESTIVE HEART FAILURE,2008
6453,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2008
6454,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2008
6455,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2008
6456,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2008
6457,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2008
6458,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2008
6459,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2008
6460,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2008
6461,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2008
6462,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2008
6463,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2008
6464,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2008
6465,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2008
6466,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2008
6467,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2008
6468,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2008
6469,I-211,FOR USE IN PEDIATRIC POPULATION,2008
6470,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2008
6471,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2008
6472,I-214,TREATMENT OF OSTEOPOROSIS,2008
6473,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2008
6474,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2008
6475,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2008
6476,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2008
6477,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2008
6478,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2008
6479,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2008
6480,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2008
6481,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2008
6482,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2008
6483,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2008
6484,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2008
6485,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2008
6486,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2008
6487,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2008
6488,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2008
6489,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2008
6490,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2008
6491,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2008
6492,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2008
6493,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2008
6494,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2008
6495,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2008
6496,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2008
6497,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2008
6498,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2008
6499,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2008
6500,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2008
6501,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2008
6502,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2008
6503,I-245,TREATMENT OF ACUTE SINUSITIS,2008
6504,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2008
6505,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2008
6506,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2008
6507,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2008
6508,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2008
6509,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2008
6510,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2008
6511,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2008
6512,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2008
6513,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2008
6514,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2008
6515,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2008
6516,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2008
6517,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2008
6518,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2008
6519,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2008
6520,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2008
6521,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2008
6522,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2008
6523,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2008
6524,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2008
6525,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2008
6526,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2008
6527,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2008
6528,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2008
6529,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6530,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2008
6531,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2008
6532,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2008
6533,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2008
6534,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2008
6535,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2008
6536,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2008
6537,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2008
6538,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2008
6539,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2008
6540,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2008
6541,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2008
6542,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2008
6543,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2008
6544,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2008
6545,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2008
6546,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2008
6547,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2008
6548,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2008
6549,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6550,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6551,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2008
6552,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2008
6553,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2008
6554,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2008
6555,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2008
6556,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2008
6557,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2008
6558,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2008
6559,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2008
6560,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2008
6561,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2008
6562,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2008
6563,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2008
6564,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2008
6565,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2008
6566,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2008
6567,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2008
6568,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2008
6569,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2008
6570,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2008
6571,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2008
6572,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2008
6573,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2008
6574,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2008
6575,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2008
6576,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2008
6577,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2008
6578,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2008
6579,I-321,JUVENILE RHEUMATOID ARTHRITIS,2008
6580,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2008
6581,I-323,COLORECTAL CANCER,2008
6582,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2008
6583,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2008
6584,I-326,GENERALIZED ANXIETY DISORDER,2008
6585,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2008
6586,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2008
6587,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2008
6588,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2008
6589,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2008
6590,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2008
6591,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2008
6592,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2008
6593,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME,2008
6594,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2008
6595,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2008
6596,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2008
6597,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2008
6598,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2008
6599,I-341,BREAST CANCER COMBINATION THERAPY,2008
6600,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2008
6601,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2008
6602,I-344,ACNE VULGARIS,2008
6603,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2008
6604,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2008
6605,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2008
6606,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2008
6607,I-349,ACUTE CORONARY SYNDROME,2008
6608,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2008
6609,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2008
6610,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2008
6611,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2008
6612,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2008
6613,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2008
6614,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2008
6615,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2008
6616,I-358,TREATMENT OF PANIC DISORDER,2008
6617,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2008
6618,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2008
6619,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2008
6620,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2008
6621,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2008
6622,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2008
6623,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2008
6624,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2008
6625,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2008
6626,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2008
6627,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2008
6628,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2008
6629,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2008
6630,I-372,NOSOCOMIAL PNEUMONIA,2008
6631,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2008
6632,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2008
6633,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2008
6634,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2008
6635,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2008
6636,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2008
6637,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2008
6638,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2008
6639,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2008
6640,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2008
6641,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2008
6642,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2008
6643,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2008
6644,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2008
6645,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2008
6646,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2008
6647,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2008
6648,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2008
6649,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2008
6650,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2008
6651,I-393,CHRONIC BACTERIAL PROSTATITIS,2008
6652,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2008
6653,I-395,TO IMPROVE PHYSICAL FUNCTION,2008
6654,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2008
6655,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2008
6656,I-398,IDIOPATHIC SHORT STATURE,2008
6657,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2008
6658,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2008
6659,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2008
6660,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2008
6661,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2008
6662,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2008
6663,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2008
6664,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2008
6665,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2008
6666,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2008
6667,I-409,ESOPHAGEAL CANDIDIASIS,2008
6668,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2008
6669,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2008
6670,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2008
6671,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2008
6672,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2008
6673,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2008
6674,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2008
6675,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2008
6676,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2008
6677,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2008
6678,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2008
6679,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2008
6680,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2008
6681,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2008
6682,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2008
6683,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2008
6684,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2008
6685,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2008
6686,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2008
6687,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2008
6688,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2008
6689,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2008
6690,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2008
6691,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2008
6692,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2008
6693,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2008
6694,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2008
6695,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2008
6696,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2008
6697,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2008
6698,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2008
6699,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2008
6700,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2008
6701,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2008
6702,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2008
6703,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2008
6704,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2008
6705,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2008
6706,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2008
6707,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2008
6708,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2008
6709,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2008
6710,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2008
6711,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2008
6712,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2008
6713,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2008
6714,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2008
6715,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2008
6716,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2008
6717,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2008
6718,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2008
6719,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2008
6720,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2008
6721,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2008
6722,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2008
6723,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2008
6724,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2008
6725,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2008
6726,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2008
6727,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2008
6728,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2008
6729,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2008
6730,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2008
6731,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2008
6732,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2008
6733,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2008
6734,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2008
6735,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2008
6736,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2008
6737,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2008
6738,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2008
6739,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2008
6740,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2008
6741,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6742,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2008
6743,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2008
6744,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2008
6745,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2008
6746,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2008
6747,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2008
6748,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2008
6749,I-491,INFLUENZA PROPHYLAXIS,2008
6750,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2008
6751,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2008
6752,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2008
6753,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2008
6754,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2008
6755,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2008
6756,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2008
6757,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM BASED THERAPY,2008
6758,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2008
6759,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2008
6760,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2008
6761,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2008
6762,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2008
6763,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2008
6764,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2008
6765,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2008
6766,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2008
6767,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2008
6768,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2008
6769,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2008
6770,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2008
6771,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2008
6772,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2008
6773,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2008
6774,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2008
6775,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2008
6776,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2008
6777,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2008
6778,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2008
6779,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2008
6780,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2008
6781,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2008
6782,I-524,GENERALIZED ANXIETY DISORDER (GAD),2008
6783,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2008
6784,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2008
6785,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2008
6786,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2008
6787,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2008
6788,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2008
6789,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2008
6790,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2008
6791,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2008
6792,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2008
6793,I-535,MANAGEMENT OF FIBROMYALGIA,2008
6794,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2008
6795,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2008
6796,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2008
6797,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND WOMEN AT HIGH RISK FOR INVASIVE CANCER,2008
6798,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2008
6799,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2008
6800,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2008
6801,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2008
6802,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2008
6803,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2008
6804,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2008
6805,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2008
6806,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2008
6807,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2008
6808,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2008
6809,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2008
6810,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2008
6811,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2008
6812,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2008
6813,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2008
6814,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2008
6815,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2008
6816,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2008
6817,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2008
6818,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2008
6819,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2008
6820,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2008
6821,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2008
6822,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2008
6823,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2008
6824,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2008
6825,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2008
6826,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2008
6827,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2008
6828,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2008
6829,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2008
6830,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2008
6831,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2008
6832,M-22,CHANGE IN TIME TO ONSET OF ACTION,2008
6833,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2008
6834,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2008
6835,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2008
6836,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2008
6837,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2008
6838,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2008
6839,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2008
6840,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2008
6841,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2008
6842,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2008
6843,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2008
6844,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2008
6845,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2008
6846,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2008
6847,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2008
6848,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2008
6849,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2008
6850,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2008
6851,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2008
6852,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2008
6853,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2008
6854,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2008
6855,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2008
6856,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2008
6857,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2008
6858,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2008
6859,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2008
6860,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2008
6861,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2008
6862,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6863,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2008
6864,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2008
6865,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2008
6866,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2008
6867,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2008
6868,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2008
6869,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2008
6870,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2008
6871,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2008
6872,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2008
6873,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2008
6874,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2008
6875,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2008
6876,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2008
6877,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2008
6878,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2008
6879,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2008
6880,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2008
6881,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2008
6882,NR,NEW ROUTE,2009
6883,NCE,NEW CHEMICAL ENTITY,2009
6884,ODE,ORPHAN DRUG EXCLUSIVITY,2009
6885,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2009
6886,NP,NEW PRODUCT,2009
6887,NP*,NEW PRODUCT (MINT FLAVORED),2009
6888,PED,PEDIATRIC EXCLUSIVITY,2009
6889,PC,PATENT CHALLENGE,2009
6890,NPP,NEW PATIENT POPULATION,2009
6891,NDF,NEW DOSAGE FORM,2009
6892,RTO,RX TO OTC SWITCH OR OTC USE,2009
6893,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2009
6894,NS,NEW STRENGTH,2009
6895,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2009
6896,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2009
6897,NC,NEW COMBINATION,2009
6898,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2009
6899,D-1,ONCE A DAY APPLICATION,2009
6900,D-2,ONCE DAILY DOSING,2009
6901,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2009
6902,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2009
6903,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2009
6904,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2009
6905,D-7,BID DOSING,2009
6906,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2009
6907,D-9,NARCOTIC OVERDOSE IN ADULTS,2009
6908,D-10,NARCOTIC OVERDOSE IN CHILDREN,2009
6909,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2009
6910,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2009
6911,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2009
6912,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2009
6913,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2009
6914,D-16,CONTINUOUS INTRAVENOUS INFUSION,2009
6915,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2009
6916,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2009
6917,D-19,BOLUS DOSING GUIDELINES,2009
6918,D-20,SINGLE 32MG DOSE,2009
6919,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2009
6920,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2009
6921,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2009
6922,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2009
6923,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2009
6924,D-26,ONCE WEEKLY APPLICATION,2009
6925,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2009
6926,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2009
6927,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2009
6928,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2009
6929,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2009
6930,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2009
6931,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2009
6932,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2009
6933,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2009
6934,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2009
6935,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2009
6936,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2009
6937,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2009
6938,D-40,ONCE-A-DAY DOSING REGIMEN,2009
6939,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2009
6940,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2009
6941,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2009
6942,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2009
6943,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2009
6944,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2009
6945,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2009
6946,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2009
6947,D-49,PEDIATRIC DOSING GUIDELINES,2009
6948,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2009
6949,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2009
6950,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2009
6951,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2009
6952,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2009
6953,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2009
6954,D-56,ADDITION OF POSTPRANDIAL DOSING,2009
6955,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2009
6956,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2009
6957,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2009
6958,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2009
6959,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6960,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6961,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2009
6962,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2009
6963,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2009
6964,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2009
6965,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2009
6966,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2009
6967,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2009
6968,D-70,80MG ONCE DAILY DOSING REGIMEN,2009
6969,D-71,EIGHT WEEK DOSING REGIMEN,2009
6970,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2009
6971,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6972,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6973,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2009
6974,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2009
6975,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2009
6976,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2009
6977,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2009
6978,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2009
6979,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2009
6980,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6981,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2009
6982,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2009
6983,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2009
6984,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2009
6985,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2009
6986,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2009
6987,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2009
6988,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2009
6989,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2009
6990,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2009
6991,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2009
6992,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2009
6993,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2009
6994,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2009
6995,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2009
6996,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2009
6997,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2009
6998,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2009
6999,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2009
7000,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2009
7001,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2009
7002,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2009
7003,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7004,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2009
7005,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2009
7006,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2009
7007,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2009
7008,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2009
7009,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2009
7010,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2009
7011,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2009
7012,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2009
7013,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2009
7014,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2009
7015,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2009
7016,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2009
7017,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2009
7018,I-1,DYSMENORRHEA,2009
7019,I-2,CHOLANGIOPANCREATOGRAPHY,2009
7020,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2009
7021,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2009
7022,I-5,HYSTEROSALPINGOGRAPHY,2009
7023,I-6,TREATMENT OF JUVENILE ARTHRITIS,2009
7024,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2009
7025,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2009
7026,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2009
7027,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2009
7028,I-11,RELIEF OF MILD TO MODERATE PAIN,2009
7029,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2009
7030,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2009
7031,I-14,SEBORRHEIC DERMATITIS,2009
7032,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2009
7033,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2009
7034,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2009
7035,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2009
7036,I-19,HERNIOGRAPHY,2009
7037,I-20,KNEE ARTHROGRAPHY,2009
7038,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2009
7039,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2009
7040,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2009
7041,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2009
7042,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2009
7043,I-26,TREATMENT OF LIVER FLUKES,2009
7044,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2009
7045,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2009
7046,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2009
7047,I-30,TREATMENT OF TINEA PEDIS,2009
7048,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2009
7049,I-32,PEDIATRIC MYELOGRAPHY,2009
7050,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2009
7051,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2009
7052,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2009
7053,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2009
7054,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2009
7055,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2009
7056,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2009
7057,I-40,PRIMARY NOCTURNAL ENURESIS,2009
7058,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2009
7059,I-42,HERPES ZOSTER,2009
7060,I-43,HERPES SIMPLEX ENCEPHALITIS,2009
7061,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2009
7062,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2009
7063,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2009
7064,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2009
7065,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2009
7066,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2009
7067,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2009
7068,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2009
7069,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2009
7070,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2009
7071,I-54,RENAL CONCENTRATION CAPACITY TEST,2009
7072,I-55,HYPERTENSION,2009
7073,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2009
7074,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2009
7075,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2009
7076,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2009
7077,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2009
7078,I-61,FEMALE ANDROGENETIC ALOPECIA,2009
7079,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7080,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2009
7081,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2009
7082,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2009
7083,I-66,UNCOMPLICATED GONORRHEA,2009
7084,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2009
7085,I-68,CENTRAL PRECOCIOUS PUBERTY,2009
7086,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2009
7087,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2009
7088,I-71,VARICELLA INFECTIONS (CHICKENPOX),2009
7089,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2009
7090,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2009
7091,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2009
7092,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2009
7093,I-76,PREVENTION OF OSTEOPOROSIS,2009
7094,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2009
7095,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2009
7096,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2009
7097,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2009
7098,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2009
7099,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2009
7100,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2009
7101,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2009
7102,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2009
7103,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2009
7104,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2009
7105,I-88,MANAGEMENT OF ENDOMETRIOSIS,2009
7106,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2009
7107,I-90,INTENSIVE CARE UNIT SEDATION,2009
7108,I-91,MONOTHERAPY USE FOR HYPERTENSION,2009
7109,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2009
7110,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2009
7111,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2009
7112,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2009
7113,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2009
7114,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2009
7115,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2009
7116,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2009
7117,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2009
7118,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2009
7119,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2009
7120,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2009
7121,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2009
7122,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2009
7123,I-106,TREATMENT OF ACROMEGALY,2009
7124,I-107,VAGINAL CANDIDIASIS,2009
7125,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2009
7126,I-109,TYPHOID FEVER,2009
7127,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2009
7128,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2009
7129,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2009
7130,I-113,TREATMENT OF PROSTATITIS,2009
7131,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2009
7132,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2009
7133,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2009
7134,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2009
7135,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2009
7136,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2009
7137,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2009
7138,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2009
7139,I-122,PSORIASIS OF THE SCALP,2009
7140,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2009
7141,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2009
7142,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2009
7143,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2009
7144,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2009
7145,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2009
7146,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2009
7147,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2009
7148,I-131,PERIPHERAL ARTERIOGRAPHY,2009
7149,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2009
7150,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2009
7151,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2009
7152,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2009
7153,I-136,IDIOPATHIC CHRONIC URTICARIA,2009
7154,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2009
7155,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2009
7156,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2009
7157,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2009
7158,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2009
7159,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTIONï¿½,2009
7160,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTSï¿½,2009
7161,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2009
7162,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2009
7163,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2009
7164,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2009
7165,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2009
7166,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2009
7167,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2009
7168,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2009
7169,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2009
7170,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2009
7171,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2009
7172,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2009
7173,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2009
7174,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2009
7175,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2009
7176,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2009
7177,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2009
7178,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2009
7179,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2009
7180,I-163,TREATMENT OF PHOTOPHOBIA,2009
7181,I-164,CHRONIC BACTERIAL PROSTATITIS,2009
7182,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2009
7183,I-166,TREATMENT OF BULIMIA,2009
7184,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2009
7185,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2009
7186,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2009
7187,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2009
7188,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2009
7189,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2009
7190,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2009
7191,I-174,PELVIC INFLAMMATORY DISEASE,2009
7192,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2009
7193,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2009
7194,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2009
7195,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2009
7196,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2009
7197,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2009
7198,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2009
7199,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2009
7200,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2009
7201,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2009
7202,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
7203,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2009
7204,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7205,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2009
7206,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2009
7207,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2009
7208,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2009
7209,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2009
7210,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2009
7211,I-194,CONGESTIVE HEART FAILURE,2009
7212,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2009
7213,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2009
7214,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2009
7215,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2009
7216,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2009
7217,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2009
7218,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2009
7219,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2009
7220,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2009
7221,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2009
7222,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2009
7223,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2009
7224,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2009
7225,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2009
7226,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2009
7227,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2009
7228,I-211,FOR USE IN PEDIATRIC POPULATION,2009
7229,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2009
7230,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2009
7231,I-214,TREATMENT OF OSTEOPOROSIS,2009
7232,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2009
7233,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2009
7234,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2009
7235,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2009
7236,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2009
7237,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2009
7238,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2009
7239,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2009
7240,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2009
7241,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2009
7242,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2009
7243,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2009
7244,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2009
7245,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2009
7246,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2009
7247,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2009
7248,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2009
7249,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2009
7250,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2009
7251,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2009
7252,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2009
7253,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2009
7254,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2009
7255,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2009
7256,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2009
7257,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2009
7258,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2009
7259,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2009
7260,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2009
7261,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2009
7262,I-245,TREATMENT OF ACUTE SINUSITIS,2009
7263,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2009
7264,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2009
7265,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2009
7266,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2009
7267,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2009
7268,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2009
7269,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2009
7270,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2009
7271,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2009
7272,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2009
7273,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2009
7274,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2009
7275,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2009
7276,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2009
7277,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2009
7278,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2009
7279,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2009
7280,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2009
7281,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2009
7282,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2009
7283,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2009
7284,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2009
7285,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2009
7286,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2009
7287,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2009
7288,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
7289,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2009
7290,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2009
7291,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2009
7292,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2009
7293,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2009
7294,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2009
7295,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2009
7296,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2009
7297,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2009
7298,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2009
7299,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2009
7300,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2009
7301,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2009
7302,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2009
7303,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2009
7304,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2009
7305,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2009
7306,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2009
7307,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2009
7308,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7309,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7310,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2009
7311,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2009
7312,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2009
7313,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2009
7314,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2009
7315,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2009
7316,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2009
7317,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2009
7318,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2009
7319,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2009
7320,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2009
7321,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2009
7322,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2009
7323,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2009
7324,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2009
7325,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2009
7326,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2009
7327,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2009
7328,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2009
7329,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2009
7330,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2009
7331,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2009
7332,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2009
7333,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2009
7334,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2009
7335,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2009
7336,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2009
7337,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2009
7338,I-321,JUVENILE RHEUMATOID ARTHRITIS,2009
7339,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2009
7340,I-323,COLORECTAL CANCER,2009
7341,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2009
7342,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2009
7343,I-326,GENERALIZED ANXIETY DISORDER,2009
7344,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2009
7345,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2009
7346,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2009
7347,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2009
7348,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2009
7349,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2009
7350,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2009
7351,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2009
7352,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2009
7353,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2009
7354,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2009
7355,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2009
7356,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2009
7357,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2009
7358,I-341,BREAST CANCER COMBINATION THERAPY,2009
7359,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2009
7360,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2009
7361,I-344,ACNE VULGARIS,2009
7362,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2009
7363,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2009
7364,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2009
7365,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2009
7366,I-349,ACUTE CORONARY SYNDROME,2009
7367,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2009
7368,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2009
7369,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2009
7370,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2009
7371,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2009
7372,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2009
7373,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2009
7374,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2009
7375,I-358,TREATMENT OF PANIC DISORDER,2009
7376,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2009
7377,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2009
7378,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2009
7379,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2009
7380,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2009
7381,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2009
7382,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2009
7383,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2009
7384,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2009
7385,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2009
7386,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2009
7387,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2009
7388,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2009
7389,I-372,NOSOCOMIAL PNEUMONIA,2009
7390,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2009
7391,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2009
7392,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2009
7393,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2009
7394,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2009
7395,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2009
7396,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2009
7397,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2009
7398,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2009
7399,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2009
7400,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2009
7401,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2009
7402,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2009
7403,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2009
7404,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2009
7405,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2009
7406,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2009
7407,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2009
7408,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2009
7409,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2009
7410,I-393,CHRONIC BACTERIAL PROSTATITIS,2009
7411,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2009
7412,I-395,TO IMPROVE PHYSICAL FUNCTION,2009
7413,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2009
7414,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2009
7415,I-398,IDIOPATHIC SHORT STATURE,2009
7416,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2009
7417,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2009
7418,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2009
7419,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2009
7420,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2009
7421,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2009
7422,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2009
7423,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2009
7424,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2009
7425,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2009
7426,I-409,ESOPHAGEAL CANDIDIASIS,2009
7427,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2009
7428,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2009
7429,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2009
7430,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2009
7431,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2009
7432,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2009
7433,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2009
7434,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2009
7435,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2009
7436,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2009
7437,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2009
7438,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2009
7439,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2009
7440,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2009
7441,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2009
7442,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2009
7443,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2009
7444,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2009
7445,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2009
7446,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2009
7447,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2009
7448,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2009
7449,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2009
7450,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2009
7451,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2009
7452,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2009
7453,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2009
7454,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2009
7455,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2009
7456,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2009
7457,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2009
7458,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2009
7459,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2009
7460,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2009
7461,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2009
7462,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2009
7463,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2009
7464,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2009
7465,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2009
7466,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2009
7467,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2009
7468,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2009
7469,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2009
7470,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2009
7471,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2009
7472,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2009
7473,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2009
7474,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2009
7475,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2009
7476,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2009
7477,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2009
7478,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2009
7479,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2009
7480,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2009
7481,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2009
7482,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2009
7483,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2009
7484,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2009
7485,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2009
7486,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2009
7487,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2009
7488,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2009
7489,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2009
7490,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2009
7491,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2009
7492,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2009
7493,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2009
7494,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2009
7495,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2009
7496,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2009
7497,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2009
7498,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2009
7499,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2009
7500,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
7501,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2009
7502,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2009
7503,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2009
7504,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2009
7505,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2009
7506,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2009
7507,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2009
7508,I-491,INFLUENZA PROPHYLAXIS,2009
7509,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2009
7510,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2009
7511,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2009
7512,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2009
7513,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2009
7514,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2009
7515,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2009
7516,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2009
7517,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2009
7518,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2009
7519,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2009
7520,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2009
7521,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2009
7522,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2009
7523,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2009
7524,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2009
7525,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2009
7526,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2009
7527,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2009
7528,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2009
7529,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2009
7530,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2009
7531,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2009
7532,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2009
7533,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2009
7534,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2009
7535,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2009
7536,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2009
7537,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2009
7538,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2009
7539,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2009
7540,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2009
7541,I-524,GENERALIZED ANXIETY DISORDER (GAD),2009
7542,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2009
7543,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2009
7544,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2009
7545,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2009
7546,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2009
7547,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2009
7548,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2009
7549,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2009
7550,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2009
7551,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2009
7552,I-535,MANAGEMENT OF FIBROMYALGIA,2009
7553,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2009
7554,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2009
7555,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2009
7556,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2009
7557,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2009
7558,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2009
7559,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2009
7560,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2009
7561,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2009
7562,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2009
7563,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2009
7564,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2009
7565,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2009
7566,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2009
7567,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2009
7568,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2009
7569,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2009
7570,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2009
7571,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2009
7572,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2009
7573,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2009
7574,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2009
7575,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2009
7576,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2009
7577,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2009
7578,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2009
7579,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2009
7580,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2009
7581,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2009
7582,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2009
7583,I-566,MANAGEMENT OF FIBROMYALGIA,2009
7584,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2009
7585,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2009
7586,I-569,TREATMENT OF CHRONIC HEPATITIS B,2009
7587,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2009
7588,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2009
7589,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2009
7590,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2009
7591,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2009
7592,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2009
7593,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2009
7594,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2009
7595,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2009
7596,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2009
7597,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2009
7598,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2009
7599,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2009
7600,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2009
7601,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2009
7602,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2009
7603,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2009
7604,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2009
7605,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2009
7606,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2009
7607,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2009
7608,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2009
7609,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2009
7610,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2009
7611,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2009
7612,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2009
7613,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2009
7614,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2009
7615,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2009
7616,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2009
7617,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2009
7618,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2009
7619,M-22,CHANGE IN TIME TO ONSET OF ACTION,2009
7620,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2009
7621,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2009
7622,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2009
7623,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2009
7624,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2009
7625,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2009
7626,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2009
7627,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2009
7628,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2009
7629,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2009
7630,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2009
7631,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2009
7632,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2009
7633,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2009
7634,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2009
7635,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2009
7636,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2009
7637,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2009
7638,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2009
7639,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2009
7640,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2009
7641,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2009
7642,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2009
7643,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2009
7644,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2009
7645,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2009
7646,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2009
7647,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2009
7648,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2009
7649,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
7650,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2009
7651,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2009
7652,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2009
7653,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2009
7654,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2009
7655,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2009
7656,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2009
7657,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2009
7658,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2009
7659,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2009
7660,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2009
7661,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2009
7662,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2009
7663,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2009
7664,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2009
7665,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2009
7666,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2009
7667,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2009
7668,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2009
7669,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2009
7670,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2009
7671,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2009
7672,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2009
7673,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2009
7674,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2009
7675,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2009
7676,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2009
7677,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2009
7678,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2009
7679,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2009
7680,NPP,NEW PATIENT POPULATION,2010
7681,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2010
7682,NC,NEW COMBINATION,2010
7683,NDF,NEW DOSAGE FORM,2010
7684,NR,NEW ROUTE,2010
7685,PED,PEDIATRIC EXCLUSIVITY,2010
7686,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2010
7687,NP*,NEW PRODUCT (MINT FLAVORED),2010
7688,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2010
7689,NP,NEW PRODUCT,2010
7690,RTO,RX TO OTC SWITCH OR OTC USE,2010
7691,NS,NEW STRENGTH,2010
7692,NCE,NEW CHEMICAL ENTITY,2010
7693,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2010
7694,PC,PATENT CHALLENGE,2010
7695,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2010
7696,ODE,ORPHAN DRUG EXCLUSIVITY,2010
7697,D-1,ONCE A DAY APPLICATION,2010
7698,D-2,ONCE DAILY DOSING,2010
7699,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2010
7700,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2010
7701,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2010
7702,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2010
7703,D-7,BID DOSING,2010
7704,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2010
7705,D-9,NARCOTIC OVERDOSE IN ADULTS,2010
7706,D-10,NARCOTIC OVERDOSE IN CHILDREN,2010
7707,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2010
7708,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2010
7709,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2010
7710,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2010
7711,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2010
7712,D-16,CONTINUOUS INTRAVENOUS INFUSION,2010
7713,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2010
7714,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2010
7715,D-19,BOLUS DOSING GUIDELINES,2010
7716,D-20,SINGLE 32MG DOSE,2010
7717,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2010
7718,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2010
7719,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2010
7720,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2010
7721,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2010
7722,D-26,ONCE WEEKLY APPLICATION,2010
7723,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2010
7724,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2010
7725,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2010
7726,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2010
7727,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2010
7728,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2010
7729,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2010
7730,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2010
7731,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2010
7732,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2010
7733,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2010
7734,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2010
7735,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2010
7736,D-40,ONCE-A-DAY DOSING REGIMEN,2010
7737,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2010
7738,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2010
7739,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2010
7740,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2010
7741,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2010
7742,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2010
7743,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2010
7744,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2010
7745,D-49,PEDIATRIC DOSING GUIDELINES,2010
7746,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2010
7747,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2010
7748,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2010
7749,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2010
7750,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2010
7751,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2010
7752,D-56,ADDITION OF POSTPRANDIAL DOSING,2010
7753,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2010
7754,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2010
7755,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2010
7756,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2010
7757,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7758,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7759,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2010
7760,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2010
7761,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2010
7762,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2010
7763,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2010
7764,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2010
7765,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2010
7766,D-70,80MG ONCE DAILY DOSING REGIMEN,2010
7767,D-71,EIGHT WEEK DOSING REGIMEN,2010
7768,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2010
7769,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7770,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7771,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2010
7772,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2010
7773,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2010
7774,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2010
7775,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2010
7776,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2010
7777,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2010
7778,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7779,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2010
7780,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2010
7781,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2010
7782,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2010
7783,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
7784,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2010
7785,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2010
7786,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2010
7787,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2010
7788,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2010
7789,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2010
7790,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2010
7791,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2010
7792,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2010
7793,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2010
7794,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2010
7795,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2010
7796,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2010
7797,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2010
7798,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2010
7799,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2010
7800,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2010
7801,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7802,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2010
7803,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
7804,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2010
7805,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2010
7806,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2010
7807,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2010
7808,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2010
7809,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2010
7810,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2010
7811,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2010
7812,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2010
7813,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2010
7814,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2010
7815,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2010
7816,D-120,DOSING REGIMEN ADJUSTMENTS,2010
7817,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2010
7818,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2010
7819,I-1,DYSMENORRHEA,2010
7820,I-2,CHOLANGIOPANCREATOGRAPHY,2010
7821,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2010
7822,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2010
7823,I-5,HYSTEROSALPINGOGRAPHY,2010
7824,I-6,TREATMENT OF JUVENILE ARTHRITIS,2010
7825,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2010
7826,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2010
7827,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2010
7828,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2010
7829,I-11,RELIEF OF MILD TO MODERATE PAIN,2010
7830,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2010
7831,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2010
7832,I-14,SEBORRHEIC DERMATITIS,2010
7833,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2010
7834,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2010
7835,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2010
7836,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2010
7837,I-19,HERNIOGRAPHY,2010
7838,I-20,KNEE ARTHROGRAPHY,2010
7839,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2010
7840,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2010
7841,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2010
7842,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2010
7843,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2010
7844,I-26,TREATMENT OF LIVER FLUKES,2010
7845,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2010
7846,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2010
7847,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2010
7848,I-30,TREATMENT OF TINEA PEDIS,2010
7849,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2010
7850,I-32,PEDIATRIC MYELOGRAPHY,2010
7851,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2010
7852,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2010
7853,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2010
7854,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2010
7855,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2010
7856,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2010
7857,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2010
7858,I-40,PRIMARY NOCTURNAL ENURESIS,2010
7859,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2010
7860,I-42,HERPES ZOSTER,2010
7861,I-43,HERPES SIMPLEX ENCEPHALITIS,2010
7862,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2010
7863,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2010
7864,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2010
7865,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2010
7866,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2010
7867,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2010
7868,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2010
7869,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2010
7870,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2010
7871,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2010
7872,I-54,RENAL CONCENTRATION CAPACITY TEST,2010
7873,I-55,HYPERTENSION,2010
7874,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2010
7875,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2010
7876,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2010
7877,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2010
7878,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2010
7879,I-61,FEMALE ANDROGENETIC ALOPECIA,2010
7880,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7881,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2010
7882,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2010
7883,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2010
7884,I-66,UNCOMPLICATED GONORRHEA,2010
7885,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2010
7886,I-68,CENTRAL PRECOCIOUS PUBERTY,2010
7887,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2010
7888,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2010
7889,I-71,VARICELLA INFECTIONS (CHICKENPOX),2010
7890,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2010
7891,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2010
7892,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2010
7893,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2010
7894,I-76,PREVENTION OF OSTEOPOROSIS,2010
7895,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2010
7896,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2010
7897,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2010
7898,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2010
7899,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2010
7900,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2010
7901,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2010
7902,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2010
7903,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2010
7904,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2010
7905,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2010
7906,I-88,MANAGEMENT OF ENDOMETRIOSIS,2010
7907,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2010
7908,I-90,INTENSIVE CARE UNIT SEDATION,2010
7909,I-91,MONOTHERAPY USE FOR HYPERTENSION,2010
7910,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2010
7911,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2010
7912,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2010
7913,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2010
7914,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2010
7915,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2010
7916,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2010
7917,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2010
7918,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2010
7919,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2010
7920,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2010
7921,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2010
7922,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2010
7923,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2010
7924,I-106,TREATMENT OF ACROMEGALY,2010
7925,I-107,VAGINAL CANDIDIASIS,2010
7926,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2010
7927,I-109,TYPHOID FEVER,2010
7928,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2010
7929,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2010
7930,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2010
7931,I-113,TREATMENT OF PROSTATITIS,2010
7932,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2010
7933,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2010
7934,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2010
7935,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2010
7936,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2010
7937,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2010
7938,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2010
7939,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2010
7940,I-122,PSORIASIS OF THE SCALP,2010
7941,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2010
7942,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2010
7943,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2010
7944,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2010
7945,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2010
7946,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2010
7947,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2010
7948,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2010
7949,I-131,PERIPHERAL ARTERIOGRAPHY,2010
7950,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2010
7951,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2010
7952,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2010
7953,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2010
7954,I-136,IDIOPATHIC CHRONIC URTICARIA,2010
7955,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2010
7956,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2010
7957,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2010
7958,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2010
7959,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2010
7960,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2010
7961,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2010
7962,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2010
7963,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2010
7964,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2010
7965,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2010
7966,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2010
7967,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2010
7968,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2010
7969,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2010
7970,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2010
7971,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2010
7972,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2010
7973,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2010
7974,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2010
7975,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2010
7976,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2010
7977,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2010
7978,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2010
7979,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2010
7980,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2010
7981,I-163,TREATMENT OF PHOTOPHOBIA,2010
7982,I-164,CHRONIC BACTERIAL PROSTATITIS,2010
7983,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2010
7984,I-166,TREATMENT OF BULIMIA,2010
7985,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2010
7986,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2010
7987,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2010
7988,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2010
7989,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2010
7990,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2010
7991,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2010
7992,I-174,PELVIC INFLAMMATORY DISEASE,2010
7993,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2010
7994,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2010
7995,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2010
7996,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2010
7997,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2010
7998,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2010
7999,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2010
8000,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2010
8001,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2010
8002,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2010
8003,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
8004,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2010
8005,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
8006,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2010
8007,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2010
8008,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2010
8009,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2010
8010,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2010
8011,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2010
8012,I-194,CONGESTIVE HEART FAILURE,2010
8013,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2010
8014,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2010
8015,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2010
8016,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2010
8017,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2010
8018,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2010
8019,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2010
8020,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2010
8021,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2010
8022,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2010
8023,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2010
8024,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2010
8025,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2010
8026,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2010
8027,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2010
8028,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2010
8029,I-211,FOR USE IN PEDIATRIC POPULATION,2010
8030,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2010
8031,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2010
8032,I-214,TREATMENT OF OSTEOPOROSIS,2010
8033,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2010
8034,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2010
8035,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2010
8036,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2010
8037,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2010
8038,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2010
8039,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2010
8040,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2010
8041,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2010
8042,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2010
8043,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2010
8044,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2010
8045,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2010
8046,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2010
8047,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2010
8048,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2010
8049,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2010
8050,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2010
8051,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2010
8052,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2010
8053,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2010
8054,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2010
8055,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2010
8056,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2010
8057,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2010
8058,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2010
8059,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2010
8060,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2010
8061,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2010
8062,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2010
8063,I-245,TREATMENT OF ACUTE SINUSITIS,2010
8064,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2010
8065,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2010
8066,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2010
8067,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2010
8068,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2010
8069,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2010
8070,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2010
8071,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2010
8072,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2010
8073,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2010
8074,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2010
8075,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2010
8076,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2010
8077,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2010
8078,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2010
8079,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2010
8080,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2010
8081,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2010
8082,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2010
8083,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2010
8084,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2010
8085,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2010
8086,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2010
8087,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2010
8088,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2010
8089,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
8090,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2010
8091,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2010
8092,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2010
8093,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2010
8094,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2010
8095,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2010
8096,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2010
8097,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2010
8098,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2010
8099,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2010
8100,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2010
8101,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2010
8102,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2010
8103,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2010
8104,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2010
8105,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2010
8106,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2010
8107,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2010
8108,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2010
8109,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
8110,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2010
8111,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2010
8112,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2010
8113,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2010
8114,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2010
8115,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2010
8116,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2010
8117,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2010
8118,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2010
8119,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2010
8120,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2010
8121,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2010
8122,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2010
8123,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2010
8124,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2010
8125,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2010
8126,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2010
8127,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
8128,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2010
8129,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2010
8130,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2010
8131,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2010
8132,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2010
8133,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2010
8134,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2010
8135,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2010
8136,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2010
8137,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2010
8138,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2010
8139,I-321,JUVENILE RHEUMATOID ARTHRITIS,2010
8140,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2010
8141,I-323,COLORECTAL CANCER,2010
8142,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2010
8143,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2010
8144,I-326,GENERALIZED ANXIETY DISORDER,2010
8145,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2010
8146,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2010
8147,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2010
8148,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2010
8149,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2010
8150,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2010
8151,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2010
8152,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2010
8153,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2010
8154,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2010
8155,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2010
8156,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2010
8157,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2010
8158,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2010
8159,I-341,BREAST CANCER COMBINATION THERAPY,2010
8160,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2010
8161,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2010
8162,I-344,ACNE VULGARIS,2010
8163,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2010
8164,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2010
8165,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2010
8166,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2010
8167,I-349,ACUTE CORONARY SYNDROME,2010
8168,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2010
8169,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2010
8170,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2010
8171,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2010
8172,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2010
8173,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2010
8174,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2010
8175,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2010
8176,I-358,TREATMENT OF PANIC DISORDER,2010
8177,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2010
8178,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2010
8179,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2010
8180,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2010
8181,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2010
8182,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2010
8183,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2010
8184,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2010
8185,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2010
8186,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2010
8187,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2010
8188,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2010
8189,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2010
8190,I-372,NOSOCOMIAL PNEUMONIA,2010
8191,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2010
8192,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2010
8193,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2010
8194,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2010
8195,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2010
8196,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2010
8197,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2010
8198,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2010
8199,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2010
8200,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2010
8201,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2010
8202,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2010
8203,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2010
8204,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2010
8205,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2010
8206,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2010
8207,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2010
8208,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2010
8209,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2010
8210,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2010
8211,I-393,CHRONIC BACTERIAL PROSTATITIS,2010
8212,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2010
8213,I-395,TO IMPROVE PHYSICAL FUNCTION,2010
8214,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2010
8215,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2010
8216,I-398,IDIOPATHIC SHORT STATURE,2010
8217,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2010
8218,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2010
8219,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2010
8220,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2010
8221,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2010
8222,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2010
8223,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2010
8224,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2010
8225,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2010
8226,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2010
8227,I-409,ESOPHAGEAL CANDIDIASIS,2010
8228,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2010
8229,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2010
8230,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2010
8231,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2010
8232,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2010
8233,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2010
8234,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2010
8235,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2010
8236,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2010
8237,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2010
8238,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2010
8239,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2010
8240,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2010
8241,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2010
8242,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2010
8243,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2010
8244,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2010
8245,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2010
8246,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2010
8247,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2010
8248,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2010
8249,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2010
8250,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2010
8251,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2010
8252,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2010
8253,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2010
8254,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2010
8255,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2010
8256,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2010
8257,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2010
8258,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2010
8259,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2010
8260,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2010
8261,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2010
8262,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2010
8263,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2010
8264,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2010
8265,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2010
8266,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2010
8267,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2010
8268,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2010
8269,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2010
8270,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2010
8271,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2010
8272,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2010
8273,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2010
8274,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2010
8275,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2010
8276,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2010
8277,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2010
8278,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2010
8279,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2010
8280,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2010
8281,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2010
8282,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2010
8283,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2010
8284,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2010
8285,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2010
8286,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2010
8287,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2010
8288,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2010
8289,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2010
8290,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2010
8291,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2010
8292,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2010
8293,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2010
8294,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2010
8295,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2010
8296,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2010
8297,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2010
8298,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2010
8299,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2010
8300,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2010
8301,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
8302,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2010
8303,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2010
8304,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2010
8305,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2010
8306,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2010
8307,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2010
8308,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2010
8309,I-491,INFLUENZA PROPHYLAXIS,2010
8310,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2010
8311,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2010
8312,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2010
8313,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2010
8314,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2010
8315,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2010
8316,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2010
8317,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2010
8318,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2010
8319,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2010
8320,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2010
8321,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2010
8322,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2010
8323,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2010
8324,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2010
8325,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2010
8326,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2010
8327,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2010
8328,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2010
8329,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2010
8330,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2010
8331,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2010
8332,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2010
8333,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2010
8334,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2010
8335,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2010
8336,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2010
8337,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2010
8338,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2010
8339,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2010
8340,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2010
8341,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2010
8342,I-524,GENERALIZED ANXIETY DISORDER (GAD),2010
8343,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2010
8344,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2010
8345,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2010
8346,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2010
8347,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2010
8348,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2010
8349,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2010
8350,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2010
8351,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2010
8352,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2010
8353,I-535,MANAGEMENT OF FIBROMYALGIA,2010
8354,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2010
8355,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2010
8356,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2010
8357,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2010
8358,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2010
8359,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2010
8360,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2010
8361,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2010
8362,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2010
8363,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2010
8364,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2010
8365,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2010
8366,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2010
8367,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2010
8368,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2010
8369,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2010
8370,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2010
8371,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2010
8372,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2010
8373,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2010
8374,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2010
8375,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2010
8376,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2010
8377,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2010
8378,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2010
8379,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2010
8380,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2010
8381,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2010
8382,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2010
8383,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2010
8384,I-566,MANAGEMENT OF FIBROMYALGIA,2010
8385,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2010
8386,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2010
8387,I-569,TREATMENT OF CHRONIC HEPATITIS B,2010
8388,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2010
8389,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2010
8390,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2010
8391,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2010
8392,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2010
8393,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2010
8394,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2010
8395,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2010
8396,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2010
8397,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2010
8398,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2010
8399,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
8400,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2010
8401,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2010
8402,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2010
8403,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2010
8404,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2010
8405,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2010
8406,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2010
8407,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2010
8408,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2010
8409,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2010
8410,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2010
8411,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2010
8412,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2010
8413,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
8414,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2010
8415,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2010
8416,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2010
8417,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2010
8418,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2010
8419,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2010
8420,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2010
8421,I-603,GOUT FLARES,2010
8422,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2010
8423,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2010
8424,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2010
8425,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2010
8426,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2010
8427,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2010
8428,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2010
8429,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2010
8430,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2010
8431,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2010
8432,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2010
8433,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2010
8434,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2010
8435,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2010
8436,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2010
8437,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2010
8438,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2010
8439,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2010
8440,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2010
8441,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2010
8442,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2010
8443,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2010
8444,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2010
8445,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2010
8446,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2010
8447,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2010
8448,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2010
8449,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2010
8450,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2010
8451,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2010
8452,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2010
8453,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2010
8454,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2010
8455,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2010
8456,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2010
8457,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2010
8458,M-22,CHANGE IN TIME TO ONSET OF ACTION,2010
8459,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2010
8460,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2010
8461,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2010
8462,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2010
8463,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2010
8464,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2010
8465,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2010
8466,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2010
8467,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2010
8468,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2010
8469,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2010
8470,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2010
8471,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2010
8472,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2010
8473,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2010
8474,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2010
8475,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2010
8476,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2010
8477,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2010
8478,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2010
8479,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2010
8480,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2010
8481,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2010
8482,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2010
8483,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2010
8484,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2010
8485,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2010
8486,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2010
8487,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2010
8488,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
8489,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2010
8490,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2010
8491,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2010
8492,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2010
8493,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2010
8494,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2010
8495,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2010
8496,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2010
8497,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2010
8498,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2010
8499,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2010
8500,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2010
8501,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2010
8502,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2010
8503,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2010
8504,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2010
8505,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2010
8506,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2010
8507,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2010
8508,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2010
8509,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2010
8510,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2010
8511,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2010
8512,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2010
8513,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2010
8514,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2010
8515,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2010
8516,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2010
8517,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2010
8518,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2010
8519,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2010
8520,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2010
8521,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2010
8522,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2010
8523,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2010
8524,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2010
8525,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2010
8526,NC,NEW COMBINATION,2011
8527,NCE,NEW CHEMICAL ENTITY,2011
8528,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2011
8529,NS,NEW STRENGTH,2011
8530,NP,NEW PRODUCT,2011
8531,PC,PATENT CHALLENGE,2011
8532,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2011
8533,ODE,ORPHAN DRUG EXCLUSIVITY,2011
8534,RTO,RX TO OTC SWITCH OR OTC USE,2011
8535,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2011
8536,PED,PEDIATRIC EXCLUSIVITY,2011
8537,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2011
8538,NDF,NEW DOSAGE FORM,2011
8539,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2011
8540,NP*,NEW PRODUCT (MINT FLAVORED),2011
8541,NR,NEW ROUTE,2011
8542,NPP,NEW PATIENT POPULATION,2011
8543,D-1,ONCE A DAY APPLICATION,2011
8544,D-2,ONCE DAILY DOSING,2011
8545,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2011
8546,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2011
8547,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2011
8548,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2011
8549,D-7,BID DOSING,2011
8550,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2011
8551,D-9,NARCOTIC OVERDOSE IN ADULTS,2011
8552,D-10,NARCOTIC OVERDOSE IN CHILDREN,2011
8553,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2011
8554,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2011
8555,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2011
8556,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2011
8557,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2011
8558,D-16,CONTINUOUS INTRAVENOUS INFUSION,2011
8559,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2011
8560,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2011
8561,D-19,BOLUS DOSING GUIDELINES,2011
8562,D-20,SINGLE 32MG DOSE,2011
8563,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2011
8564,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2011
8565,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2011
8566,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2011
8567,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2011
8568,D-26,ONCE WEEKLY APPLICATION,2011
8569,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2011
8570,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2011
8571,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2011
8572,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2011
8573,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2011
8574,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2011
8575,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2011
8576,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2011
8577,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2011
8578,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2011
8579,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2011
8580,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2011
8581,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2011
8582,D-40,ONCE-A-DAY DOSING REGIMEN,2011
8583,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2011
8584,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2011
8585,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2011
8586,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2011
8587,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2011
8588,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2011
8589,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2011
8590,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2011
8591,D-49,PEDIATRIC DOSING GUIDELINES,2011
8592,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2011
8593,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2011
8594,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2011
8595,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2011
8596,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2011
8597,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2011
8598,D-56,ADDITION OF POSTPRANDIAL DOSING,2011
8599,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2011
8600,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2011
8601,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2011
8602,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2011
8603,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8604,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8605,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2011
8606,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2011
8607,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2011
8608,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2011
8609,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2011
8610,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2011
8611,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2011
8612,D-70,80MG ONCE DAILY DOSING REGIMEN,2011
8613,D-71,EIGHT WEEK DOSING REGIMEN,2011
8614,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2011
8615,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8616,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8617,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2011
8618,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2011
8619,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2011
8620,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2011
8621,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2011
8622,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2011
8623,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2011
8624,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8625,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2011
8626,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2011
8627,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2011
8628,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2011
8629,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
8630,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2011
8631,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2011
8632,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2011
8633,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2011
8634,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2011
8635,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2011
8636,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2011
8637,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2011
8638,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2011
8639,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2011
8640,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2011
8641,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2011
8642,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2011
8643,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2011
8644,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2011
8645,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2011
8646,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2011
8647,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8648,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2011
8649,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
8650,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2011
8651,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2011
8652,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2011
8653,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2011
8654,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2011
8655,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2011
8656,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2011
8657,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2011
8658,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2011
8659,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2011
8660,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2011
8661,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2011
8662,D-120,DOSING REGIMEN ADJUSTMENTS,2011
8663,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2011
8664,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2011
8665,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2011
8666,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2011
8667,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2011
8668,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2011
8669,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2011
8670,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2011
8671,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2011
8672,I-1,DYSMENORRHEA,2011
8673,I-2,CHOLANGIOPANCREATOGRAPHY,2011
8674,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2011
8675,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2011
8676,I-5,HYSTEROSALPINGOGRAPHY,2011
8677,I-6,TREATMENT OF JUVENILE ARTHRITIS,2011
8678,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2011
8679,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2011
8680,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2011
8681,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2011
8682,I-11,RELIEF OF MILD TO MODERATE PAIN,2011
8683,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2011
8684,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2011
8685,I-14,SEBORRHEIC DERMATITIS,2011
8686,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2011
8687,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2011
8688,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2011
8689,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2011
8690,I-19,HERNIOGRAPHY,2011
8691,I-20,KNEE ARTHROGRAPHY,2011
8692,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2011
8693,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2011
8694,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2011
8695,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2011
8696,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2011
8697,I-26,TREATMENT OF LIVER FLUKES,2011
8698,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2011
8699,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2011
8700,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2011
8701,I-30,TREATMENT OF TINEA PEDIS,2011
8702,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2011
8703,I-32,PEDIATRIC MYELOGRAPHY,2011
8704,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2011
8705,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2011
8706,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2011
8707,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2011
8708,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2011
8709,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2011
8710,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2011
8711,I-40,PRIMARY NOCTURNAL ENURESIS,2011
8712,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2011
8713,I-42,HERPES ZOSTER,2011
8714,I-43,HERPES SIMPLEX ENCEPHALITIS,2011
8715,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2011
8716,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2011
8717,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2011
8718,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2011
8719,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2011
8720,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2011
8721,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2011
8722,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2011
8723,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2011
8724,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2011
8725,I-54,RENAL CONCENTRATION CAPACITY TEST,2011
8726,I-55,HYPERTENSION,2011
8727,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2011
8728,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2011
8729,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2011
8730,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2011
8731,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2011
8732,I-61,FEMALE ANDROGENETIC ALOPECIA,2011
8733,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8734,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2011
8735,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2011
8736,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2011
8737,I-66,UNCOMPLICATED GONORRHEA,2011
8738,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2011
8739,I-68,CENTRAL PRECOCIOUS PUBERTY,2011
8740,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2011
8741,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2011
8742,I-71,VARICELLA INFECTIONS (CHICKENPOX),2011
8743,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2011
8744,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2011
8745,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2011
8746,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2011
8747,I-76,PREVENTION OF OSTEOPOROSIS,2011
8748,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2011
8749,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2011
8750,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2011
8751,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2011
8752,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2011
8753,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2011
8754,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2011
8755,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2011
8756,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2011
8757,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2011
8758,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2011
8759,I-88,MANAGEMENT OF ENDOMETRIOSIS,2011
8760,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2011
8761,I-90,INTENSIVE CARE UNIT SEDATION,2011
8762,I-91,MONOTHERAPY USE FOR HYPERTENSION,2011
8763,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2011
8764,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2011
8765,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2011
8766,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2011
8767,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2011
8768,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2011
8769,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2011
8770,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2011
8771,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2011
8772,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2011
8773,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2011
8774,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2011
8775,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2011
8776,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2011
8777,I-106,TREATMENT OF ACROMEGALY,2011
8778,I-107,VAGINAL CANDIDIASIS,2011
8779,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2011
8780,I-109,TYPHOID FEVER,2011
8781,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2011
8782,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2011
8783,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2011
8784,I-113,TREATMENT OF PROSTATITIS,2011
8785,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2011
8786,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2011
8787,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2011
8788,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2011
8789,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2011
8790,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2011
8791,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2011
8792,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2011
8793,I-122,PSORIASIS OF THE SCALP,2011
8794,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2011
8795,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2011
8796,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2011
8797,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2011
8798,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2011
8799,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2011
8800,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2011
8801,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2011
8802,I-131,PERIPHERAL ARTERIOGRAPHY,2011
8803,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2011
8804,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2011
8805,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2011
8806,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2011
8807,I-136,IDIOPATHIC CHRONIC URTICARIA,2011
8808,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2011
8809,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2011
8810,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2011
8811,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2011
8812,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2011
8813,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2011
8814,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2011
8815,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2011
8816,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2011
8817,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2011
8818,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2011
8819,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2011
8820,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2011
8821,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2011
8822,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2011
8823,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2011
8824,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2011
8825,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2011
8826,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2011
8827,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2011
8828,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2011
8829,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2011
8830,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2011
8831,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2011
8832,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2011
8833,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2011
8834,I-163,TREATMENT OF PHOTOPHOBIA,2011
8835,I-164,CHRONIC BACTERIAL PROSTATITIS,2011
8836,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2011
8837,I-166,TREATMENT OF BULIMIA,2011
8838,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2011
8839,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2011
8840,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2011
8841,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2011
8842,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2011
8843,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2011
8844,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2011
8845,I-174,PELVIC INFLAMMATORY DISEASE,2011
8846,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2011
8847,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2011
8848,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2011
8849,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2011
8850,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2011
8851,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2011
8852,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2011
8853,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2011
8854,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2011
8855,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2011
8856,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
8857,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2011
8858,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8859,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2011
8860,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2011
8861,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2011
8862,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2011
8863,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2011
8864,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2011
8865,I-194,CONGESTIVE HEART FAILURE,2011
8866,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2011
8867,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2011
8868,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2011
8869,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2011
8870,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2011
8871,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2011
8872,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2011
8873,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2011
8874,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2011
8875,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2011
8876,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2011
8877,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2011
8878,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2011
8879,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2011
8880,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2011
8881,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2011
8882,I-211,FOR USE IN PEDIATRIC POPULATION,2011
8883,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2011
8884,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2011
8885,I-214,TREATMENT OF OSTEOPOROSIS,2011
8886,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2011
8887,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2011
8888,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2011
8889,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2011
8890,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2011
8891,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2011
8892,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2011
8893,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2011
8894,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2011
8895,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2011
8896,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2011
8897,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2011
8898,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2011
8899,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2011
8900,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2011
8901,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2011
8902,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2011
8903,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2011
8904,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2011
8905,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2011
8906,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2011
8907,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2011
8908,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2011
8909,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2011
8910,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2011
8911,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2011
8912,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2011
8913,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2011
8914,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2011
8915,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2011
8916,I-245,TREATMENT OF ACUTE SINUSITIS,2011
8917,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2011
8918,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2011
8919,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2011
8920,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2011
8921,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2011
8922,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2011
8923,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2011
8924,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2011
8925,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2011
8926,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2011
8927,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2011
8928,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2011
8929,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2011
8930,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2011
8931,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2011
8932,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2011
8933,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2011
8934,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2011
8935,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2011
8936,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2011
8937,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2011
8938,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2011
8939,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2011
8940,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2011
8941,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2011
8942,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
8943,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2011
8944,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2011
8945,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2011
8946,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2011
8947,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2011
8948,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2011
8949,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2011
8950,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2011
8951,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2011
8952,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2011
8953,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2011
8954,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2011
8955,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2011
8956,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2011
8957,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2011
8958,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2011
8959,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2011
8960,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2011
8961,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2011
8962,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8963,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8964,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2011
8965,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2011
8966,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2011
8967,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2011
8968,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2011
8969,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2011
8970,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2011
8971,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2011
8972,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2011
8973,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2011
8974,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2011
8975,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2011
8976,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2011
8977,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2011
8978,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2011
8979,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2011
8980,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
8981,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2011
8982,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2011
8983,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2011
8984,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2011
8985,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2011
8986,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2011
8987,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2011
8988,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2011
8989,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2011
8990,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2011
8991,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2011
8992,I-321,JUVENILE RHEUMATOID ARTHRITIS,2011
8993,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2011
8994,I-323,COLORECTAL CANCER,2011
8995,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2011
8996,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2011
8997,I-326,GENERALIZED ANXIETY DISORDER,2011
8998,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2011
8999,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2011
9000,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2011
9001,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2011
9002,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2011
9003,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2011
9004,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2011
9005,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2011
9006,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2011
9007,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2011
9008,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2011
9009,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2011
9010,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2011
9011,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2011
9012,I-341,BREAST CANCER COMBINATION THERAPY,2011
9013,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2011
9014,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2011
9015,I-344,ACNE VULGARIS,2011
9016,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2011
9017,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2011
9018,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2011
9019,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2011
9020,I-349,ACUTE CORONARY SYNDROME,2011
9021,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2011
9022,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2011
9023,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2011
9024,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2011
9025,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2011
9026,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2011
9027,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2011
9028,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2011
9029,I-358,TREATMENT OF PANIC DISORDER,2011
9030,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2011
9031,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2011
9032,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2011
9033,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2011
9034,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2011
9035,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2011
9036,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2011
9037,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2011
9038,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2011
9039,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2011
9040,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2011
9041,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2011
9042,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2011
9043,I-372,NOSOCOMIAL PNEUMONIA,2011
9044,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2011
9045,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2011
9046,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2011
9047,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2011
9048,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2011
9049,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2011
9050,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2011
9051,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2011
9052,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2011
9053,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2011
9054,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2011
9055,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2011
9056,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2011
9057,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2011
9058,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2011
9059,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2011
9060,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2011
9061,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2011
9062,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2011
9063,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2011
9064,I-393,CHRONIC BACTERIAL PROSTATITIS,2011
9065,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2011
9066,I-395,TO IMPROVE PHYSICAL FUNCTION,2011
9067,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2011
9068,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2011
9069,I-398,IDIOPATHIC SHORT STATURE,2011
9070,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2011
9071,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2011
9072,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2011
9073,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2011
9074,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2011
9075,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2011
9076,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2011
9077,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2011
9078,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2011
9079,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2011
9080,I-409,ESOPHAGEAL CANDIDIASIS,2011
9081,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2011
9082,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2011
9083,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2011
9084,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2011
9085,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2011
9086,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2011
9087,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2011
9088,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2011
9089,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2011
9090,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2011
9091,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2011
9092,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2011
9093,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2011
9094,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2011
9095,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2011
9096,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2011
9097,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2011
9098,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2011
9099,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2011
9100,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2011
9101,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2011
9102,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2011
9103,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2011
9104,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2011
9105,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2011
9106,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2011
9107,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2011
9108,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2011
9109,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2011
9110,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2011
9111,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2011
9112,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2011
9113,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2011
9114,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2011
9115,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2011
9116,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2011
9117,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2011
9118,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2011
9119,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2011
9120,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2011
9121,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2011
9122,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2011
9123,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2011
9124,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2011
9125,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2011
9126,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2011
9127,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2011
9128,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2011
9129,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2011
9130,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2011
9131,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2011
9132,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2011
9133,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2011
9134,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2011
9135,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2011
9136,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2011
9137,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2011
9138,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2011
9139,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2011
9140,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2011
9141,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2011
9142,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2011
9143,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2011
9144,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2011
9145,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2011
9146,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2011
9147,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2011
9148,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2011
9149,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2011
9150,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2011
9151,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2011
9152,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2011
9153,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2011
9154,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
9155,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2011
9156,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2011
9157,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2011
9158,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2011
9159,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2011
9160,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2011
9161,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2011
9162,I-491,INFLUENZA PROPHYLAXIS,2011
9163,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2011
9164,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2011
9165,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2011
9166,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2011
9167,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2011
9168,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2011
9169,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2011
9170,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2011
9171,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2011
9172,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2011
9173,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2011
9174,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2011
9175,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2011
9176,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2011
9177,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2011
9178,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2011
9179,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2011
9180,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2011
9181,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2011
9182,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2011
9183,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2011
9184,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2011
9185,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2011
9186,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2011
9187,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2011
9188,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2011
9189,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2011
9190,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2011
9191,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2011
9192,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2011
9193,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2011
9194,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2011
9195,I-524,GENERALIZED ANXIETY DISORDER (GAD),2011
9196,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2011
9197,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2011
9198,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2011
9199,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2011
9200,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2011
9201,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2011
9202,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2011
9203,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2011
9204,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2011
9205,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2011
9206,I-535,MANAGEMENT OF FIBROMYALGIA,2011
9207,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2011
9208,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2011
9209,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2011
9210,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2011
9211,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2011
9212,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2011
9213,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2011
9214,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2011
9215,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2011
9216,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2011
9217,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2011
9218,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2011
9219,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2011
9220,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2011
9221,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2011
9222,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2011
9223,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2011
9224,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2011
9225,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2011
9226,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2011
9227,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2011
9228,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2011
9229,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2011
9230,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2011
9231,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2011
9232,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2011
9233,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2011
9234,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2011
9235,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2011
9236,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2011
9237,I-566,MANAGEMENT OF FIBROMYALGIA,2011
9238,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2011
9239,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2011
9240,I-569,TREATMENT OF CHRONIC HEPATITIS B,2011
9241,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2011
9242,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2011
9243,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2011
9244,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2011
9245,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2011
9246,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2011
9247,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2011
9248,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2011
9249,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2011
9250,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2011
9251,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2011
9252,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
9253,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2011
9254,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2011
9255,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2011
9256,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2011
9257,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2011
9258,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2011
9259,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2011
9260,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2011
9261,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2011
9262,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2011
9263,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2011
9264,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2011
9265,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2011
9266,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
9267,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2011
9268,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2011
9269,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2011
9270,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2011
9271,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2011
9272,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2011
9273,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2011
9274,I-603,GOUT FLARES,2011
9275,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2011
9276,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2011
9277,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2011
9278,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2011
9279,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2011
9280,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2011
9281,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2011
9282,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2011
9283,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2011
9284,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2011
9285,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2011
9286,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2011
9287,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2011
9288,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2011
9289,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2011
9290,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2011
9291,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2011
9292,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2011
9293,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2011
9294,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2011
9295,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2011
9296,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2011
9297,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2011
9298,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2011
9299,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2011
9300,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2011
9301,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2011
9302,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2011
9303,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2011
9304,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2011
9305,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2011
9306,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2011
9307,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2011
9308,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2011
9309,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2011
9310,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2011
9311,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2011
9312,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2011
9313,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2011
9314,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2011
9315,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2011
9316,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2011
9317,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2011
9318,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2011
9319,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2011
9320,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2011
9321,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2011
9322,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2011
9323,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2011
9324,M-22,CHANGE IN TIME TO ONSET OF ACTION,2011
9325,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2011
9326,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2011
9327,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2011
9328,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2011
9329,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2011
9330,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2011
9331,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2011
9332,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2011
9333,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2011
9334,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2011
9335,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2011
9336,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2011
9337,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2011
9338,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2011
9339,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2011
9340,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2011
9341,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2011
9342,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2011
9343,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2011
9344,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2011
9345,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2011
9346,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2011
9347,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2011
9348,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2011
9349,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2011
9350,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2011
9351,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2011
9352,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2011
9353,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2011
9354,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
9355,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2011
9356,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2011
9357,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2011
9358,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2011
9359,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2011
9360,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2011
9361,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2011
9362,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2011
9363,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2011
9364,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2011
9365,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2011
9366,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2011
9367,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2011
9368,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2011
9369,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2011
9370,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2011
9371,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2011
9372,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2011
9373,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2011
9374,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2011
9375,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2011
9376,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2011
9377,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2011
9378,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2011
9379,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2011
9380,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2011
9381,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2011
9382,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2011
9383,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2011
9384,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2011
9385,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2011
9386,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2011
9387,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2011
9388,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2011
9389,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2011
9390,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2011
9391,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2011
9392,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2011
9393,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2011
9394,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2011
9395,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2011
9396,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2011
9397,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2011
9398,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2011
9399,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2011
9400,PED,PEDIATRIC EXCLUSIVITY,2012
9401,NDF,NEW DOSAGE FORM,2012
9402,NPP,NEW PATIENT POPULATION,2012
9403,NP*,NEW PRODUCT (MINT FLAVORED),2012
9404,NR,NEW ROUTE,2012
9405,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2012
9406,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2012
9407,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2012
9408,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2012
9409,RTO,RX TO OTC SWITCH OR OTC USE,2012
9410,PC,PATENT CHALLENGE,2012
9411,ODE,ORPHAN DRUG EXCLUSIVITY,2012
9412,NS,NEW STRENGTH,2012
9413,NCE,NEW CHEMICAL ENTITY,2012
9414,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2012
9415,NP,NEW PRODUCT,2012
9416,NC,NEW COMBINATION,2012
9417,D-1,ONCE A DAY APPLICATION,2012
9418,D-2,ONCE DAILY DOSING,2012
9419,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2012
9420,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2012
9421,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2012
9422,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2012
9423,D-7,BID DOSING,2012
9424,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2012
9425,D-9,NARCOTIC OVERDOSE IN ADULTS,2012
9426,D-10,NARCOTIC OVERDOSE IN CHILDREN,2012
9427,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2012
9428,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2012
9429,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2012
9430,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2012
9431,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2012
9432,D-16,CONTINUOUS INTRAVENOUS INFUSION,2012
9433,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2012
9434,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2012
9435,D-19,BOLUS DOSING GUIDELINES,2012
9436,D-20,SINGLE 32MG DOSE,2012
9437,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2012
9438,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2012
9439,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2012
9440,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2012
9441,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2012
9442,D-26,ONCE WEEKLY APPLICATION,2012
9443,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2012
9444,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2012
9445,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2012
9446,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2012
9447,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2012
9448,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2012
9449,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2012
9450,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2012
9451,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2012
9452,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2012
9453,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2012
9454,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2012
9455,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2012
9456,D-40,ONCE-A-DAY DOSING REGIMEN,2012
9457,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2012
9458,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2012
9459,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2012
9460,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2012
9461,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2012
9462,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2012
9463,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2012
9464,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2012
9465,D-49,PEDIATRIC DOSING GUIDELINES,2012
9466,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2012
9467,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2012
9468,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2012
9469,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2012
9470,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2012
9471,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2012
9472,D-56,ADDITION OF POSTPRANDIAL DOSING,2012
9473,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2012
9474,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2012
9475,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2012
9476,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2012
9477,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9478,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9479,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2012
9480,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2012
9481,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2012
9482,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2012
9483,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2012
9484,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2012
9485,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2012
9486,D-70,80MG ONCE DAILY DOSING REGIMEN,2012
9487,D-71,EIGHT WEEK DOSING REGIMEN,2012
9488,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2012
9489,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9490,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9491,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2012
9492,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2012
9493,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2012
9494,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2012
9495,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2012
9496,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2012
9497,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2012
9498,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9499,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2012
9500,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2012
9501,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2012
9502,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2012
9503,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
9504,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2012
9505,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2012
9506,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2012
9507,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2012
9508,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2012
9509,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2012
9510,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2012
9511,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2012
9512,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2012
9513,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2012
9514,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2012
9515,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2012
9516,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2012
9517,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2012
9518,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2012
9519,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2012
9520,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2012
9521,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9522,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2012
9523,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
9524,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2012
9525,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2012
9526,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2012
9527,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2012
9528,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2012
9529,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2012
9530,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2012
9531,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2012
9532,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2012
9533,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2012
9534,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2012
9535,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2012
9536,D-120,DOSING REGIMEN ADJUSTMENTS,2012
9537,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2012
9538,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2012
9539,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2012
9540,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2012
9541,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2012
9542,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2012
9543,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2012
9544,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2012
9545,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2012
9546,D-130,"DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN",2012
9547,D-131,EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG,2012
9548,D-132,45MG FOR 6 MONTH ADMINISTRATION,2012
9549,D-133,NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE,2012
9550,I-1,DYSMENORRHEA,2012
9551,I-2,CHOLANGIOPANCREATOGRAPHY,2012
9552,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2012
9553,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2012
9554,I-5,HYSTEROSALPINGOGRAPHY,2012
9555,I-6,TREATMENT OF JUVENILE ARTHRITIS,2012
9556,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2012
9557,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2012
9558,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2012
9559,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2012
9560,I-11,RELIEF OF MILD TO MODERATE PAIN,2012
9561,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2012
9562,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2012
9563,I-14,SEBORRHEIC DERMATITIS,2012
9564,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2012
9565,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2012
9566,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2012
9567,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2012
9568,I-19,HERNIOGRAPHY,2012
9569,I-20,KNEE ARTHROGRAPHY,2012
9570,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2012
9571,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2012
9572,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2012
9573,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2012
9574,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2012
9575,I-26,TREATMENT OF LIVER FLUKES,2012
9576,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2012
9577,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2012
9578,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2012
9579,I-30,TREATMENT OF TINEA PEDIS,2012
9580,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2012
9581,I-32,PEDIATRIC MYELOGRAPHY,2012
9582,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2012
9583,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2012
9584,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2012
9585,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2012
9586,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2012
9587,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2012
9588,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2012
9589,I-40,PRIMARY NOCTURNAL ENURESIS,2012
9590,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2012
9591,I-42,HERPES ZOSTER,2012
9592,I-43,HERPES SIMPLEX ENCEPHALITIS,2012
9593,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2012
9594,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2012
9595,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2012
9596,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2012
9597,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2012
9598,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2012
9599,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2012
9600,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2012
9601,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2012
9602,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2012
9603,I-54,RENAL CONCENTRATION CAPACITY TEST,2012
9604,I-55,HYPERTENSION,2012
9605,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2012
9606,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2012
9607,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2012
9608,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2012
9609,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2012
9610,I-61,FEMALE ANDROGENETIC ALOPECIA,2012
9611,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9612,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2012
9613,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2012
9614,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2012
9615,I-66,UNCOMPLICATED GONORRHEA,2012
9616,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2012
9617,I-68,CENTRAL PRECOCIOUS PUBERTY,2012
9618,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2012
9619,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2012
9620,I-71,VARICELLA INFECTIONS (CHICKENPOX),2012
9621,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2012
9622,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2012
9623,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2012
9624,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2012
9625,I-76,PREVENTION OF OSTEOPOROSIS,2012
9626,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2012
9627,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2012
9628,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2012
9629,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2012
9630,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2012
9631,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2012
9632,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2012
9633,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2012
9634,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2012
9635,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2012
9636,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2012
9637,I-88,MANAGEMENT OF ENDOMETRIOSIS,2012
9638,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2012
9639,I-90,INTENSIVE CARE UNIT SEDATION,2012
9640,I-91,MONOTHERAPY USE FOR HYPERTENSION,2012
9641,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2012
9642,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2012
9643,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2012
9644,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2012
9645,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2012
9646,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2012
9647,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2012
9648,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2012
9649,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2012
9650,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2012
9651,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2012
9652,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2012
9653,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2012
9654,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2012
9655,I-106,TREATMENT OF ACROMEGALY,2012
9656,I-107,VAGINAL CANDIDIASIS,2012
9657,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2012
9658,I-109,TYPHOID FEVER,2012
9659,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2012
9660,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2012
9661,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2012
9662,I-113,TREATMENT OF PROSTATITIS,2012
9663,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2012
9664,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2012
9665,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2012
9666,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2012
9667,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2012
9668,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2012
9669,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2012
9670,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2012
9671,I-122,PSORIASIS OF THE SCALP,2012
9672,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2012
9673,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2012
9674,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2012
9675,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2012
9676,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2012
9677,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2012
9678,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2012
9679,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2012
9680,I-131,PERIPHERAL ARTERIOGRAPHY,2012
9681,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2012
9682,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2012
9683,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2012
9684,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2012
9685,I-136,IDIOPATHIC CHRONIC URTICARIA,2012
9686,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2012
9687,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2012
9688,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2012
9689,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2012
9690,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2012
9691,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2012
9692,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2012
9693,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2012
9694,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2012
9695,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2012
9696,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2012
9697,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2012
9698,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2012
9699,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2012
9700,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2012
9701,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2012
9702,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2012
9703,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2012
9704,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2012
9705,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2012
9706,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2012
9707,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2012
9708,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2012
9709,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2012
9710,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2012
9711,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2012
9712,I-163,TREATMENT OF PHOTOPHOBIA,2012
9713,I-164,CHRONIC BACTERIAL PROSTATITIS,2012
9714,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2012
9715,I-166,TREATMENT OF BULIMIA,2012
9716,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2012
9717,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2012
9718,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2012
9719,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2012
9720,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2012
9721,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2012
9722,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2012
9723,I-174,PELVIC INFLAMMATORY DISEASE,2012
9724,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2012
9725,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2012
9726,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2012
9727,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2012
9728,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2012
9729,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2012
9730,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2012
9731,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2012
9732,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2012
9733,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2012
9734,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
9735,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2012
9736,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9737,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2012
9738,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2012
9739,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2012
9740,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2012
9741,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2012
9742,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2012
9743,I-194,CONGESTIVE HEART FAILURE,2012
9744,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2012
9745,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2012
9746,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2012
9747,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2012
9748,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2012
9749,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2012
9750,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2012
9751,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2012
9752,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2012
9753,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2012
9754,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2012
9755,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2012
9756,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2012
9757,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2012
9758,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2012
9759,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2012
9760,I-211,FOR USE IN PEDIATRIC POPULATION,2012
9761,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2012
9762,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2012
9763,I-214,TREATMENT OF OSTEOPOROSIS,2012
9764,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2012
9765,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2012
9766,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2012
9767,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2012
9768,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2012
9769,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2012
9770,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2012
9771,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2012
9772,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2012
9773,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2012
9774,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2012
9775,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2012
9776,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2012
9777,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2012
9778,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2012
9779,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2012
9780,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2012
9781,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2012
9782,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2012
9783,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2012
9784,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2012
9785,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2012
9786,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2012
9787,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2012
9788,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2012
9789,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2012
9790,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2012
9791,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2012
9792,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2012
9793,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2012
9794,I-245,TREATMENT OF ACUTE SINUSITIS,2012
9795,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2012
9796,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2012
9797,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2012
9798,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2012
9799,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2012
9800,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2012
9801,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2012
9802,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2012
9803,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2012
9804,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2012
9805,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2012
9806,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2012
9807,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2012
9808,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2012
9809,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2012
9810,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2012
9811,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2012
9812,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2012
9813,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2012
9814,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2012
9815,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2012
9816,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2012
9817,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2012
9818,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2012
9819,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2012
9820,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
9821,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2012
9822,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2012
9823,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2012
9824,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2012
9825,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2012
9826,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2012
9827,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2012
9828,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2012
9829,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2012
9830,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2012
9831,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2012
9832,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2012
9833,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2012
9834,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2012
9835,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2012
9836,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2012
9837,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2012
9838,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2012
9839,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2012
9840,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9841,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2012
9842,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2012
9843,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2012
9844,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2012
9845,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2012
9846,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2012
9847,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2012
9848,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2012
9849,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2012
9850,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2012
9851,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2012
9852,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2012
9853,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2012
9854,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2012
9855,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2012
9856,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2012
9857,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2012
9858,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
9859,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2012
9860,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2012
9861,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2012
9862,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2012
9863,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2012
9864,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2012
9865,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2012
9866,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2012
9867,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2012
9868,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2012
9869,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2012
9870,I-321,JUVENILE RHEUMATOID ARTHRITIS,2012
9871,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2012
9872,I-323,COLORECTAL CANCER,2012
9873,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2012
9874,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2012
9875,I-326,GENERALIZED ANXIETY DISORDER,2012
9876,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2012
9877,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2012
9878,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2012
9879,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2012
9880,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2012
9881,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2012
9882,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2012
9883,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2012
9884,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2012
9885,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2012
9886,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2012
9887,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2012
9888,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2012
9889,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2012
9890,I-341,BREAST CANCER COMBINATION THERAPY,2012
9891,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2012
9892,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2012
9893,I-344,ACNE VULGARIS,2012
9894,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2012
9895,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2012
9896,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2012
9897,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2012
9898,I-349,ACUTE CORONARY SYNDROME,2012
9899,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2012
9900,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2012
9901,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2012
9902,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2012
9903,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2012
9904,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2012
9905,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2012
9906,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2012
9907,I-358,TREATMENT OF PANIC DISORDER,2012
9908,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2012
9909,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2012
9910,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2012
9911,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2012
9912,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2012
9913,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2012
9914,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2012
9915,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2012
9916,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2012
9917,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2012
9918,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2012
9919,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2012
9920,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2012
9921,I-372,NOSOCOMIAL PNEUMONIA,2012
9922,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2012
9923,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2012
9924,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2012
9925,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2012
9926,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2012
9927,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2012
9928,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2012
9929,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2012
9930,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2012
9931,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2012
9932,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2012
9933,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2012
9934,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2012
9935,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2012
9936,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2012
9937,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2012
9938,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2012
9939,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2012
9940,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2012
9941,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2012
9942,I-393,CHRONIC BACTERIAL PROSTATITIS,2012
9943,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2012
9944,I-395,TO IMPROVE PHYSICAL FUNCTION,2012
9945,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2012
9946,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2012
9947,I-398,IDIOPATHIC SHORT STATURE,2012
9948,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2012
9949,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2012
9950,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2012
9951,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2012
9952,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2012
9953,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2012
9954,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2012
9955,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2012
9956,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2012
9957,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2012
9958,I-409,ESOPHAGEAL CANDIDIASIS,2012
9959,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2012
9960,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2012
9961,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2012
9962,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2012
9963,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2012
9964,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2012
9965,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2012
9966,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2012
9967,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2012
9968,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2012
9969,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2012
9970,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2012
9971,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2012
9972,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2012
9973,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2012
9974,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2012
9975,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2012
9976,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2012
9977,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2012
9978,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2012
9979,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2012
9980,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2012
9981,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2012
9982,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2012
9983,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2012
9984,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2012
9985,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2012
9986,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2012
9987,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2012
9988,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2012
9989,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2012
9990,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2012
9991,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2012
9992,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2012
9993,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2012
9994,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2012
9995,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2012
9996,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2012
9997,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2012
9998,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2012
9999,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2012
10000,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2012
10001,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2012
10002,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2012
10003,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2012
10004,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2012
10005,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2012
10006,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2012
10007,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2012
10008,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2012
10009,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2012
10010,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2012
10011,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2012
10012,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2012
10013,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2012
10014,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2012
10015,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2012
10016,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2012
10017,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2012
10018,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2012
10019,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2012
10020,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2012
10021,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2012
10022,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2012
10023,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2012
10024,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2012
10025,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2012
10026,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2012
10027,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2012
10028,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2012
10029,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2012
10030,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2012
10031,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2012
10032,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
10033,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2012
10034,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2012
10035,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2012
10036,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2012
10037,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2012
10038,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2012
10039,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2012
10040,I-491,INFLUENZA PROPHYLAXIS,2012
10041,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2012
10042,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2012
10043,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2012
10044,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2012
10045,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2012
10046,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2012
10047,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2012
10048,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2012
10049,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2012
10050,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2012
10051,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2012
10052,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2012
10053,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2012
10054,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2012
10055,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2012
10056,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2012
10057,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2012
10058,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2012
10059,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2012
10060,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2012
10061,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2012
10062,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2012
10063,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2012
10064,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2012
10065,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2012
10066,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2012
10067,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2012
10068,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2012
10069,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2012
10070,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2012
10071,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2012
10072,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2012
10073,I-524,GENERALIZED ANXIETY DISORDER (GAD),2012
10074,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2012
10075,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2012
10076,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2012
10077,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2012
10078,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2012
10079,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2012
10080,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2012
10081,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2012
10082,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2012
10083,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2012
10084,I-535,MANAGEMENT OF FIBROMYALGIA,2012
10085,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2012
10086,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2012
10087,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2012
10088,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2012
10089,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2012
10090,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2012
10091,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2012
10092,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2012
10093,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2012
10094,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2012
10095,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2012
10096,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2012
10097,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2012
10098,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2012
10099,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2012
10100,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2012
10101,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2012
10102,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2012
10103,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2012
10104,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2012
10105,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2012
10106,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2012
10107,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2012
10108,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2012
10109,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2012
10110,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2012
10111,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2012
10112,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2012
10113,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2012
10114,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2012
10115,I-566,MANAGEMENT OF FIBROMYALGIA,2012
10116,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2012
10117,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2012
10118,I-569,TREATMENT OF CHRONIC HEPATITIS B,2012
10119,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2012
10120,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2012
10121,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2012
10122,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2012
10123,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2012
10124,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2012
10125,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2012
10126,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2012
10127,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2012
10128,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2012
10129,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2012
10130,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
10131,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2012
10132,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2012
10133,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2012
10134,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2012
10135,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2012
10136,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2012
10137,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2012
10138,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2012
10139,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2012
10140,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2012
10141,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2012
10142,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2012
10143,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2012
10144,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10145,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2012
10146,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2012
10147,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2012
10148,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2012
10149,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2012
10150,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2012
10151,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2012
10152,I-603,GOUT FLARES,2012
10153,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2012
10154,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2012
10155,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2012
10156,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2012
10157,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2012
10158,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2012
10159,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2012
10160,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2012
10161,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2012
10162,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2012
10163,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2012
10164,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2012
10165,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2012
10166,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2012
10167,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2012
10168,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2012
10169,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2012
10170,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2012
10171,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2012
10172,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2012
10173,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2012
10174,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2012
10175,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2012
10176,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2012
10177,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2012
10178,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2012
10179,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2012
10180,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2012
10181,I-633,MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2012
10182,I-634,TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY,2012
10183,I-635,ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2012
10184,I-636,TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER,2012
10185,I-637,USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER,2012
10186,I-638,"FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.",2012
10187,I-639,"TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE",2012
10188,I-640,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2012
10189,I-641,TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2012
10190,I-642,TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2012
10191,I-643,REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.,2012
10192,I-644,MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED),2012
10193,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2012
10194,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2012
10195,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2012
10196,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2012
10197,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2012
10198,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2012
10199,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2012
10200,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2012
10201,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2012
10202,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2012
10203,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2012
10204,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2012
10205,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2012
10206,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2012
10207,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2012
10208,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2012
10209,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2012
10210,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2012
10211,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2012
10212,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2012
10213,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2012
10214,M-22,CHANGE IN TIME TO ONSET OF ACTION,2012
10215,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2012
10216,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2012
10217,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2012
10218,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2012
10219,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2012
10220,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2012
10221,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2012
10222,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2012
10223,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2012
10224,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2012
10225,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2012
10226,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2012
10227,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2012
10228,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2012
10229,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2012
10230,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2012
10231,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2012
10232,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2012
10233,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2012
10234,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2012
10235,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2012
10236,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2012
10237,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2012
10238,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2012
10239,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2012
10240,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2012
10241,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2012
10242,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2012
10243,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2012
10244,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10245,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2012
10246,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2012
10247,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2012
10248,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2012
10249,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2012
10250,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2012
10251,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2012
10252,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2012
10253,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2012
10254,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2012
10255,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2012
10256,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2012
10257,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2012
10258,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2012
10259,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2012
10260,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2012
10261,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2012
10262,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2012
10263,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2012
10264,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2012
10265,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2012
10266,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2012
10267,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2012
10268,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2012
10269,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2012
10270,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2012
10271,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2012
10272,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2012
10273,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2012
10274,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2012
10275,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2012
10276,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2012
10277,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2012
10278,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2012
10279,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2012
10280,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2012
10281,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2012
10282,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2012
10283,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2012
10284,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2012
10285,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2012
10286,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2012
10287,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2012
10288,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2012
10289,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2012
10290,M-98,NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.,2012
10291,M-99,ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.,2012
10292,M-100,INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS,2012
10293,M-101,INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL,2012
10294,M-102,"INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, ""INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY.""",2012
10295,M-103,"SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING",2012
10296,M-104,INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY,2012
10297,M-105,"NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE",2012
10298,M-106,ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT,2012
10299,M-107,"INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED ""STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY"".",2012
10300,M-108,CHANGES ARE BASED ON RESULTS FROM STUDY CV181057,2012
10301,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2013
10302,NP,NEW PRODUCT,2013
10303,NDF,NEW DOSAGE FORM,2013
10304,PED,PEDIATRIC EXCLUSIVITY,2013
10305,NC,NEW COMBINATION,2013
10306,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2013
10307,NP*,NEW PRODUCT (MINT FLAVORED),2013
10308,ODE,ORPHAN DRUG EXCLUSIVITY,2013
10309,NR,NEW ROUTE,2013
10310,NCE,NEW CHEMICAL ENTITY,2013
10311,RTO,RX TO OTC SWITCH OR OTC USE,2013
10312,NS,NEW STRENGTH,2013
10313,NPP,NEW PATIENT POPULATION,2013
10314,PC,PATENT CHALLENGE,2013
10315,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2013
10316,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2013
10317,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2013
10318,D-1,ONCE A DAY APPLICATION,2013
10319,D-2,ONCE DAILY DOSING,2013
10320,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2013
10321,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2013
10322,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2013
10323,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2013
10324,D-7,BID DOSING,2013
10325,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2013
10326,D-9,NARCOTIC OVERDOSE IN ADULTS,2013
10327,D-10,NARCOTIC OVERDOSE IN CHILDREN,2013
10328,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2013
10329,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2013
10330,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2013
10331,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2013
10332,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2013
10333,D-16,CONTINUOUS INTRAVENOUS INFUSION,2013
10334,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2013
10335,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2013
10336,D-19,BOLUS DOSING GUIDELINES,2013
10337,D-20,SINGLE 32MG DOSE,2013
10338,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2013
10339,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2013
10340,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2013
10341,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2013
10342,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2013
10343,D-26,ONCE WEEKLY APPLICATION,2013
10344,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2013
10345,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2013
10346,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2013
10347,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2013
10348,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2013
10349,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2013
10350,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2013
10351,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2013
10352,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2013
10353,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2013
10354,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2013
10355,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2013
10356,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2013
10357,D-40,ONCE-A-DAY DOSING REGIMEN,2013
10358,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2013
10359,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2013
10360,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2013
10361,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2013
10362,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2013
10363,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2013
10364,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2013
10365,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2013
10366,D-49,PEDIATRIC DOSING GUIDELINES,2013
10367,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2013
10368,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2013
10369,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2013
10370,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2013
10371,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2013
10372,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2013
10373,D-56,ADDITION OF POSTPRANDIAL DOSING,2013
10374,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2013
10375,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2013
10376,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2013
10377,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2013
10378,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10379,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10380,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2013
10381,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2013
10382,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2013
10383,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2013
10384,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2013
10385,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2013
10386,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2013
10387,D-70,80MG ONCE DAILY DOSING REGIMEN,2013
10388,D-71,EIGHT WEEK DOSING REGIMEN,2013
10389,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2013
10390,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10391,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10392,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2013
10393,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2013
10394,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2013
10395,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2013
10396,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2013
10397,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2013
10398,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2013
10399,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10400,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2013
10401,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2013
10402,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2013
10403,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2013
10404,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
10405,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2013
10406,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2013
10407,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2013
10408,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2013
10409,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2013
10410,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2013
10411,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2013
10412,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2013
10413,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2013
10414,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2013
10415,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2013
10416,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2013
10417,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2013
10418,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2013
10419,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2013
10420,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2013
10421,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2013
10422,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10423,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2013
10424,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
10425,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2013
10426,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2013
10427,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2013
10428,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2013
10429,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2013
10430,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2013
10431,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2013
10432,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2013
10433,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2013
10434,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2013
10435,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2013
10436,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2013
10437,D-120,DOSING REGIMEN ADJUSTMENTS,2013
10438,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2013
10439,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2013
10440,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2013
10441,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2013
10442,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2013
10443,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2013
10444,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2013
10445,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2013
10446,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2013
10447,D-130,"DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN",2013
10448,D-131,EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG,2013
10449,D-132,45MG FOR 6 MONTH ADMINISTRATION,2013
10450,D-133,NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE,2013
10451,D-134,INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY,2013
10452,I-1,DYSMENORRHEA,2013
10453,I-2,CHOLANGIOPANCREATOGRAPHY,2013
10454,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2013
10455,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2013
10456,I-5,HYSTEROSALPINGOGRAPHY,2013
10457,I-6,TREATMENT OF JUVENILE ARTHRITIS,2013
10458,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2013
10459,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2013
10460,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2013
10461,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2013
10462,I-11,RELIEF OF MILD TO MODERATE PAIN,2013
10463,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2013
10464,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2013
10465,I-14,SEBORRHEIC DERMATITIS,2013
10466,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2013
10467,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2013
10468,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2013
10469,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2013
10470,I-19,HERNIOGRAPHY,2013
10471,I-20,KNEE ARTHROGRAPHY,2013
10472,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2013
10473,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2013
10474,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2013
10475,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2013
10476,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2013
10477,I-26,TREATMENT OF LIVER FLUKES,2013
10478,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2013
10479,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2013
10480,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2013
10481,I-30,TREATMENT OF TINEA PEDIS,2013
10482,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2013
10483,I-32,PEDIATRIC MYELOGRAPHY,2013
10484,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2013
10485,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2013
10486,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2013
10487,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2013
10488,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2013
10489,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2013
10490,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2013
10491,I-40,PRIMARY NOCTURNAL ENURESIS,2013
10492,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2013
10493,I-42,HERPES ZOSTER,2013
10494,I-43,HERPES SIMPLEX ENCEPHALITIS,2013
10495,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2013
10496,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2013
10497,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2013
10498,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2013
10499,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2013
10500,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2013
10501,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2013
10502,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2013
10503,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2013
10504,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2013
10505,I-54,RENAL CONCENTRATION CAPACITY TEST,2013
10506,I-55,HYPERTENSION,2013
10507,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2013
10508,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2013
10509,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2013
10510,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2013
10511,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2013
10512,I-61,FEMALE ANDROGENETIC ALOPECIA,2013
10513,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10514,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2013
10515,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2013
10516,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2013
10517,I-66,UNCOMPLICATED GONORRHEA,2013
10518,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2013
10519,I-68,CENTRAL PRECOCIOUS PUBERTY,2013
10520,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2013
10521,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2013
10522,I-71,VARICELLA INFECTIONS (CHICKENPOX),2013
10523,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2013
10524,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2013
10525,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2013
10526,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2013
10527,I-76,PREVENTION OF OSTEOPOROSIS,2013
10528,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2013
10529,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2013
10530,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2013
10531,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2013
10532,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2013
10533,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2013
10534,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2013
10535,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2013
10536,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2013
10537,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2013
10538,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2013
10539,I-88,MANAGEMENT OF ENDOMETRIOSIS,2013
10540,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2013
10541,I-90,INTENSIVE CARE UNIT SEDATION,2013
10542,I-91,MONOTHERAPY USE FOR HYPERTENSION,2013
10543,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2013
10544,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2013
10545,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2013
10546,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2013
10547,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2013
10548,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2013
10549,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2013
10550,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2013
10551,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2013
10552,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2013
10553,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2013
10554,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2013
10555,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2013
10556,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2013
10557,I-106,TREATMENT OF ACROMEGALY,2013
10558,I-107,VAGINAL CANDIDIASIS,2013
10559,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2013
10560,I-109,TYPHOID FEVER,2013
10561,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2013
10562,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2013
10563,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2013
10564,I-113,TREATMENT OF PROSTATITIS,2013
10565,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2013
10566,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2013
10567,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2013
10568,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2013
10569,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2013
10570,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2013
10571,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2013
10572,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2013
10573,I-122,PSORIASIS OF THE SCALP,2013
10574,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2013
10575,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2013
10576,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2013
10577,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2013
10578,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2013
10579,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2013
10580,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2013
10581,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2013
10582,I-131,PERIPHERAL ARTERIOGRAPHY,2013
10583,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2013
10584,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2013
10585,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2013
10586,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2013
10587,I-136,IDIOPATHIC CHRONIC URTICARIA,2013
10588,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2013
10589,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2013
10590,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2013
10591,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2013
10592,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2013
10593,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2013
10594,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2013
10595,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2013
10596,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2013
10597,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2013
10598,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2013
10599,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2013
10600,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2013
10601,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2013
10602,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2013
10603,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2013
10604,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2013
10605,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2013
10606,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2013
10607,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2013
10608,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2013
10609,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2013
10610,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2013
10611,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2013
10612,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2013
10613,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2013
10614,I-163,TREATMENT OF PHOTOPHOBIA,2013
10615,I-164,CHRONIC BACTERIAL PROSTATITIS,2013
10616,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2013
10617,I-166,TREATMENT OF BULIMIA,2013
10618,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2013
10619,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2013
10620,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2013
10621,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2013
10622,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2013
10623,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2013
10624,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2013
10625,I-174,PELVIC INFLAMMATORY DISEASE,2013
10626,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2013
10627,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2013
10628,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2013
10629,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2013
10630,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2013
10631,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2013
10632,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2013
10633,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2013
10634,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2013
10635,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2013
10636,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
10637,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2013
10638,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10639,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2013
10640,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2013
10641,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2013
10642,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2013
10643,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2013
10644,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2013
10645,I-194,CONGESTIVE HEART FAILURE,2013
10646,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2013
10647,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2013
10648,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2013
10649,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2013
10650,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2013
10651,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2013
10652,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2013
10653,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2013
10654,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2013
10655,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2013
10656,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2013
10657,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2013
10658,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2013
10659,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2013
10660,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2013
10661,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2013
10662,I-211,FOR USE IN PEDIATRIC POPULATION,2013
10663,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2013
10664,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2013
10665,I-214,TREATMENT OF OSTEOPOROSIS,2013
10666,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2013
10667,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2013
10668,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2013
10669,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2013
10670,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2013
10671,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2013
10672,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2013
10673,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2013
10674,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2013
10675,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2013
10676,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2013
10677,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2013
10678,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2013
10679,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2013
10680,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2013
10681,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2013
10682,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2013
10683,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2013
10684,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2013
10685,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2013
10686,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2013
10687,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2013
10688,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2013
10689,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2013
10690,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2013
10691,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2013
10692,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2013
10693,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2013
10694,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2013
10695,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2013
10696,I-245,TREATMENT OF ACUTE SINUSITIS,2013
10697,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2013
10698,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2013
10699,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2013
10700,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2013
10701,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2013
10702,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2013
10703,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2013
10704,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2013
10705,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2013
10706,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2013
10707,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2013
10708,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2013
10709,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2013
10710,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2013
10711,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2013
10712,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2013
10713,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2013
10714,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2013
10715,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2013
10716,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2013
10717,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2013
10718,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2013
10719,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2013
10720,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2013
10721,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2013
10722,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
10723,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2013
10724,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2013
10725,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2013
10726,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2013
10727,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2013
10728,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2013
10729,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2013
10730,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2013
10731,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2013
10732,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2013
10733,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2013
10734,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2013
10735,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2013
10736,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2013
10737,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2013
10738,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2013
10739,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2013
10740,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2013
10741,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2013
10742,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10743,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10744,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2013
10745,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2013
10746,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2013
10747,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2013
10748,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2013
10749,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2013
10750,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2013
10751,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2013
10752,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2013
10753,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2013
10754,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2013
10755,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2013
10756,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2013
10757,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2013
10758,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2013
10759,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2013
10760,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
10761,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2013
10762,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2013
10763,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2013
10764,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2013
10765,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2013
10766,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2013
10767,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2013
10768,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2013
10769,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2013
10770,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2013
10771,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2013
10772,I-321,JUVENILE RHEUMATOID ARTHRITIS,2013
10773,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2013
10774,I-323,COLORECTAL CANCER,2013
10775,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2013
10776,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2013
10777,I-326,GENERALIZED ANXIETY DISORDER,2013
10778,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2013
10779,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2013
10780,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2013
10781,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2013
10782,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2013
10783,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2013
10784,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2013
10785,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2013
10786,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2013
10787,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2013
10788,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2013
10789,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2013
10790,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2013
10791,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2013
10792,I-341,BREAST CANCER COMBINATION THERAPY,2013
10793,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2013
10794,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2013
10795,I-344,ACNE VULGARIS,2013
10796,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2013
10797,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2013
10798,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2013
10799,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2013
10800,I-349,ACUTE CORONARY SYNDROME,2013
10801,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2013
10802,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2013
10803,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2013
10804,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2013
10805,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2013
10806,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2013
10807,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2013
10808,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2013
10809,I-358,TREATMENT OF PANIC DISORDER,2013
10810,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2013
10811,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2013
10812,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2013
10813,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2013
10814,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2013
10815,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2013
10816,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2013
10817,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2013
10818,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2013
10819,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2013
10820,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2013
10821,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2013
10822,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2013
10823,I-372,NOSOCOMIAL PNEUMONIA,2013
10824,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2013
10825,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2013
10826,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2013
10827,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2013
10828,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2013
10829,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2013
10830,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2013
10831,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2013
10832,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2013
10833,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2013
10834,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2013
10835,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2013
10836,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2013
10837,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2013
10838,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2013
10839,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2013
10840,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2013
10841,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....",2013
10842,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2013
10843,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2013
10844,I-393,CHRONIC BACTERIAL PROSTATITIS,2013
10845,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2013
10846,I-395,TO IMPROVE PHYSICAL FUNCTION,2013
10847,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2013
10848,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2013
10849,I-398,IDIOPATHIC SHORT STATURE,2013
10850,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2013
10851,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2013
10852,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2013
10853,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2013
10854,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2013
10855,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2013
10856,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2013
10857,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2013
10858,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2013
10859,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2013
10860,I-409,ESOPHAGEAL CANDIDIASIS,2013
10861,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2013
10862,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2013
10863,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2013
10864,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2013
10865,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2013
10866,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2013
10867,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2013
10868,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2013
10869,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2013
10870,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2013
10871,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2013
10872,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2013
10873,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2013
10874,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2013
10875,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2013
10876,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2013
10877,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2013
10878,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2013
10879,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2013
10880,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2013
10881,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2013
10882,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2013
10883,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2013
10884,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2013
10885,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2013
10886,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2013
10887,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2013
10888,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2013
10889,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2013
10890,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2013
10891,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2013
10892,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2013
10893,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2013
10894,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2013
10895,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2013
10896,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2013
10897,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2013
10898,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2013
10899,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2013
10900,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2013
10901,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2013
10902,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2013
10903,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2013
10904,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2013
10905,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2013
10906,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2013
10907,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2013
10908,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2013
10909,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2013
10910,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2013
10911,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2013
10912,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2013
10913,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2013
10914,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2013
10915,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2013
10916,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2013
10917,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2013
10918,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2013
10919,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2013
10920,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2013
10921,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2013
10922,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2013
10923,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2013
10924,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2013
10925,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2013
10926,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2013
10927,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2013
10928,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2013
10929,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2013
10930,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2013
10931,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2013
10932,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2013
10933,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2013
10934,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
10935,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2013
10936,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2013
10937,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2013
10938,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2013
10939,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2013
10940,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2013
10941,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2013
10942,I-491,INFLUENZA PROPHYLAXIS,2013
10943,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2013
10944,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2013
10945,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2013
10946,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2013
10947,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2013
10948,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2013
10949,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2013
10950,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2013
10951,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2013
10952,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2013
10953,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2013
10954,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2013
10955,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2013
10956,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2013
10957,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2013
10958,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2013
10959,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2013
10960,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2013
10961,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2013
10962,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2013
10963,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2013
10964,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2013
10965,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2013
10966,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2013
10967,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2013
10968,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2013
10969,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2013
10970,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2013
10971,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2013
10972,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2013
10973,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2013
10974,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2013
10975,I-524,GENERALIZED ANXIETY DISORDER (GAD),2013
10976,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2013
10977,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2013
10978,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2013
10979,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2013
10980,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2013
10981,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2013
10982,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2013
10983,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2013
10984,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2013
10985,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2013
10986,I-535,MANAGEMENT OF FIBROMYALGIA,2013
10987,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2013
10988,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2013
10989,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2013
10990,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2013
10991,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2013
10992,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2013
10993,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2013
10994,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2013
10995,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2013
10996,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2013
10997,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2013
10998,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2013
10999,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2013
11000,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2013
11001,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2013
11002,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2013
11003,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2013
11004,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2013
11005,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2013
11006,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2013
11007,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2013
11008,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2013
11009,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2013
11010,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2013
11011,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2013
11012,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2013
11013,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2013
11014,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2013
11015,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2013
11016,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2013
11017,I-566,MANAGEMENT OF FIBROMYALGIA,2013
11018,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2013
11019,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2013
11020,I-569,TREATMENT OF CHRONIC HEPATITIS B,2013
11021,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2013
11022,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2013
11023,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2013
11024,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2013
11025,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2013
11026,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2013
11027,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2013
11028,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2013
11029,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2013
11030,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2013
11031,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2013
11032,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
11033,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2013
11034,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2013
11035,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2013
11036,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2013
11037,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2013
11038,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2013
11039,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2013
11040,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2013
11041,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2013
11042,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2013
11043,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2013
11044,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2013
11045,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2013
11046,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11047,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2013
11048,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2013
11049,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2013
11050,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2013
11051,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2013
11052,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2013
11053,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2013
11054,I-603,GOUT FLARES,2013
11055,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2013
11056,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2013
11057,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2013
11058,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2013
11059,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2013
11060,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2013
11061,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2013
11062,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2013
11063,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2013
11064,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2013
11065,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2013
11066,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2013
11067,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2013
11068,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2013
11069,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2013
11070,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2013
11071,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2013
11072,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2013
11073,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2013
11074,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2013
11075,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2013
11076,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2013
11077,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2013
11078,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2013
11079,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2013
11080,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2013
11081,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2013
11082,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2013
11083,I-633,MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2013
11084,I-634,TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY,2013
11085,I-635,ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2013
11086,I-636,TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER,2013
11087,I-637,USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER,2013
11088,I-638,"FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.",2013
11089,I-639,"TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE",2013
11090,I-640,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2013
11091,I-641,TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2013
11092,I-642,TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2013
11093,I-643,REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.,2013
11094,I-644,MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED),2013
11095,I-645,MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2013
11096,I-646,SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD),2013
11097,I-647,SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2013
11098,I-648,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2013
11099,I-649,TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY,2013
11100,I-650,"TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY",2013
11101,I-651,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY,2013
11102,I-652,MANAGEMENT OF POSTHERPETIC NEURALGIA,2013
11103,I-653,TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS,2013
11104,I-654,MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE,2013
11105,I-655,"TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2013
11106,I-656,"MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2013
11107,I-657,PLAQUE PSORIASIS OF THE SCALP,2013
11108,I-658,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY",2013
11109,I-659,PLAQUE PSORIASIS OF THE BODY,2013
11110,I-660,TREATMENT OF DEEP VEIN THROMBOSIS,2013
11111,I-661,TREATMENT OF PULMONARY EMBOLISM,2013
11112,I-662,REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM,2013
11113,I-663,IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2013
11114,I-664,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2013
11115,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2013
11116,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2013
11117,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2013
11118,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2013
11119,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2013
11120,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2013
11121,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2013
11122,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2013
11123,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2013
11124,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2013
11125,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2013
11126,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2013
11127,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2013
11128,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2013
11129,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2013
11130,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2013
11131,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2013
11132,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2013
11133,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2013
11134,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2013
11135,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2013
11136,M-22,CHANGE IN TIME TO ONSET OF ACTION,2013
11137,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2013
11138,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2013
11139,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2013
11140,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2013
11141,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2013
11142,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2013
11143,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2013
11144,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2013
11145,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2013
11146,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2013
11147,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2013
11148,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2013
11149,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2013
11150,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2013
11151,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2013
11152,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2013
11153,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2013
11154,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2013
11155,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2013
11156,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2013
11157,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2013
11158,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2013
11159,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2013
11160,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2013
11161,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2013
11162,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2013
11163,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2013
11164,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2013
11165,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2013
11166,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11167,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2013
11168,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2013
11169,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2013
11170,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2013
11171,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2013
11172,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2013
11173,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2013
11174,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2013
11175,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2013
11176,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2013
11177,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2013
11178,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2013
11179,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2013
11180,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2013
11181,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2013
11182,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2013
11183,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2013
11184,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2013
11185,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2013
11186,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2013
11187,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2013
11188,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2013
11189,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2013
11190,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2013
11191,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2013
11192,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2013
11193,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2013
11194,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2013
11195,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2013
11196,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2013
11197,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2013
11198,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2013
11199,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2013
11200,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2013
11201,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2013
11202,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2013
11203,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2013
11204,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2013
11205,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2013
11206,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2013
11207,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2013
11208,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2013
11209,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2013
11210,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2013
11211,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2013
11212,M-98,NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.,2013
11213,M-99,ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.,2013
11214,M-100,INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS,2013
11215,M-101,INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL,2013
11216,M-102,"INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, ""INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY.""",2013
11217,M-103,"SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING",2013
11218,M-104,INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY,2013
11219,M-105,"NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE",2013
11220,M-106,ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT,2013
11221,M-107,"INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED ""STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY"".",2013
11222,M-108,CHANGES ARE BASED ON RESULTS FROM STUDY CV181057,2013
11223,M-109,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2013
11224,M-110,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2013
11225,M-111,LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS,2013
11226,M-112,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS,2013
11227,M-113,LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS,2013
11228,M-114,CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR),2013
11229,M-115,"REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES",2013
11230,M-116,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008,2013
11231,M-117,ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL,2013
11232,M-118,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36,2013
11233,M-119,LABELING CHANGES REGARDING MISSED DOSES,2013
11234,M-120,CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS,2013
11235,M-121,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43,2013
11236,M-122,LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL,2013
11237,M-123,UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY,2013
11238,ODE,ORPHAN DRUG EXCLUSIVITY,2014
11239,NPP,NEW PATIENT POPULATION,2014
11240,RTO**,OTC USE FOR WOMEN 14 AND BELOW,2014
11241,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2014
11242,NCE*,NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).,2014
11243,NS,NEW STRENGTH,2014
11244,NR,NEW ROUTE,2014
11245,NP*,NEW PRODUCT (MINT FLAVORED),2014
11246,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2014
11247,RTO,RX TO OTC SWITCH OR OTC USE,2014
11248,NP,NEW PRODUCT,2014
11249,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2014
11250,NC,NEW COMBINATION,2014
11251,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2014
11252,NCE,NEW CHEMICAL ENTITY,2014
11253,RTO*,OTC USE FOR WOMEN AGES 15 AND 16,2014
11254,PED,PEDIATRIC EXCLUSIVITY,2014
11255,NDF,NEW DOSAGE FORM,2014
11256,PC,PATENT CHALLENGE,2014
11257,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2014
11258,D-1,ONCE A DAY APPLICATION,2014
11259,D-2,ONCE DAILY DOSING,2014
11260,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2014
11261,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2014
11262,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2014
11263,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2014
11264,D-7,BID DOSING,2014
11265,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2014
11266,D-9,NARCOTIC OVERDOSE IN ADULTS,2014
11267,D-10,NARCOTIC OVERDOSE IN CHILDREN,2014
11268,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2014
11269,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2014
11270,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2014
11271,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2014
11272,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2014
11273,D-16,CONTINUOUS INTRAVENOUS INFUSION,2014
11274,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2014
11275,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2014
11276,D-19,BOLUS DOSING GUIDELINES,2014
11277,D-20,SINGLE 32MG DOSE,2014
11278,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2014
11279,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2014
11280,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2014
11281,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2014
11282,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2014
11283,D-26,ONCE WEEKLY APPLICATION,2014
11284,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2014
11285,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2014
11286,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2014
11287,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2014
11288,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2014
11289,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2014
11290,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2014
11291,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2014
11292,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2014
11293,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2014
11294,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2014
11295,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2014
11296,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2014
11297,D-40,ONCE-A-DAY DOSING REGIMEN,2014
11298,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2014
11299,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2014
11300,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2014
11301,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2014
11302,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2014
11303,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2014
11304,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2014
11305,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2014
11306,D-49,PEDIATRIC DOSING GUIDELINES,2014
11307,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2014
11308,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2014
11309,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2014
11310,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2014
11311,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2014
11312,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2014
11313,D-56,ADDITION OF POSTPRANDIAL DOSING,2014
11314,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2014
11315,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2014
11316,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2014
11317,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2014
11318,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11319,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11320,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2014
11321,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2014
11322,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2014
11323,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2014
11324,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2014
11325,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2014
11326,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2014
11327,D-70,80MG ONCE DAILY DOSING REGIMEN,2014
11328,D-71,EIGHT WEEK DOSING REGIMEN,2014
11329,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2014
11330,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11331,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11332,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2014
11333,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2014
11334,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2014
11335,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2014
11336,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2014
11337,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2014
11338,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2014
11339,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11340,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2014
11341,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2014
11342,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2014
11343,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2014
11344,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
11345,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2014
11346,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2014
11347,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2014
11348,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2014
11349,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2014
11350,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2014
11351,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2014
11352,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2014
11353,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2014
11354,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2014
11355,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2014
11356,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2014
11357,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2014
11358,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2014
11359,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2014
11360,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2014
11361,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2014
11362,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11363,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2014
11364,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
11365,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2014
11366,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2014
11367,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2014
11368,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2014
11369,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2014
11370,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2014
11371,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2014
11372,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2014
11373,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2014
11374,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2014
11375,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2014
11376,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2014
11377,D-120,DOSING REGIMEN ADJUSTMENTS,2014
11378,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2014
11379,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2014
11380,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2014
11381,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2014
11382,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2014
11383,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2014
11384,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2014
11385,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2014
11386,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2014
11387,D-130,"DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN",2014
11388,D-131,EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG,2014
11389,D-132,45MG FOR 6 MONTH ADMINISTRATION,2014
11390,D-133,NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE,2014
11391,D-134,INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY,2014
11392,D-135,"UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE",2014
11393,D-136,"ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS",2014
11394,I-1,DYSMENORRHEA,2014
11395,I-2,CHOLANGIOPANCREATOGRAPHY,2014
11396,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2014
11397,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2014
11398,I-5,HYSTEROSALPINGOGRAPHY,2014
11399,I-6,TREATMENT OF JUVENILE ARTHRITIS,2014
11400,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2014
11401,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2014
11402,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2014
11403,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2014
11404,I-11,RELIEF OF MILD TO MODERATE PAIN,2014
11405,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2014
11406,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2014
11407,I-14,SEBORRHEIC DERMATITIS,2014
11408,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2014
11409,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2014
11410,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2014
11411,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2014
11412,I-19,HERNIOGRAPHY,2014
11413,I-20,KNEE ARTHROGRAPHY,2014
11414,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2014
11415,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2014
11416,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2014
11417,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2014
11418,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2014
11419,I-26,TREATMENT OF LIVER FLUKES,2014
11420,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2014
11421,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2014
11422,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2014
11423,I-30,TREATMENT OF TINEA PEDIS,2014
11424,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2014
11425,I-32,PEDIATRIC MYELOGRAPHY,2014
11426,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2014
11427,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2014
11428,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2014
11429,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2014
11430,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2014
11431,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2014
11432,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2014
11433,I-40,PRIMARY NOCTURNAL ENURESIS,2014
11434,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2014
11435,I-42,HERPES ZOSTER,2014
11436,I-43,HERPES SIMPLEX ENCEPHALITIS,2014
11437,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2014
11438,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2014
11439,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2014
11440,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2014
11441,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2014
11442,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2014
11443,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2014
11444,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2014
11445,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2014
11446,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2014
11447,I-54,RENAL CONCENTRATION CAPACITY TEST,2014
11448,I-55,HYPERTENSION,2014
11449,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2014
11450,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2014
11451,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2014
11452,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2014
11453,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2014
11454,I-61,FEMALE ANDROGENETIC ALOPECIA,2014
11455,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11456,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2014
11457,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2014
11458,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2014
11459,I-66,UNCOMPLICATED GONORRHEA,2014
11460,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2014
11461,I-68,CENTRAL PRECOCIOUS PUBERTY,2014
11462,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2014
11463,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2014
11464,I-71,VARICELLA INFECTIONS (CHICKENPOX),2014
11465,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2014
11466,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2014
11467,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2014
11468,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2014
11469,I-76,PREVENTION OF OSTEOPOROSIS,2014
11470,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2014
11471,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2014
11472,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2014
11473,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2014
11474,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2014
11475,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2014
11476,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2014
11477,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2014
11478,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2014
11479,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2014
11480,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2014
11481,I-88,MANAGEMENT OF ENDOMETRIOSIS,2014
11482,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2014
11483,I-90,INTENSIVE CARE UNIT SEDATION,2014
11484,I-91,MONOTHERAPY USE FOR HYPERTENSION,2014
11485,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2014
11486,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2014
11487,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2014
11488,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2014
11489,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2014
11490,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2014
11491,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2014
11492,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2014
11493,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2014
11494,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2014
11495,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2014
11496,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2014
11497,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2014
11498,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2014
11499,I-106,TREATMENT OF ACROMEGALY,2014
11500,I-107,VAGINAL CANDIDIASIS,2014
11501,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2014
11502,I-109,TYPHOID FEVER,2014
11503,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2014
11504,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2014
11505,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2014
11506,I-113,TREATMENT OF PROSTATITIS,2014
11507,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2014
11508,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2014
11509,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2014
11510,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2014
11511,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2014
11512,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2014
11513,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2014
11514,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2014
11515,I-122,PSORIASIS OF THE SCALP,2014
11516,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2014
11517,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2014
11518,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2014
11519,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2014
11520,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2014
11521,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2014
11522,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2014
11523,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2014
11524,I-131,PERIPHERAL ARTERIOGRAPHY,2014
11525,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2014
11526,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2014
11527,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2014
11528,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2014
11529,I-136,IDIOPATHIC CHRONIC URTICARIA,2014
11530,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2014
11531,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2014
11532,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2014
11533,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2014
11534,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2014
11535,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2014
11536,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2014
11537,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2014
11538,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2014
11539,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2014
11540,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2014
11541,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2014
11542,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2014
11543,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2014
11544,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2014
11545,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2014
11546,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2014
11547,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2014
11548,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2014
11549,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2014
11550,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2014
11551,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2014
11552,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2014
11553,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2014
11554,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2014
11555,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2014
11556,I-163,TREATMENT OF PHOTOPHOBIA,2014
11557,I-164,CHRONIC BACTERIAL PROSTATITIS,2014
11558,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2014
11559,I-166,TREATMENT OF BULIMIA,2014
11560,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2014
11561,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2014
11562,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2014
11563,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2014
11564,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2014
11565,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2014
11566,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2014
11567,I-174,PELVIC INFLAMMATORY DISEASE,2014
11568,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2014
11569,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2014
11570,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2014
11571,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2014
11572,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2014
11573,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2014
11574,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2014
11575,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2014
11576,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2014
11577,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2014
11578,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
11579,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2014
11580,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11581,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2014
11582,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2014
11583,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2014
11584,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2014
11585,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2014
11586,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2014
11587,I-194,CONGESTIVE HEART FAILURE,2014
11588,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2014
11589,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2014
11590,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2014
11591,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2014
11592,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2014
11593,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2014
11594,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2014
11595,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2014
11596,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2014
11597,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2014
11598,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2014
11599,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2014
11600,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2014
11601,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2014
11602,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2014
11603,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2014
11604,I-211,FOR USE IN PEDIATRIC POPULATION,2014
11605,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2014
11606,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2014
11607,I-214,TREATMENT OF OSTEOPOROSIS,2014
11608,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2014
11609,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2014
11610,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2014
11611,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2014
11612,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2014
11613,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2014
11614,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2014
11615,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2014
11616,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2014
11617,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2014
11618,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2014
11619,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2014
11620,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2014
11621,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2014
11622,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2014
11623,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2014
11624,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2014
11625,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2014
11626,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2014
11627,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2014
11628,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2014
11629,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2014
11630,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2014
11631,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2014
11632,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2014
11633,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2014
11634,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2014
11635,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2014
11636,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2014
11637,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2014
11638,I-245,TREATMENT OF ACUTE SINUSITIS,2014
11639,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2014
11640,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2014
11641,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2014
11642,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2014
11643,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2014
11644,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2014
11645,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2014
11646,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2014
11647,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2014
11648,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2014
11649,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2014
11650,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2014
11651,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2014
11652,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2014
11653,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2014
11654,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2014
11655,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2014
11656,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2014
11657,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2014
11658,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2014
11659,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2014
11660,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2014
11661,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2014
11662,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2014
11663,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2014
11664,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
11665,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2014
11666,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2014
11667,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2014
11668,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2014
11669,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2014
11670,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2014
11671,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2014
11672,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2014
11673,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2014
11674,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2014
11675,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2014
11676,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2014
11677,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2014
11678,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2014
11679,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2014
11680,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2014
11681,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2014
11682,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2014
11683,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2014
11684,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11685,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11686,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2014
11687,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2014
11688,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2014
11689,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2014
11690,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2014
11691,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2014
11692,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2014
11693,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2014
11694,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2014
11695,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2014
11696,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2014
11697,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2014
11698,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2014
11699,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2014
11700,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2014
11701,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2014
11702,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
11703,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2014
11704,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2014
11705,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2014
11706,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2014
11707,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2014
11708,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2014
11709,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2014
11710,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2014
11711,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2014
11712,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2014
11713,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2014
11714,I-321,JUVENILE RHEUMATOID ARTHRITIS,2014
11715,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2014
11716,I-323,COLORECTAL CANCER,2014
11717,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2014
11718,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2014
11719,I-326,GENERALIZED ANXIETY DISORDER,2014
11720,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2014
11721,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2014
11722,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2014
11723,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2014
11724,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2014
11725,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2014
11726,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2014
11727,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2014
11728,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2014
11729,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2014
11730,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2014
11731,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2014
11732,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2014
11733,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2014
11734,I-341,BREAST CANCER COMBINATION THERAPY,2014
11735,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2014
11736,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2014
11737,I-344,ACNE VULGARIS,2014
11738,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2014
11739,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2014
11740,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2014
11741,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2014
11742,I-349,ACUTE CORONARY SYNDROME,2014
11743,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2014
11744,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2014
11745,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2014
11746,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2014
11747,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2014
11748,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2014
11749,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2014
11750,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2014
11751,I-358,TREATMENT OF PANIC DISORDER,2014
11752,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2014
11753,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2014
11754,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2014
11755,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2014
11756,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2014
11757,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2014
11758,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2014
11759,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2014
11760,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2014
11761,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2014
11762,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2014
11763,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2014
11764,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2014
11765,I-372,NOSOCOMIAL PNEUMONIA,2014
11766,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2014
11767,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2014
11768,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2014
11769,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2014
11770,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2014
11771,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2014
11772,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2014
11773,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2014
11774,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2014
11775,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2014
11776,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2014
11777,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2014
11778,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2014
11779,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2014
11780,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2014
11781,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2014
11782,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2014
11783,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &",2014
11784,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2014
11785,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2014
11786,I-393,CHRONIC BACTERIAL PROSTATITIS,2014
11787,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2014
11788,I-395,TO IMPROVE PHYSICAL FUNCTION,2014
11789,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2014
11790,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2014
11791,I-398,IDIOPATHIC SHORT STATURE,2014
11792,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2014
11793,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2014
11794,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2014
11795,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2014
11796,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2014
11797,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2014
11798,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2014
11799,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2014
11800,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2014
11801,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2014
11802,I-409,ESOPHAGEAL CANDIDIASIS,2014
11803,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2014
11804,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2014
11805,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2014
11806,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2014
11807,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2014
11808,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2014
11809,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2014
11810,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2014
11811,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2014
11812,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2014
11813,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2014
11814,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2014
11815,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2014
11816,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2014
11817,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2014
11818,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2014
11819,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2014
11820,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2014
11821,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2014
11822,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2014
11823,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2014
11824,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2014
11825,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2014
11826,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2014
11827,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2014
11828,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2014
11829,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2014
11830,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2014
11831,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2014
11832,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2014
11833,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2014
11834,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2014
11835,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2014
11836,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2014
11837,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2014
11838,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2014
11839,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2014
11840,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2014
11841,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2014
11842,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2014
11843,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2014
11844,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2014
11845,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2014
11846,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2014
11847,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2014
11848,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2014
11849,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2014
11850,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2014
11851,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2014
11852,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2014
11853,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2014
11854,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2014
11855,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2014
11856,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2014
11857,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2014
11858,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2014
11859,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2014
11860,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2014
11861,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2014
11862,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2014
11863,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2014
11864,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2014
11865,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2014
11866,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2014
11867,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2014
11868,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2014
11869,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2014
11870,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2014
11871,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2014
11872,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2014
11873,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2014
11874,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2014
11875,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2014
11876,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
11877,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2014
11878,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2014
11879,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2014
11880,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2014
11881,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2014
11882,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2014
11883,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2014
11884,I-491,INFLUENZA PROPHYLAXIS,2014
11885,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2014
11886,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2014
11887,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2014
11888,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2014
11889,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2014
11890,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2014
11891,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2014
11892,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2014
11893,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2014
11894,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2014
11895,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2014
11896,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2014
11897,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2014
11898,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2014
11899,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2014
11900,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2014
11901,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2014
11902,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2014
11903,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2014
11904,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2014
11905,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2014
11906,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2014
11907,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2014
11908,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2014
11909,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2014
11910,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2014
11911,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2014
11912,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2014
11913,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2014
11914,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2014
11915,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2014
11916,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2014
11917,I-524,GENERALIZED ANXIETY DISORDER (GAD),2014
11918,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2014
11919,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2014
11920,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2014
11921,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2014
11922,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2014
11923,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2014
11924,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2014
11925,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2014
11926,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2014
11927,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2014
11928,I-535,MANAGEMENT OF FIBROMYALGIA,2014
11929,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2014
11930,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2014
11931,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2014
11932,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2014
11933,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2014
11934,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2014
11935,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2014
11936,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2014
11937,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2014
11938,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2014
11939,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2014
11940,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2014
11941,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2014
11942,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2014
11943,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2014
11944,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2014
11945,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2014
11946,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2014
11947,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2014
11948,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2014
11949,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2014
11950,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2014
11951,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2014
11952,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2014
11953,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2014
11954,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2014
11955,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2014
11956,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2014
11957,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2014
11958,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2014
11959,I-566,MANAGEMENT OF FIBROMYALGIA,2014
11960,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2014
11961,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2014
11962,I-569,TREATMENT OF CHRONIC HEPATITIS B,2014
11963,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2014
11964,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2014
11965,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2014
11966,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2014
11967,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2014
11968,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2014
11969,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2014
11970,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2014
11971,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2014
11972,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2014
11973,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2014
11974,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
11975,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2014
11976,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2014
11977,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2014
11978,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2014
11979,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2014
11980,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2014
11981,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2014
11982,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2014
11983,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2014
11984,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2014
11985,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2014
11986,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2014
11987,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2014
11988,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
11989,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2014
11990,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2014
11991,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2014
11992,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2014
11993,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2014
11994,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2014
11995,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2014
11996,I-603,GOUT FLARES,2014
11997,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2014
11998,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2014
11999,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2014
12000,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2014
12001,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2014
12002,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2014
12003,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2014
12004,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2014
12005,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2014
12006,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2014
12007,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2014
12008,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2014
12009,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2014
12010,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2014
12011,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2014
12012,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2014
12013,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2014
12014,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2014
12015,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2014
12016,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2014
12017,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2014
12018,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2014
12019,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2014
12020,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2014
12021,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2014
12022,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2014
12023,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2014
12024,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2014
12025,I-633,MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2014
12026,I-634,TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY,2014
12027,I-635,ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2014
12028,I-636,TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER,2014
12029,I-637,USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER,2014
12030,I-638,"FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.",2014
12031,I-639,"TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE",2014
12032,I-640,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2014
12033,I-641,TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2014
12034,I-642,TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2014
12035,I-643,REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.,2014
12036,I-644,MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED),2014
12037,I-645,MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2014
12038,I-646,SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD),2014
12039,I-647,SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2014
12040,I-648,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2014
12041,I-649,TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY,2014
12042,I-650,"TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY",2014
12043,I-651,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY,2014
12044,I-652,MANAGEMENT OF POSTHERPETIC NEURALGIA,2014
12045,I-653,TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS,2014
12046,I-654,MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE,2014
12047,I-655,"TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2014
12048,I-656,"MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2014
12049,I-657,PLAQUE PSORIASIS OF THE SCALP,2014
12050,I-658,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY",2014
12051,I-659,PLAQUE PSORIASIS OF THE BODY,2014
12052,I-660,TREATMENT OF DEEP VEIN THROMBOSIS,2014
12053,I-661,TREATMENT OF PULMONARY EMBOLISM,2014
12054,I-662,REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM,2014
12055,I-663,IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2014
12056,I-664,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2014
12057,I-665,TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L,2014
12058,I-666,TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY,2014
12059,I-667,"TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE",2014
12060,I-668,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2014
12061,I-669,SCINTIGRAPIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%,2014
12062,I-670,"TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN",2014
12063,I-671,FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2014
12064,I-672,"USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",2014
12065,I-673,TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE,2014
12066,I-674,TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE,2014
12067,I-675,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER,2014
12068,I-676,"FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARACINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE",2014
12069,I-677,"TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOCACTIVE IODINE TREATMENT",2014
12070,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2014
12071,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2014
12072,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2014
12073,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2014
12074,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2014
12075,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2014
12076,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2014
12077,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2014
12078,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2014
12079,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2014
12080,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2014
12081,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2014
12082,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2014
12083,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2014
12084,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2014
12085,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2014
12086,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2014
12087,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2014
12088,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2014
12089,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2014
12090,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2014
12091,M-22,CHANGE IN TIME TO ONSET OF ACTION,2014
12092,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2014
12093,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2014
12094,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2014
12095,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2014
12096,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2014
12097,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2014
12098,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2014
12099,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2014
12100,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2014
12101,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2014
12102,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2014
12103,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2014
12104,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2014
12105,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2014
12106,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2014
12107,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2014
12108,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2014
12109,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2014
12110,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2014
12111,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2014
12112,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2014
12113,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2014
12114,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2014
12115,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2014
12116,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2014
12117,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2014
12118,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2014
12119,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2014
12120,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2014
12121,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
12122,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2014
12123,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2014
12124,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2014
12125,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2014
12126,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2014
12127,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2014
12128,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2014
12129,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2014
12130,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2014
12131,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2014
12132,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2014
12133,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2014
12134,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2014
12135,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2014
12136,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2014
12137,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2014
12138,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2014
12139,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2014
12140,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2014
12141,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2014
12142,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2014
12143,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2014
12144,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2014
12145,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2014
12146,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2014
12147,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2014
12148,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2014
12149,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2014
12150,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2014
12151,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2014
12152,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2014
12153,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2014
12154,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2014
12155,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2014
12156,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2014
12157,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2014
12158,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2014
12159,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2014
12160,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2014
12161,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2014
12162,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2014
12163,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2014
12164,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2014
12165,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2014
12166,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2014
12167,M-98,NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.,2014
12168,M-99,ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.,2014
12169,M-100,INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS,2014
12170,M-101,INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL,2014
12171,M-102,"INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, ""INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY.""",2014
12172,M-103,"SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING",2014
12173,M-104,INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY,2014
12174,M-105,"NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE",2014
12175,M-106,ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT,2014
12176,M-107,"INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED ""STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY"".",2014
12177,M-108,CHANGES ARE BASED ON RESULTS FROM STUDY CV181057,2014
12178,M-109,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2014
12179,M-110,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2014
12180,M-111,LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS,2014
12181,M-112,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS,2014
12182,M-113,LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS,2014
12183,M-114,CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR),2014
12184,M-115,"REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES",2014
12185,M-116,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008,2014
12186,M-117,ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL,2014
12187,M-118,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36,2014
12188,M-119,LABELING CHANGES REGARDING MISSED DOSES,2014
12189,M-120,CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS,2014
12190,M-121,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43,2014
12191,M-122,LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL,2014
12192,M-123,UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY,2014
12193,M-124,LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS,2014
12194,M-125,LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE,2014
12195,M-126,"UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086",2014
12196,M-127,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004,2014
12197,M-128,CLINICAL TRIAL STUDY RESULTS,2014
12198,M-129,RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE,2014
12199,M-130,ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT,2014
12200,M-131,INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS,2014
12201,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2015
12202,RTO*,OTC USE FOR WOMEN AGES 15 AND 16,2015
12203,RTO,RX TO OTC SWITCH OR OTC USE,2015
12204,PC,PATENT CHALLENGE,2015
12205,NP*,NEW PRODUCT (MINT FLAVORED),2015
12206,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2015
12207,PED,PEDIATRIC EXCLUSIVITY,2015
12208,NC,NEW COMBINATION,2015
12209,NDF,NEW DOSAGE FORM,2015
12210,NPP,NEW PATIENT POPULATION,2015
12211,NCE,NEW CHEMICAL ENTITY,2015
12212,NS,NEW STRENGTH,2015
12213,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2015
12214,RTO**,OTC USE FOR WOMEN 14 AND BELOW,2015
12215,ODE,ORPHAN DRUG EXCLUSIVITY,2015
12216,NCE*,NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).,2015
12217,NP,NEW PRODUCT,2015
12218,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2015
12219,NR,NEW ROUTE,2015
12220,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2015
12221,D-1,ONCE A DAY APPLICATION,2015
12222,D-2,ONCE DAILY DOSING,2015
12223,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2015
12224,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2015
12225,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2015
12226,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2015
12227,D-7,BID DOSING,2015
12228,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2015
12229,D-9,NARCOTIC OVERDOSE IN ADULTS,2015
12230,D-10,NARCOTIC OVERDOSE IN CHILDREN,2015
12231,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2015
12232,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2015
12233,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2015
12234,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2015
12235,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2015
12236,D-16,CONTINUOUS INTRAVENOUS INFUSION,2015
12237,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2015
12238,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2015
12239,D-19,BOLUS DOSING GUIDELINES,2015
12240,D-20,SINGLE 32MG DOSE,2015
12241,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2015
12242,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2015
12243,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2015
12244,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2015
12245,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2015
12246,D-26,ONCE WEEKLY APPLICATION,2015
12247,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2015
12248,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2015
12249,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2015
12250,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2015
12251,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2015
12252,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2015
12253,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2015
12254,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2015
12255,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2015
12256,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2015
12257,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2015
12258,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2015
12259,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2015
12260,D-40,ONCE-A-DAY DOSING REGIMEN,2015
12261,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2015
12262,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2015
12263,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2015
12264,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2015
12265,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2015
12266,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2015
12267,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2015
12268,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2015
12269,D-49,PEDIATRIC DOSING GUIDELINES,2015
12270,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2015
12271,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2015
12272,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2015
12273,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2015
12274,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2015
12275,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2015
12276,D-56,ADDITION OF POSTPRANDIAL DOSING,2015
12277,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2015
12278,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2015
12279,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2015
12280,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2015
12281,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12282,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12283,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2015
12284,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2015
12285,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2015
12286,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2015
12287,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2015
12288,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2015
12289,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2015
12290,D-70,80MG ONCE DAILY DOSING REGIMEN,2015
12291,D-71,EIGHT WEEK DOSING REGIMEN,2015
12292,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2015
12293,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12294,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12295,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2015
12296,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2015
12297,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2015
12298,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2015
12299,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2015
12300,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2015
12301,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2015
12302,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12303,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2015
12304,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2015
12305,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2015
12306,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2015
12307,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
12308,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2015
12309,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2015
12310,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2015
12311,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2015
12312,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2015
12313,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2015
12314,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2015
12315,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2015
12316,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2015
12317,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2015
12318,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2015
12319,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2015
12320,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2015
12321,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2015
12322,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2015
12323,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2015
12324,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2015
12325,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12326,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2015
12327,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
12328,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2015
12329,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2015
12330,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2015
12331,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2015
12332,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2015
12333,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2015
12334,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2015
12335,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2015
12336,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2015
12337,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2015
12338,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2015
12339,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2015
12340,D-120,DOSING REGIMEN ADJUSTMENTS,2015
12341,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2015
12342,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2015
12343,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2015
12344,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2015
12345,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2015
12346,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2015
12347,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2015
12348,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2015
12349,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2015
12350,D-130,"DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN",2015
12351,D-131,EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG,2015
12352,D-132,45MG FOR 6 MONTH ADMINISTRATION,2015
12353,D-133,NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE,2015
12354,D-134,INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY,2015
12355,D-135,"UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE",2015
12356,D-136,"ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS",2015
12357,D-137,NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS,2015
12358,D-138,80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS,2015
12359,D-139,ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE,2015
12360,D-140,REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY,2015
12361,D-141,DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA,2015
12362,D-142,"DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE",2015
12363,D-143,INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG,2015
12364,D-144,LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION,2015
12365,D-145,UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.,2015
12366,I-1,DYSMENORRHEA,2015
12367,I-2,CHOLANGIOPANCREATOGRAPHY,2015
12368,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2015
12369,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2015
12370,I-5,HYSTEROSALPINGOGRAPHY,2015
12371,I-6,TREATMENT OF JUVENILE ARTHRITIS,2015
12372,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2015
12373,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2015
12374,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2015
12375,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2015
12376,I-11,RELIEF OF MILD TO MODERATE PAIN,2015
12377,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2015
12378,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2015
12379,I-14,SEBORRHEIC DERMATITIS,2015
12380,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2015
12381,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2015
12382,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2015
12383,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2015
12384,I-19,HERNIOGRAPHY,2015
12385,I-20,KNEE ARTHROGRAPHY,2015
12386,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2015
12387,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2015
12388,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2015
12389,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2015
12390,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2015
12391,I-26,TREATMENT OF LIVER FLUKES,2015
12392,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2015
12393,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2015
12394,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2015
12395,I-30,TREATMENT OF TINEA PEDIS,2015
12396,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2015
12397,I-32,PEDIATRIC MYELOGRAPHY,2015
12398,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2015
12399,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2015
12400,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2015
12401,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2015
12402,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2015
12403,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2015
12404,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2015
12405,I-40,PRIMARY NOCTURNAL ENURESIS,2015
12406,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2015
12407,I-42,HERPES ZOSTER,2015
12408,I-43,HERPES SIMPLEX ENCEPHALITIS,2015
12409,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2015
12410,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2015
12411,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2015
12412,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2015
12413,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2015
12414,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2015
12415,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2015
12416,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2015
12417,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2015
12418,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2015
12419,I-54,RENAL CONCENTRATION CAPACITY TEST,2015
12420,I-55,HYPERTENSION,2015
12421,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2015
12422,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2015
12423,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2015
12424,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2015
12425,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2015
12426,I-61,FEMALE ANDROGENETIC ALOPECIA,2015
12427,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12428,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2015
12429,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2015
12430,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2015
12431,I-66,UNCOMPLICATED GONORRHEA,2015
12432,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2015
12433,I-68,CENTRAL PRECOCIOUS PUBERTY,2015
12434,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2015
12435,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2015
12436,I-71,VARICELLA INFECTIONS (CHICKENPOX),2015
12437,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2015
12438,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2015
12439,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2015
12440,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2015
12441,I-76,PREVENTION OF OSTEOPOROSIS,2015
12442,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2015
12443,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2015
12444,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2015
12445,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2015
12446,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2015
12447,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2015
12448,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2015
12449,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2015
12450,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2015
12451,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2015
12452,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2015
12453,I-88,MANAGEMENT OF ENDOMETRIOSIS,2015
12454,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2015
12455,I-90,INTENSIVE CARE UNIT SEDATION,2015
12456,I-91,MONOTHERAPY USE FOR HYPERTENSION,2015
12457,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2015
12458,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2015
12459,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2015
12460,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2015
12461,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2015
12462,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2015
12463,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2015
12464,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2015
12465,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2015
12466,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2015
12467,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2015
12468,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2015
12469,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2015
12470,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2015
12471,I-106,TREATMENT OF ACROMEGALY,2015
12472,I-107,VAGINAL CANDIDIASIS,2015
12473,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2015
12474,I-109,TYPHOID FEVER,2015
12475,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2015
12476,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2015
12477,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2015
12478,I-113,TREATMENT OF PROSTATITIS,2015
12479,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2015
12480,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2015
12481,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2015
12482,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2015
12483,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2015
12484,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2015
12485,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2015
12486,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2015
12487,I-122,PSORIASIS OF THE SCALP,2015
12488,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2015
12489,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2015
12490,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2015
12491,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2015
12492,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2015
12493,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2015
12494,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2015
12495,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2015
12496,I-131,PERIPHERAL ARTERIOGRAPHY,2015
12497,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2015
12498,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2015
12499,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2015
12500,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2015
12501,I-136,IDIOPATHIC CHRONIC URTICARIA,2015
12502,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2015
12503,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2015
12504,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2015
12505,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2015
12506,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2015
12507,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2015
12508,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2015
12509,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2015
12510,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2015
12511,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2015
12512,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2015
12513,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2015
12514,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2015
12515,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2015
12516,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2015
12517,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2015
12518,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2015
12519,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2015
12520,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2015
12521,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2015
12522,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2015
12523,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2015
12524,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2015
12525,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2015
12526,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2015
12527,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2015
12528,I-163,TREATMENT OF PHOTOPHOBIA,2015
12529,I-164,CHRONIC BACTERIAL PROSTATITIS,2015
12530,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2015
12531,I-166,TREATMENT OF BULIMIA,2015
12532,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2015
12533,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2015
12534,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2015
12535,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2015
12536,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2015
12537,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2015
12538,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2015
12539,I-174,PELVIC INFLAMMATORY DISEASE,2015
12540,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2015
12541,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2015
12542,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2015
12543,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2015
12544,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2015
12545,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2015
12546,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2015
12547,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2015
12548,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2015
12549,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2015
12550,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
12551,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2015
12552,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12553,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2015
12554,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2015
12555,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2015
12556,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2015
12557,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2015
12558,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2015
12559,I-194,CONGESTIVE HEART FAILURE,2015
12560,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2015
12561,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2015
12562,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2015
12563,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2015
12564,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2015
12565,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2015
12566,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2015
12567,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2015
12568,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2015
12569,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2015
12570,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2015
12571,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2015
12572,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2015
12573,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2015
12574,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2015
12575,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2015
12576,I-211,FOR USE IN PEDIATRIC POPULATION,2015
12577,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2015
12578,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2015
12579,I-214,TREATMENT OF OSTEOPOROSIS,2015
12580,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2015
12581,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2015
12582,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2015
12583,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2015
12584,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2015
12585,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2015
12586,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2015
12587,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2015
12588,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2015
12589,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2015
12590,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2015
12591,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2015
12592,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2015
12593,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2015
12594,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2015
12595,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2015
12596,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2015
12597,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2015
12598,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2015
12599,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2015
12600,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2015
12601,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2015
12602,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2015
12603,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2015
12604,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2015
12605,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2015
12606,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2015
12607,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2015
12608,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2015
12609,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2015
12610,I-245,TREATMENT OF ACUTE SINUSITIS,2015
12611,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2015
12612,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2015
12613,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2015
12614,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2015
12615,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2015
12616,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2015
12617,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2015
12618,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2015
12619,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2015
12620,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2015
12621,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2015
12622,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2015
12623,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2015
12624,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2015
12625,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2015
12626,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2015
12627,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2015
12628,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2015
12629,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2015
12630,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2015
12631,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2015
12632,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2015
12633,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2015
12634,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2015
12635,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2015
12636,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
12637,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2015
12638,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2015
12639,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2015
12640,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2015
12641,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2015
12642,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2015
12643,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2015
12644,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2015
12645,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2015
12646,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2015
12647,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2015
12648,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2015
12649,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2015
12650,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2015
12651,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2015
12652,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2015
12653,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2015
12654,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2015
12655,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2015
12656,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12657,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12658,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2015
12659,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2015
12660,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2015
12661,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2015
12662,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2015
12663,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2015
12664,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2015
12665,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2015
12666,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2015
12667,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2015
12668,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2015
12669,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2015
12670,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2015
12671,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2015
12672,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2015
12673,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2015
12674,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
12675,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2015
12676,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2015
12677,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2015
12678,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2015
12679,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2015
12680,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2015
12681,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2015
12682,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2015
12683,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2015
12684,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2015
12685,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2015
12686,I-321,JUVENILE RHEUMATOID ARTHRITIS,2015
12687,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2015
12688,I-323,COLORECTAL CANCER,2015
12689,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2015
12690,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2015
12691,I-326,GENERALIZED ANXIETY DISORDER,2015
12692,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2015
12693,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2015
12694,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2015
12695,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2015
12696,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2015
12697,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2015
12698,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2015
12699,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2015
12700,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2015
12701,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2015
12702,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2015
12703,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2015
12704,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2015
12705,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2015
12706,I-341,BREAST CANCER COMBINATION THERAPY,2015
12707,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2015
12708,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2015
12709,I-344,ACNE VULGARIS,2015
12710,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2015
12711,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2015
12712,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2015
12713,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2015
12714,I-349,ACUTE CORONARY SYNDROME,2015
12715,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2015
12716,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2015
12717,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2015
12718,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2015
12719,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2015
12720,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2015
12721,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2015
12722,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2015
12723,I-358,TREATMENT OF PANIC DISORDER,2015
12724,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2015
12725,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2015
12726,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2015
12727,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2015
12728,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2015
12729,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2015
12730,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2015
12731,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2015
12732,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2015
12733,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2015
12734,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2015
12735,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2015
12736,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2015
12737,I-372,NOSOCOMIAL PNEUMONIA,2015
12738,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2015
12739,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2015
12740,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2015
12741,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2015
12742,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2015
12743,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2015
12744,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2015
12745,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2015
12746,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2015
12747,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2015
12748,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2015
12749,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2015
12750,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2015
12751,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2015
12752,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2015
12753,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2015
12754,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2015
12755,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &",2015
12756,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2015
12757,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2015
12758,I-393,CHRONIC BACTERIAL PROSTATITIS,2015
12759,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2015
12760,I-395,TO IMPROVE PHYSICAL FUNCTION,2015
12761,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2015
12762,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2015
12763,I-398,IDIOPATHIC SHORT STATURE,2015
12764,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2015
12765,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2015
12766,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2015
12767,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2015
12768,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2015
12769,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2015
12770,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2015
12771,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2015
12772,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2015
12773,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2015
12774,I-409,ESOPHAGEAL CANDIDIASIS,2015
12775,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2015
12776,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2015
12777,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2015
12778,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2015
12779,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2015
12780,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2015
12781,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2015
12782,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2015
12783,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2015
12784,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2015
12785,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2015
12786,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2015
12787,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2015
12788,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2015
12789,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2015
12790,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2015
12791,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2015
12792,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2015
12793,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2015
12794,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2015
12795,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2015
12796,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2015
12797,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2015
12798,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2015
12799,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2015
12800,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2015
12801,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2015
12802,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2015
12803,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2015
12804,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2015
12805,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2015
12806,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2015
12807,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2015
12808,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2015
12809,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2015
12810,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2015
12811,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2015
12812,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2015
12813,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2015
12814,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2015
12815,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2015
12816,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2015
12817,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2015
12818,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2015
12819,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2015
12820,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2015
12821,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2015
12822,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2015
12823,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2015
12824,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2015
12825,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2015
12826,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2015
12827,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2015
12828,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2015
12829,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2015
12830,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2015
12831,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2015
12832,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2015
12833,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2015
12834,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2015
12835,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2015
12836,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2015
12837,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2015
12838,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2015
12839,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2015
12840,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2015
12841,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2015
12842,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2015
12843,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2015
12844,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2015
12845,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2015
12846,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2015
12847,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2015
12848,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
12849,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2015
12850,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2015
12851,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2015
12852,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2015
12853,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2015
12854,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2015
12855,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2015
12856,I-491,INFLUENZA PROPHYLAXIS,2015
12857,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2015
12858,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2015
12859,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2015
12860,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2015
12861,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2015
12862,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2015
12863,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2015
12864,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2015
12865,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2015
12866,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2015
12867,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2015
12868,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2015
12869,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2015
12870,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2015
12871,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2015
12872,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2015
12873,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2015
12874,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2015
12875,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2015
12876,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2015
12877,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2015
12878,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2015
12879,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2015
12880,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2015
12881,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2015
12882,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2015
12883,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2015
12884,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2015
12885,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2015
12886,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2015
12887,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2015
12888,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2015
12889,I-524,GENERALIZED ANXIETY DISORDER (GAD),2015
12890,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2015
12891,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2015
12892,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2015
12893,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2015
12894,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2015
12895,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2015
12896,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2015
12897,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2015
12898,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2015
12899,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2015
12900,I-535,MANAGEMENT OF FIBROMYALGIA,2015
12901,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2015
12902,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2015
12903,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2015
12904,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2015
12905,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2015
12906,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2015
12907,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2015
12908,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2015
12909,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2015
12910,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2015
12911,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2015
12912,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2015
12913,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2015
12914,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2015
12915,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2015
12916,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2015
12917,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2015
12918,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2015
12919,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2015
12920,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2015
12921,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2015
12922,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2015
12923,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2015
12924,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2015
12925,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2015
12926,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2015
12927,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2015
12928,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2015
12929,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2015
12930,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2015
12931,I-566,MANAGEMENT OF FIBROMYALGIA,2015
12932,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2015
12933,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2015
12934,I-569,TREATMENT OF CHRONIC HEPATITIS B,2015
12935,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2015
12936,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2015
12937,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2015
12938,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2015
12939,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2015
12940,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2015
12941,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2015
12942,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2015
12943,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2015
12944,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2015
12945,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2015
12946,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
12947,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2015
12948,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2015
12949,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2015
12950,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2015
12951,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2015
12952,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2015
12953,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2015
12954,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2015
12955,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2015
12956,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2015
12957,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2015
12958,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2015
12959,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2015
12960,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
12961,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2015
12962,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2015
12963,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2015
12964,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2015
12965,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2015
12966,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2015
12967,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2015
12968,I-603,GOUT FLARES,2015
12969,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2015
12970,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2015
12971,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2015
12972,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2015
12973,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2015
12974,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2015
12975,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2015
12976,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2015
12977,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2015
12978,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2015
12979,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2015
12980,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2015
12981,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2015
12982,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2015
12983,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2015
12984,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2015
12985,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2015
12986,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2015
12987,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2015
12988,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2015
12989,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2015
12990,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2015
12991,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2015
12992,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2015
12993,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2015
12994,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2015
12995,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2015
12996,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2015
12997,I-633,MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2015
12998,I-634,TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY,2015
12999,I-635,ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2015
13000,I-636,TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER,2015
13001,I-637,USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER,2015
13002,I-638,"FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.",2015
13003,I-639,"TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE",2015
13004,I-640,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2015
13005,I-641,TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2015
13006,I-642,TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2015
13007,I-643,REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.,2015
13008,I-644,MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED),2015
13009,I-645,MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2015
13010,I-646,SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD),2015
13011,I-647,SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2015
13012,I-648,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2015
13013,I-649,TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY,2015
13014,I-650,"TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY",2015
13015,I-651,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY,2015
13016,I-652,MANAGEMENT OF POSTHERPETIC NEURALGIA,2015
13017,I-653,TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS,2015
13018,I-654,MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE,2015
13019,I-655,"TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2015
13020,I-656,"MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2015
13021,I-657,PLAQUE PSORIASIS OF THE SCALP,2015
13022,I-658,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY",2015
13023,I-659,PLAQUE PSORIASIS OF THE BODY,2015
13024,I-660,TREATMENT OF DEEP VEIN THROMBOSIS,2015
13025,I-661,TREATMENT OF PULMONARY EMBOLISM,2015
13026,I-662,REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM,2015
13027,I-663,IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2015
13028,I-664,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2015
13029,I-665,TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L,2015
13030,I-666,TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY,2015
13031,I-667,"TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE",2015
13032,I-668,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2015
13033,I-669,SCINTIGRAPIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%,2015
13034,I-670,"TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN",2015
13035,I-671,FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2015
13036,I-672,"USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",2015
13037,I-673,TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE,2015
13038,I-674,TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE,2015
13039,I-675,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER,2015
13040,I-676,"FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARACINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE",2015
13041,I-677,"TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOCACTIVE IODINE TREATMENT",2015
13042,I-678,"TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST",2015
13043,I-679,RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS,2015
13044,I-680,TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2015
13045,I-681,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT",2015
13046,I-682,TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS,2015
13047,I-683,TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED,2015
13048,I-684,"PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS",2015
13049,I-685,EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE,2015
13050,I-686,INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY,2015
13051,I-687,"GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY",2015
13052,I-688,GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE,2015
13053,I-689,TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION,2015
13054,I-690,INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2015
13055,I-691,INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY,2015
13056,I-692,INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.,2015
13057,I-693,TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-REISISTANT PROSTATE CANCER (CRPC),2015
13058,I-694,TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY,2015
13059,I-695,REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA,2015
13060,I-696,USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER,2015
13061,I-697,FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION,2015
13062,I-698,SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS,2015
13063,I-699,FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA,2015
13064,I-700,TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS),2015
13065,I-701,"FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSIONFREE SURVIVAL.",2015
13066,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2015
13067,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2015
13068,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2015
13069,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2015
13070,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2015
13071,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2015
13072,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2015
13073,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2015
13074,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2015
13075,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2015
13076,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2015
13077,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2015
13078,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2015
13079,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2015
13080,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2015
13081,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2015
13082,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2015
13083,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2015
13084,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2015
13085,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2015
13086,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2015
13087,M-22,CHANGE IN TIME TO ONSET OF ACTION,2015
13088,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2015
13089,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2015
13090,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2015
13091,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2015
13092,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2015
13093,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2015
13094,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2015
13095,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2015
13096,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2015
13097,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2015
13098,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2015
13099,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2015
13100,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2015
13101,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2015
13102,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2015
13103,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2015
13104,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2015
13105,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2015
13106,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2015
13107,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2015
13108,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2015
13109,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2015
13110,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2015
13111,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2015
13112,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2015
13113,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2015
13114,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2015
13115,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2015
13116,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2015
13117,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
13118,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2015
13119,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2015
13120,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2015
13121,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2015
13122,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2015
13123,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2015
13124,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2015
13125,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2015
13126,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2015
13127,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2015
13128,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2015
13129,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2015
13130,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2015
13131,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2015
13132,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2015
13133,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2015
13134,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2015
13135,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2015
13136,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2015
13137,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2015
13138,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2015
13139,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2015
13140,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2015
13141,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2015
13142,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2015
13143,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2015
13144,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2015
13145,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2015
13146,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2015
13147,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2015
13148,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2015
13149,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2015
13150,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2015
13151,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2015
13152,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2015
13153,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2015
13154,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2015
13155,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2015
13156,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2015
13157,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2015
13158,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2015
13159,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2015
13160,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2015
13161,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2015
13162,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2015
13163,M-98,NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.,2015
13164,M-99,ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.,2015
13165,M-100,INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS,2015
13166,M-101,INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL,2015
13167,M-102,"INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, ""INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY.""",2015
13168,M-103,"SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING",2015
13169,M-104,INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY,2015
13170,M-105,"NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE",2015
13171,M-106,ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT,2015
13172,M-107,"INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED ""STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY"".",2015
13173,M-108,CHANGES ARE BASED ON RESULTS FROM STUDY CV181057,2015
13174,M-109,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2015
13175,M-110,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2015
13176,M-111,LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS,2015
13177,M-112,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS,2015
13178,M-113,LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS,2015
13179,M-114,CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR),2015
13180,M-115,"REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES",2015
13181,M-116,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008,2015
13182,M-117,ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL,2015
13183,M-118,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36,2015
13184,M-119,LABELING CHANGES REGARDING MISSED DOSES,2015
13185,M-120,CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS,2015
13186,M-121,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43,2015
13187,M-122,LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL,2015
13188,M-123,UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY,2015
13189,M-124,LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS,2015
13190,M-125,LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE,2015
13191,M-126,"UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086",2015
13192,M-127,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004,2015
13193,M-128,CLINICAL TRIAL STUDY RESULTS,2015
13194,M-129,RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE,2015
13195,M-130,ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT,2015
13196,M-131,INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS,2015
13197,M-132,REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS,2015
13198,M-133,INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY,2015
13199,M-134,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING,2015
13200,M-135,ADDITION OF INFORMATION TO THE CLINICAL STUDIES -RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT,2015
13201,M-136,ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS,2015
13202,M-137,LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER,2015
13203,M-138,INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER,2015
13204,M-139,INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA,2015
13205,M-140,"INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION",2015
13206,M-141,REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17),2015
13207,M-142,ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY,2015
13208,M-143,INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER,2015
13209,M-144,INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE,2015
13210,M-145,ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING,2015
13211,M-146,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS,2015
13212,M-147,OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES,2015
13213,M-148,LABELING CHANGES BASED ON STUDY H80-EW-GWDM,2015
13214,M-149,INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD,2015
13215,M-150,ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE,2015
13216,GAIN,"GENERATING ANTIBIOTIC INCENTIVES NOW (CONSTRUCTED, NOT IN RAW LIST)",2015
13217,NCE*,NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).,2016
13218,GAIN,GAIN EXCLUSIVITY,2016
13219,NS,NEW STRENGTH,2016
13220,RTO*,OTC USE FOR WOMEN AGES 15 AND 16,2016
13221,NR,NEW ROUTE,2016
13222,RTO**,OTC USE FOR WOMEN 14 AND BELOW,2016
13223,NDF,NEW DOSAGE FORM,2016
13224,NP,NEW PRODUCT,2016
13225,PC,PATENT CHALLENGE,2016
13226,M,MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES),2016
13227,NE,NEW ESTER OR SALT OF AN ACTIVE INGREDIENT,2016
13228,NPP,NEW PATIENT POPULATION,2016
13229,NC,NEW COMBINATION,2016
13230,NP*,NEW PRODUCT (MINT FLAVORED),2016
13231,I,NEW INDICATION (SEE INDIVIDUAL REFERENCES),2016
13232,NCE,NEW CHEMICAL ENTITY,2016
13233,PED,PEDIATRIC EXCLUSIVITY,2016
13234,ODE,ORPHAN DRUG EXCLUSIVITY,2016
13235,W,EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR -SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY,2016
13236,D,NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES),2016
13237,RTO,RX TO OTC SWITCH OR OTC USE,2016
13238,D-1,ONCE A DAY APPLICATION,2016
13239,D-2,ONCE DAILY DOSING,2016
13240,D-3,SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE,2016
13241,D-4,SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE,2016
13242,D-5,TEN DAYS/ELEVEN DAYS DOSING SCHEDULE,2016
13243,D-6,SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE,2016
13244,D-7,BID DOSING,2016
13245,D-8,"INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING",2016
13246,D-9,NARCOTIC OVERDOSE IN ADULTS,2016
13247,D-10,NARCOTIC OVERDOSE IN CHILDREN,2016
13248,D-11,POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN,2016
13249,D-12,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER,2016
13250,D-13,INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION,2016
13251,D-14,BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2016
13252,D-15,SINGLE DAILY DOSE OF 25MG/37.5MG,2016
13253,D-16,CONTINUOUS INTRAVENOUS INFUSION,2016
13254,D-17,400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS,2016
13255,D-18,LOWER RECOMMENDED STARTING DOSE GUIDELINES,2016
13256,D-19,BOLUS DOSING GUIDELINES,2016
13257,D-20,SINGLE 32MG DOSE,2016
13258,D-21,ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL,2016
13259,D-22,REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE,2016
13260,D-23,INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN,2016
13261,D-24,FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS,2016
13262,D-25,ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN,2016
13263,D-26,ONCE WEEKLY APPLICATION,2016
13264,D-27,BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY,2016
13265,D-28,USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300,2016
13266,D-29,INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS,2016
13267,D-30,5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS,2016
13268,D-31,CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID),2016
13269,D-32,REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS,2016
13270,D-33,ONCE DAILY DOSING FOR PLAQUE PSORIASIS,2016
13271,D-34,EVERY FOUR MONTHS DOSAGE REGIMEN,2016
13272,D-35,FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS,2016
13273,D-36,FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY,2016
13274,D-37,DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID),2016
13275,D-38,CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION,2016
13276,D-39,"CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ""..1/2 TO 1 HOUR BEFORE EATING"" TO "".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING...""",2016
13277,D-40,ONCE-A-DAY DOSING REGIMEN,2016
13278,D-41,DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS,2016
13279,D-42,"TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2016
13280,D-43,INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD,2016
13281,D-44,"IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED",2016
13282,D-45,ONCE DAILY DOSING FOR MAINTENANCE ONLY,2016
13283,D-46,NEW DOSING REGIMEN OF 80MG DAILY,2016
13284,D-47,"PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL",2016
13285,D-48,ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL,2016
13286,D-49,PEDIATRIC DOSING GUIDELINES,2016
13287,D-50,INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS,2016
13288,D-51,OPTIONAL STARTING DOSE OF 40MG/DAY,2016
13289,D-52,ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY,2016
13290,D-53,USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE,2016
13291,D-54,USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS,2016
13292,D-55,ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK),2016
13293,D-56,ADDITION OF POSTPRANDIAL DOSING,2016
13294,D-57,3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER,2016
13295,D-58,CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION,2016
13296,D-59,"REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY",2016
13297,D-60,ADDITION OF A POST-OPERATIVE DOSING REGIMEN,2016
13298,D-61,ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13299,D-62,ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13300,D-63,TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE,2016
13301,D-64,INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML,2016
13302,D-65,CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS,2016
13303,D-66,DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI,2016
13304,D-67,SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES,2016
13305,D-68,CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS,2016
13306,D-69,SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS,2016
13307,D-70,80MG ONCE DAILY DOSING REGIMEN,2016
13308,D-71,EIGHT WEEK DOSING REGIMEN,2016
13309,D-72,INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON,2016
13310,D-73,ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13311,D-74,ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13312,D-75,"INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE",2016
13313,D-76,"FOR USE ON AN ""AS NEEDED"" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED",2016
13314,D-77,ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%),2016
13315,D-78,"USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS",2016
13316,D-79,NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE,2016
13317,D-80,CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING,2016
13318,D-81,NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS,2016
13319,D-82,USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13320,D-83,"750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)",2016
13321,D-84,"ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS",2016
13322,D-85,LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE,2016
13323,D-86,FOR USE IN SELECT EXTERNAL INSULIN PUMPS,2016
13324,D-87,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
13325,D-88,NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES,2016
13326,D-89,USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS,2016
13327,D-90,ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS,2016
13328,D-91,ALTERNATE INTERMITTENT DOSING REGIMEN,2016
13329,D-92,ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME,2016
13330,D-93,ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS,2016
13331,D-94,NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD),2016
13332,D-95,BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE,2016
13333,D-96,ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS,2016
13334,D-97,PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE,2016
13335,D-98,DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE,2016
13336,D-99,ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS,2016
13337,D-100,750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS,2016
13338,D-101,ONCE DAILY IN CHRONIC IDIOPATHIC UTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2016
13339,D-102,NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER,2016
13340,D-103,"NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.",2016
13341,D-104,0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS,2016
13342,D-105,USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13343,D-106,"FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA",2016
13344,D-107,PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
13345,D-108,TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS,2016
13346,D-109,PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE,2016
13347,D-110,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17,2016
13348,D-111,"PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION",2016
13349,D-112,PROVIDES FOR PEDIATRIC PUMP USE,2016
13350,D-113,ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN,2016
13351,D-114,NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS,2016
13352,D-115,"STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2016
13353,D-116,ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS,2016
13354,D-117,50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER,2016
13355,D-118,"TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR",2016
13356,D-119,DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE,2016
13357,D-120,DOSING REGIMEN ADJUSTMENTS,2016
13358,D-121,CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION,2016
13359,D-122,USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2016
13360,D-123,ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS,2016
13361,D-124,ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2016
13362,D-125,EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.,2016
13363,D-126,CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG,2016
13364,D-127,DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE,2016
13365,D-128,"SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO",2016
13366,D-129,"800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS",2016
13367,D-130,"DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN",2016
13368,D-131,EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG,2016
13369,D-132,45MG FOR 6 MONTH ADMINISTRATION,2016
13370,D-133,NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE,2016
13371,D-134,INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY,2016
13372,D-135,"UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE",2016
13373,D-136,"ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS",2016
13374,D-137,NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS,2016
13375,D-138,80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS,2016
13376,D-139,ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE,2016
13377,D-140,REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY,2016
13378,D-141,DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA,2016
13379,D-142,"DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE",2016
13380,D-143,INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG,2016
13381,D-144,LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION,2016
13382,D-145,UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.,2016
13383,D-146,CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY,2016
13384,D-147,ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION,2016
13385,D-148,EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT,2016
13386,D-149,DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP,2016
13387,D-150,1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE,2016
13388,D-151,DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1,2016
13389,D-152,DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.,2016
13390,D-153,"IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY",2016
13391,I-1,DYSMENORRHEA,2016
13392,I-2,CHOLANGIOPANCREATOGRAPHY,2016
13393,I-3,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2016
13394,I-4,PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY),2016
13395,I-5,HYSTEROSALPINGOGRAPHY,2016
13396,I-6,TREATMENT OF JUVENILE ARTHRITIS,2016
13397,I-7,BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN,2016
13398,I-8,ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY,2016
13399,I-9,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2016
13400,I-10,PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY,2016
13401,I-11,RELIEF OF MILD TO MODERATE PAIN,2016
13402,I-12,TREATMENT OF CUTANEOUS CANDIDIASIS,2016
13403,I-13,URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI,2016
13404,I-14,SEBORRHEIC DERMATITIS,2016
13405,I-15,PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT,2016
13406,I-16,STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM,2016
13407,I-17,MANAGEMENT OF CONGESTIVE HEART FAILURE,2016
13408,I-18,ENDOSCOPIC RETROGRADE PANCREATOGRAPHY,2016
13409,I-19,HERNIOGRAPHY,2016
13410,I-20,KNEE ARTHROGRAPHY,2016
13411,I-21,HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR,2016
13412,I-22,RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA,2016
13413,I-23,SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2016
13414,I-24,TREATMENT OF RHEUMATOID ARTHRITIS,2016
13415,I-25,"ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS",2016
13416,I-26,TREATMENT OF LIVER FLUKES,2016
13417,I-27,ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE,2016
13418,I-28,SELECTIVE ADULT VISCERAL ARTERIOGRAPHY,2016
13419,I-29,METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION,2016
13420,I-30,TREATMENT OF TINEA PEDIS,2016
13421,I-31,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES,2016
13422,I-32,PEDIATRIC MYELOGRAPHY,2016
13423,I-33,ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN,2016
13424,I-34,ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT,2016
13425,I-35,PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING,2016
13426,I-36,ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS,2016
13427,I-37,RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS,2016
13428,I-38,CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER),2016
13429,I-39,TREATMENT OF ACUTE MYOCARDIAL INFARCTION,2016
13430,I-40,PRIMARY NOCTURNAL ENURESIS,2016
13431,I-41,MIGRAINE HEADACHE PROPHYLAXIS,2016
13432,I-42,HERPES ZOSTER,2016
13433,I-43,HERPES SIMPLEX ENCEPHALITIS,2016
13434,I-44,MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY,2016
13435,I-45,ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS,2016
13436,I-46,USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING,2016
13437,I-47,TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE,2016
13438,I-48,PEDIATRIC ANGIOCARDIOGRAPHY,2016
13439,I-49,TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI,2016
13440,I-50,FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER,2016
13441,I-51,TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS,2016
13442,I-52,PEDIATRIC EXCRETORY UROGRAPHY,2016
13443,I-53,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2016
13444,I-54,RENAL CONCENTRATION CAPACITY TEST,2016
13445,I-55,HYPERTENSION,2016
13446,I-56,EROSIVE GASTROESOPHAGEAL REFLUX DISEASE,2016
13447,I-57,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER,2016
13448,I-58,INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS,2016
13449,I-59,"ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE",2016
13450,I-60,SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE,2016
13451,I-61,FEMALE ANDROGENETIC ALOPECIA,2016
13452,I-62,PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13453,I-63,ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION,2016
13454,I-64,PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS,2016
13455,I-65,PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2016
13456,I-66,UNCOMPLICATED GONORRHEA,2016
13457,I-67,TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER,2016
13458,I-68,CENTRAL PRECOCIOUS PUBERTY,2016
13459,I-69,"SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY",2016
13460,I-70,USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER,2016
13461,I-71,VARICELLA INFECTIONS (CHICKENPOX),2016
13462,I-72,PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE,2016
13463,I-73,INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES,2016
13464,I-74,INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY,2016
13465,I-75,TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS,2016
13466,I-76,PREVENTION OF OSTEOPOROSIS,2016
13467,I-77,"DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM",2016
13468,I-78,CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY,2016
13469,I-79,MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM,2016
13470,I-80,DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE,2016
13471,I-81,PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS,2016
13472,I-82,TREATMENT OF TRAVELERS' DIARRHEA,2016
13473,I-83,"ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN",2016
13474,I-84,INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION,2016
13475,I-85,TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS,2016
13476,I-86,TREATMENT OF SECONDARY CARNITINE DEFICIENCY,2016
13477,I-87,RENAL IMAGING AGENT FOR USE IN CHILDREN,2016
13478,I-88,MANAGEMENT OF ENDOMETRIOSIS,2016
13479,I-89,EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE,2016
13480,I-90,INTENSIVE CARE UNIT SEDATION,2016
13481,I-91,MONOTHERAPY USE FOR HYPERTENSION,2016
13482,I-92,ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE,2016
13483,I-93,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS,2016
13484,I-94,USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART],2016
13485,I-95,TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2016
13486,I-96,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2016
13487,I-97,ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT,2016
13488,I-98,TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY,2016
13489,I-99,PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER,2016
13490,I-100,TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY,2016
13491,I-101,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2016
13492,I-102,TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER,2016
13493,I-103,PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA,2016
13494,I-104,TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY,2016
13495,I-105,TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY,2016
13496,I-106,TREATMENT OF ACROMEGALY,2016
13497,I-107,VAGINAL CANDIDIASIS,2016
13498,I-108,EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION,2016
13499,I-109,TYPHOID FEVER,2016
13500,I-110,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY,2016
13501,I-111,TREATMENT OF PAGET'S DISEASE OF BONE,2016
13502,I-112,MANAGEMENT OF MODERATE TO SEVERE PAIN,2016
13503,I-113,TREATMENT OF PROSTATITIS,2016
13504,I-114,"USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE",2016
13505,I-115,USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK,2016
13506,I-116,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2016
13507,I-117,TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE,2016
13508,I-118,"PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY",2016
13509,I-119,TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY,2016
13510,I-120,MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS,2016
13511,I-121,EXPANDED PATIENT POPULATION --USE IN ICU PATIENTS,2016
13512,I-122,PSORIASIS OF THE SCALP,2016
13513,I-123,RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER,2016
13514,I-124,LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE,2016
13515,I-125,EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES,2016
13516,I-126,ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY,2016
13517,I-127,TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS,2016
13518,I-128,IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...,2016
13519,I-129,TREATMENT OF ALCOHOL DEPENDENCE,2016
13520,I-130,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2016
13521,I-131,PERIPHERAL ARTERIOGRAPHY,2016
13522,I-132,TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER,2016
13523,I-133,MANAGEMENT OF CHRONIC STABLE ANGINA,2016
13524,I-134,HEART FAILURE POST MYOCARDIAL INFARCTION,2016
13525,I-135,BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA,2016
13526,I-136,IDIOPATHIC CHRONIC URTICARIA,2016
13527,I-137,"PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES",2016
13528,I-138,TREATMENT OF ACUTE RECURRENT GENITAL HERPES,2016
13529,I-139,PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE-AND PERIMENOPAUSAL WOMEN,2016
13530,I-140,PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE,2016
13531,I-141,TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL,2016
13532,I-142,LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION,2016
13533,I-143,EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2016
13534,I-144,ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS,2016
13535,I-145,0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN,2016
13536,I-146,CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS,2016
13537,I-147,PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS,2016
13538,I-148,TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AADO2) IS LESS THAN OR EQUAL TO 55 TORR,2016
13539,I-149,TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER,2016
13540,I-150,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER,2016
13541,I-151,PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA,2016
13542,I-152,SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS,2016
13543,I-153,MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN],2016
13544,I-154,PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE,2016
13545,I-155,TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT,2016
13546,I-156,ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE,2016
13547,I-157,TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES,2016
13548,I-158,TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER,2016
13549,I-159,"FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES",2016
13550,I-160,TREATMENT OF BACTERIAL CORNEAL ULCERS,2016
13551,I-161,TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY,2016
13552,I-162,FOR USE IN PATIENTS 6-11 YEARS OF AGE,2016
13553,I-163,TREATMENT OF PHOTOPHOBIA,2016
13554,I-164,CHRONIC BACTERIAL PROSTATITIS,2016
13555,I-165,"MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS",2016
13556,I-166,TREATMENT OF BULIMIA,2016
13557,I-167,COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS,2016
13558,I-168,MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS),2016
13559,I-169,USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER,2016
13560,I-170,PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS,2016
13561,I-171,RELIEF OF SYMPTOMS OF THE COMMON COLD,2016
13562,I-172,TREATMENT OF INITIAL EPISODE OF GENITAL HERPES,2016
13563,I-173,PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY,2016
13564,I-174,PELVIC INFLAMMATORY DISEASE,2016
13565,I-175,TREATMENT OF TINEA CORPORIS AND TINEA CRURIS,2016
13566,I-176,TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2016
13567,I-177,"TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS",2016
13568,I-178,TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN,2016
13569,I-179,NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE,2016
13570,I-180,TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE),2016
13571,I-181,TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION,2016
13572,I-182,TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME,2016
13573,I-183,MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11,2016
13574,I-184,TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG),2016
13575,I-185,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
13576,I-186,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE),2016
13577,I-187,PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13578,I-188,TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS,2016
13579,I-189,TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS,2016
13580,I-190,PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS,2016
13581,I-191,ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING,2016
13582,I-192,"THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION",2016
13583,I-193,TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY,2016
13584,I-194,CONGESTIVE HEART FAILURE,2016
13585,I-195,FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER,2016
13586,I-196,ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2016
13587,I-197,MAINTENANCE OF HEALING OF DUODENAL ULCER,2016
13588,I-198,FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER,2016
13589,I-199,MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES,2016
13590,I-200,TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR,2016
13591,I-201,EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS,2016
13592,I-202,SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA,2016
13593,I-203,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2016
13594,I-204,USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2016
13595,I-205,INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS,2016
13596,I-206,TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE,2016
13597,I-207,FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS,2016
13598,I-208,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION,2016
13599,I-209,PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT),2016
13600,I-210,TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS,2016
13601,I-211,FOR USE IN PEDIATRIC POPULATION,2016
13602,I-212,TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME,2016
13603,I-213,TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY,2016
13604,I-214,TREATMENT OF OSTEOPOROSIS,2016
13605,I-215,PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS,2016
13606,I-216,"FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2016
13607,I-217,"PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2016
13608,I-218,USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV),2016
13609,I-219,USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET,2016
13610,I-220,"TREATMENT OF EPISODIC-HEARTBURN, ACID INDIGESTION AND SOUR STOMACH",2016
13611,I-221,"TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY",2016
13612,I-222,"PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN",2016
13613,I-223,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS,2016
13614,I-224,FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2016
13615,I-225,"USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS",2016
13616,I-226,FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN,2016
13617,I-227,SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD),2016
13618,I-228,PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL,2016
13619,I-229,"PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE",2016
13620,I-230,"IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION",2016
13621,I-231,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,2016
13622,I-232,TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY,2016
13623,I-233,PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY,2016
13624,I-234,FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER,2016
13625,I-235,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER,2016
13626,I-236,PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2016
13627,I-237,MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2016
13628,I-238,ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS,2016
13629,I-239,TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2016
13630,I-240,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS,2016
13631,I-241,USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER,2016
13632,I-242,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS,2016
13633,I-243,USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS,2016
13634,I-244,REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER,2016
13635,I-245,TREATMENT OF ACUTE SINUSITIS,2016
13636,I-246,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2016
13637,I-247,USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG,2016
13638,I-248,INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM,2016
13639,I-249,TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY,2016
13640,I-250,PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C,2016
13641,I-251,TREATMENT OF GENERALIZED ANXIETY DISORDER,2016
13642,I-252,NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN,2016
13643,I-253,COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN,2016
13644,I-254,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS),2016
13645,I-255,PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP),2016
13646,I-256,USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY,2016
13647,I-257,TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION,2016
13648,I-258,FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE,2016
13649,I-259,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY",2016
13650,I-260,EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER),2016
13651,I-261,TREATMENT OF SOCIAL ANXIETY DISORDER,2016
13652,I-262,TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12,2016
13653,I-263,TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY,2016
13654,I-264,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION",2016
13655,I-265,TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER,2016
13656,I-266,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES,2016
13657,I-267,USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER -FOR CORTICOSTEROID-RESPONSIVE DERMATOSES,2016
13658,I-268,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE,2016
13659,I-269,"PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN",2016
13660,I-270,ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY,2016
13661,I-271,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
13662,I-272,TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY,2016
13663,I-273,ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2016
13664,I-274,USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2016
13665,I-275,USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES,2016
13666,I-276,USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES,2016
13667,I-277,TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA,2016
13668,I-278,TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV),2016
13669,I-279,TREATMENT OF POST-TRAUMATIC STRESS DISORDER,2016
13670,I-280,USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2016
13671,I-281,INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB),2016
13672,I-282,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY,2016
13673,I-283,"TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS",2016
13674,I-284,TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE,2016
13675,I-285,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER,2016
13676,I-286,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III,2016
13677,I-287,USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH,2016
13678,I-288,CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE,2016
13679,I-289,USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL,2016
13680,I-290,PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2016
13681,I-291,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13682,I-292,TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13683,I-293,TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS,2016
13684,I-294,TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS,2016
13685,I-295,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS,2016
13686,I-296,LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY,2016
13687,I-297,SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
13688,I-298,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA,2016
13689,I-299,USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM,2016
13690,I-300,PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE,2016
13691,I-301,TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS,2016
13692,I-302,TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME,2016
13693,I-303,INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS,2016
13694,I-304,TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV,2016
13695,I-305,TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA,2016
13696,I-306,INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE,2016
13697,I-307,NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES,2016
13698,I-308,TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS,2016
13699,I-309,USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
13700,I-310,"REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES",2016
13701,I-311,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS,2016
13702,I-312,FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2016
13703,I-313,EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE,2016
13704,I-314,TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES,2016
13705,I-315,"THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2016
13706,I-316,TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID,2016
13707,I-317,PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER,2016
13708,I-318,FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER,2016
13709,I-319,"USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS",2016
13710,I-320,TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS),2016
13711,I-321,JUVENILE RHEUMATOID ARTHRITIS,2016
13712,I-322,USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS,2016
13713,I-323,COLORECTAL CANCER,2016
13714,I-324,"REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS",2016
13715,I-325,PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION,2016
13716,I-326,GENERALIZED ANXIETY DISORDER,2016
13717,I-327,SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER,2016
13718,I-328,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE,2016
13719,I-329,UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2016
13720,I-330,MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD,2016
13721,I-331,TREATMENT OF MODERATE ACNE VULGARIS,2016
13722,I-332,EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN),2016
13723,I-333,TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE),2016
13724,I-334,LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE,2016
13725,I-335,ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME,2016
13726,I-336,EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS,2016
13727,I-337,PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME,2016
13728,I-338,MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA,2016
13729,I-339,TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS,2016
13730,I-340,ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5,2016
13731,I-341,BREAST CANCER COMBINATION THERAPY,2016
13732,I-342,"USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2016
13733,I-343,USE OF COREG FOR SEVERE HEART FAILURE,2016
13734,I-344,ACNE VULGARIS,2016
13735,I-345,TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2016
13736,I-346,TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD),2016
13737,I-347,TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE,2016
13738,I-348,"LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)",2016
13739,I-349,ACUTE CORONARY SYNDROME,2016
13740,I-350,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY",2016
13741,I-351,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS,2016
13742,I-352,ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI),2016
13743,I-353,TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS,2016
13744,I-354,MANAGEMENT OF POST HERPETIC NEURALGIA,2016
13745,I-355,PREMENSTRUAL DYSPHORIC DISORDER,2016
13746,I-356,"TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME",2016
13747,I-357,TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS,2016
13748,I-358,TREATMENT OF PANIC DISORDER,2016
13749,I-359,TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE,2016
13750,I-360,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE,2016
13751,I-361,"TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY",2016
13752,I-362,"TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA",2016
13753,I-363,ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2016
13754,I-364,TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS,2016
13755,I-365,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR,2016
13756,I-366,PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2016
13757,I-367,"COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES",2016
13758,I-368,USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE,2016
13759,I-369,PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING,2016
13760,I-370,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY",2016
13761,I-371,HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2016
13762,I-372,NOSOCOMIAL PNEUMONIA,2016
13763,I-373,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2016
13764,I-374,SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS,2016
13765,I-375,FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2016
13766,I-376,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML),2016
13767,I-377,USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION,2016
13768,I-378,RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2016
13769,I-379,"USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION",2016
13770,I-380,TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR,2016
13771,I-381,TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER,2016
13772,I-382,FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION,2016
13773,I-383,TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY,2016
13774,I-384,USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS,2016
13775,I-385,"MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD""INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE",2016
13776,I-386,RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION,2016
13777,I-387,ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE,2016
13778,I-388,TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2016
13779,I-389,SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS,2016
13780,I-390,"USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &",2016
13781,I-391,ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY,2016
13782,I-392,TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL,2016
13783,I-393,CHRONIC BACTERIAL PROSTATITIS,2016
13784,I-394,USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES,2016
13785,I-395,TO IMPROVE PHYSICAL FUNCTION,2016
13786,I-396,EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION,2016
13787,I-397,EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY,2016
13788,I-398,IDIOPATHIC SHORT STATURE,2016
13789,I-399,"TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS",2016
13790,I-400,USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2016
13791,I-401,LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA,2016
13792,I-402,DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS,2016
13793,I-403,USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE,2016
13794,I-404,"MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY",2016
13795,I-405,TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN,2016
13796,I-406,"PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2016
13797,I-407,IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION,2016
13798,I-408,STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP),2016
13799,I-409,ESOPHAGEAL CANDIDIASIS,2016
13800,I-410,USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS,2016
13801,I-411,EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS,2016
13802,I-412,MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
13803,I-413,ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
13804,I-414,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS",2016
13805,I-415,SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY,2016
13806,I-416,THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2016
13807,I-417,USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER,2016
13808,I-418,ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS,2016
13809,I-419,MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
13810,I-420,"TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS",2016
13811,I-421,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE,2016
13812,I-422,INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS,2016
13813,I-423,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2016
13814,I-424,MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS,2016
13815,I-425,FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER,2016
13816,I-426,TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2016
13817,I-427,TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM,2016
13818,I-428,FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED,2016
13819,I-429,FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER,2016
13820,I-430,FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS,2016
13821,I-431,NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS,2016
13822,I-432,TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE,2016
13823,I-433,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)",2016
13824,I-434,"PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA",2016
13825,I-435,CHRONIC IDIOPATHIC CONSTIPATION,2016
13826,I-436,FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER,2016
13827,I-437,TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2016
13828,I-438,"EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS",2016
13829,I-439,USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY,2016
13830,I-440,FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2016
13831,I-441,"USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS",2016
13832,I-442,"USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS",2016
13833,I-443,TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER,2016
13834,I-444,USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS,2016
13835,I-445,"TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)",2016
13836,I-446,EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS,2016
13837,I-447,USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A),2016
13838,I-448,TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE,2016
13839,I-449,TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER,2016
13840,I-450,TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT,2016
13841,I-451,MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN,2016
13842,I-452,EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2016
13843,I-453,"USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)",2016
13844,I-454,MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS,2016
13845,I-455,MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%,2016
13846,I-456,TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR,2016
13847,I-457,TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SUREGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLIATIONS,2016
13848,I-458,USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI),2016
13849,I-459,NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN,2016
13850,I-460,TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER,2016
13851,I-461,USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED,2016
13852,I-462,LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE,2016
13853,I-463,TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION,2016
13854,I-464,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME,2016
13855,I-465,PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER,2016
13856,I-466,FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS,2016
13857,I-467,USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES,2016
13858,I-468,USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION,2016
13859,I-469,RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2016
13860,I-470,DIABETIC PERIPHERAL NEUROPATHIC PAIN,2016
13861,I-471,INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE,2016
13862,I-472,USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE,2016
13863,I-473,USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2016
13864,I-474,TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN,2016
13865,I-475,PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY,2016
13866,I-476,TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS,2016
13867,I-477,"TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE",2016
13868,I-478,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS,2016
13869,I-479,"TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES",2016
13870,I-480,PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE,2016
13871,I-481,INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER,2016
13872,I-482,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES,2016
13873,I-483,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
13874,I-484,FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS,2016
13875,I-485,TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION,2016
13876,I-486,"ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI",2016
13877,I-487,INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER,2016
13878,I-488,MAINTENANCE THERAPY IN BIPOLAR I DISORDER,2016
13879,I-489,FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES,2016
13880,I-490,"FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE",2016
13881,I-491,INFLUENZA PROPHYLAXIS,2016
13882,I-492,"MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES",2016
13883,I-493,"ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA",2016
13884,I-494,CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE,2016
13885,I-495,ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY,2016
13886,I-496,LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES,2016
13887,I-497,PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER,2016
13888,I-498,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2016
13889,I-499,USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY,2016
13890,I-500,FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2016
13891,I-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.,2016
13892,I-502,"FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY",2016
13893,I-503,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER,2016
13894,I-504,TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME,2016
13895,I-505,"TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES",2016
13896,I-506,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2016
13897,I-507,"ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2016
13898,I-508,PREMENSTRUAL DYSPHONIC DISORDER,2016
13899,I-509,TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER,2016
13900,I-510,ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP),2016
13901,I-511,ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP),2016
13902,I-512,ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY,2016
13903,I-513,ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM),2016
13904,I-514,ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL),2016
13905,I-515,PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY,2016
13906,I-516,PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER,2016
13907,I-517,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS),2016
13908,I-518,TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED,2016
13909,I-519,USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2016
13910,I-520,USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL,2016
13911,I-521,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY,2016
13912,I-522,"TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.",2016
13913,I-523,"USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE",2016
13914,I-524,GENERALIZED ANXIETY DISORDER (GAD),2016
13915,I-525,USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS,2016
13916,I-526,TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS,2016
13917,I-527,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2016
13918,I-528,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE",2016
13919,I-529,TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE,2016
13920,I-530,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER,2016
13921,I-531,MAINTENANCE TREATMENT OF SCHIZOPHRENIA,2016
13922,I-532,TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES,2016
13923,I-533,ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI),2016
13924,I-534,EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER,2016
13925,I-535,MANAGEMENT OF FIBROMYALGIA,2016
13926,I-536,FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME,2016
13927,I-537,LONG TERM TREATMENT OF PANIC DISORDER,2016
13928,I-538,SHORT TERM TREATMENT OF PANIC DISORDER,2016
13929,I-539,REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER,2016
13930,I-540,TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17,2016
13931,I-541,TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17,2016
13932,I-542,"EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM ""INOPERABLE"" PATIENTS TO ALL PATIENTS",2016
13933,I-543,USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN),2016
13934,I-544,ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY,2016
13935,I-545,ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2016
13936,I-546,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2016
13937,I-547,ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS,2016
13938,I-548,SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE,2016
13939,I-549,USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2016
13940,I-550,TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE,2016
13941,I-551,TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME,2016
13942,I-552,ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER,2016
13943,I-553,FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2016
13944,I-554,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES",2016
13945,I-555,TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS,2016
13946,I-556,PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY,2016
13947,I-557,USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD,2016
13948,I-558,MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA,2016
13949,I-559,"ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED",2016
13950,I-560,"MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX",2016
13951,I-561,LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER,2016
13952,I-562,MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS,2016
13953,I-563,ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY,2016
13954,I-564,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2016
13955,I-565,USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH),2016
13956,I-566,MANAGEMENT OF FIBROMYALGIA,2016
13957,I-567,INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2016
13958,I-568,"USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",2016
13959,I-569,TREATMENT OF CHRONIC HEPATITIS B,2016
13960,I-570,TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE,2016
13961,I-571,NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER,2016
13962,I-572,TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.,2016
13963,I-573,TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET,2016
13964,I-574,MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION,2016
13965,I-575,MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA,2016
13966,I-576,ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA,2016
13967,I-577,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES,2016
13968,I-578,EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS,2016
13969,I-579,"TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION",2016
13970,I-580,INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN,2016
13971,I-581,TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
13972,I-582,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2016
13973,I-583,ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST),2016
13974,I-584,TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS,2016
13975,I-585,TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS,2016
13976,I-586,COMMUNITY ACQUIRED BACTERIAL PNEUMONIA,2016
13977,I-587,ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION,2016
13978,I-588,ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION,2016
13979,I-589,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE,2016
13980,I-590,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE),2016
13981,I-591,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE,2016
13982,I-592,ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE),2016
13983,I-593,TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD),2016
13984,I-594,INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS,2016
13985,I-595,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
13986,I-596,USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2016
13987,I-597,MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2016
13988,I-598,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING,2016
13989,I-599,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS,2016
13990,I-600,FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS,2016
13991,I-601,MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,2016
13992,I-602,TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE,2016
13993,I-603,GOUT FLARES,2016
13994,I-604,PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK,2016
13995,I-605,ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER,2016
13996,I-606,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY,2016
13997,I-607,INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTENAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS,2016
13998,I-608,"REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY",2016
13999,I-610,TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION,2016
14000,I-611,"TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY",2016
14001,I-612,"MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS",2016
14002,I-613,MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE,2016
14003,I-614,SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER,2016
14004,I-615,MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2016
14005,I-616,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE,2016
14006,I-617,MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD),2016
14007,I-618,ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2016
14008,I-619,INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY,2016
14009,I-620,FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED,2016
14010,I-621,"PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)",2016
14011,I-622,ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER,2016
14012,I-623,TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE,2016
14013,I-624,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY,2016
14014,I-625,PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,2016
14015,I-626,RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER,2016
14016,I-627,TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.,2016
14017,I-628,MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS,2016
14018,I-629,ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
14019,I-630,TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.,2016
14020,I-631,PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION,2016
14021,I-632,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2016
14022,I-633,MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE,2016
14023,I-634,TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY,2016
14024,I-635,ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2016
14025,I-636,TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER,2016
14026,I-637,USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER,2016
14027,I-638,"FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.",2016
14028,I-639,"TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE",2016
14029,I-640,MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2016
14030,I-641,TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2016
14031,I-642,TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2016
14032,I-643,REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.,2016
14033,I-644,MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED),2016
14034,I-645,MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2016
14035,I-646,SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD),2016
14036,I-647,SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2016
14037,I-648,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2016
14038,I-649,TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY,2016
14039,I-650,"TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY",2016
14040,I-651,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY,2016
14041,I-652,MANAGEMENT OF POSTHERPETIC NEURALGIA,2016
14042,I-653,TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS,2016
14043,I-654,MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE,2016
14044,I-655,"TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2016
14045,I-656,"MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2016
14046,I-657,PLAQUE PSORIASIS OF THE SCALP,2016
14047,I-658,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY",2016
14048,I-659,PLAQUE PSORIASIS OF THE BODY,2016
14049,I-660,TREATMENT OF DEEP VEIN THROMBOSIS,2016
14050,I-661,TREATMENT OF PULMONARY EMBOLISM,2016
14051,I-662,REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM,2016
14052,I-663,IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2016
14053,I-664,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2016
14054,I-665,TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L,2016
14055,I-666,TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY,2016
14056,I-667,"TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE",2016
14057,I-668,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2016
14058,I-669,SCINTIGRAPIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%,2016
14059,I-670,"TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN",2016
14060,I-671,FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2016
14061,I-672,"USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",2016
14062,I-673,TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE,2016
14063,I-674,TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE,2016
14064,I-675,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER,2016
14065,I-676,"FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARACINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE",2016
14066,I-677,"TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOCACTIVE IODINE TREATMENT",2016
14067,I-678,"TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST",2016
14068,I-679,RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS,2016
14069,I-680,TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,2016
14070,I-681,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT",2016
14071,I-682,TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS,2016
14072,I-683,TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED,2016
14073,I-684,"PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS",2016
14074,I-685,EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE,2016
14075,I-686,INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY,2016
14076,I-687,"GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY",2016
14077,I-688,GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE,2016
14078,I-689,TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION,2016
14079,I-690,INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2016
14080,I-691,INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY,2016
14081,I-692,INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.,2016
14082,I-693,TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-REISISTANT PROSTATE CANCER (CRPC),2016
14083,I-694,TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY,2016
14084,I-695,REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA,2016
14085,I-696,USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER,2016
14086,I-697,FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION,2016
14087,I-698,SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS,2016
14088,I-699,FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA,2016
14089,I-700,TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS),2016
14090,I-701,"FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSIONFREE SURVIVAL.",2016
14091,I-702,FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA,2016
14092,I-703,MODERATE TO SEVERE BINGE EATING DISORDER (BED),2016
14093,I-704,EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN,2016
14094,I-705,TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE,2016
14095,I-706,EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2016
14096,I-707,"POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY",2016
14097,I-708,DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER,2016
14098,I-709,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS,2016
14099,I-710,ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC -CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.,2016
14100,I-711,"INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.",2016
14101,I-712,EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THEREPY,2016
14102,I-713,"REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL (""INDUCTION"") TREATMENT OF OPIOID DEPENDENCE",2016
14103,I-714,EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION,2016
14104,I-715,FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.,2016
14105,I-716,"REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY",2016
14106,I-717,EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4,2016
14107,I-718,"EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON-2 STUDY",2016
14108,I-719,EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.,2016
14109,I-720,"EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.",2016
14110,M-1,INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION,2016
14111,M-2,APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE,2016
14112,M-3,ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN,2016
14113,M-4,CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD,2016
14114,M-5,INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION,2016
14115,M-6,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION,2016
14116,M-7,CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION,2016
14117,M-8,ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING,2016
14118,M-9,"ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY",2016
14119,M-10,INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING,2016
14120,M-11,USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER,2016
14121,M-12,NEW LANGUAGE FOR PEDIATRIC USE,2016
14122,M-13,"INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION",2016
14123,M-14,ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION,2016
14124,M-15,LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,2016
14125,M-16,CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT,2016
14126,M-17,INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE,2016
14127,M-18,INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD),2016
14128,M-19,INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER,2016
14129,M-20,LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME,2016
14130,M-21,COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR,2016
14131,M-22,CHANGE IN TIME TO ONSET OF ACTION,2016
14132,M-23,"INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT",2016
14133,M-24,INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION,2016
14134,M-25,ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT,2016
14135,M-26,INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01,2016
14136,M-27,INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY,2016
14137,M-28,INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION,2016
14138,M-29,LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS,2016
14139,M-30,"CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION",2016
14140,M-31,INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE),2016
14141,M-32,ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES,2016
14142,M-33,INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA,2016
14143,M-34,EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2016
14144,M-35,"ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY",2016
14145,M-36,ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE,2016
14146,M-37,INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS,2016
14147,M-38,"SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL",2016
14148,M-39,FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST,2016
14149,M-40,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS,2016
14150,M-41,"REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED ""THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENISTY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA""",2016
14151,M-42,ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION,2016
14152,M-43,"INCLUSION OF RESULTS OF STUDY-""PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",2016
14153,M-44,CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18,2016
14154,M-45,INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING -EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY,2016
14155,M-46,PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY,2016
14156,M-47,PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS,2016
14157,M-48,CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES,2016
14158,M-49,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN,2016
14159,M-50,"NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION",2016
14160,M-51,INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY,2016
14161,M-52,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
14162,M-53,FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT,2016
14163,M-54,INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL,2016
14164,M-55,INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.,2016
14165,M-56,"INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON ""GEMINI"" TRIAL",2016
14166,M-57,CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS,2016
14167,M-58,"CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS",2016
14168,M-59,"RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS",2016
14169,M-60,"CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA",2016
14170,M-61,REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST,2016
14171,M-62,CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES,2016
14172,M-63,DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY,2016
14173,M-64,CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS,2016
14174,M-65,ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS),2016
14175,M-66,USE IN SPECIFIC POPULATIONS -PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER,2016
14176,M-67,INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS,2016
14177,M-68,DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL,2016
14178,M-69,RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY,2016
14179,M-70,PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY,2016
14180,M-71,REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER,2016
14181,M-72,INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS,2016
14182,M-73,NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH -SECRETING PITUITARY ADENOMAS,2016
14183,M-74,REVISIONS TO CLINICAL STUDIES -CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS,2016
14184,M-75,PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS),2016
14185,M-76,REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA,2016
14186,M-77,"USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS",2016
14187,M-78,CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY,2016
14188,M-79,LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE,2016
14189,M-80,ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD),2016
14190,M-81,"ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)",2016
14191,M-82,LABELING REVISIONS RELATED TO CLINICAL STUDIES,2016
14192,M-83,ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL,2016
14193,M-84,STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY,2016
14194,M-85,INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD,2016
14195,M-86,LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION,2016
14196,M-87,INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION,2016
14197,M-88,ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE,2016
14198,M-89,PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM,2016
14199,M-90,LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12,2016
14200,M-91,"UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS",2016
14201,M-92,"UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED ""A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION",2016
14202,M-93,EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS,2016
14203,M-94,INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE,2016
14204,M-95,INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108,2016
14205,M-96,UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION,2016
14206,M-97,LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES -NOT INDICATED FOR USE IN PEDIATRIC POPULATION,2016
14207,M-98,NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.,2016
14208,M-99,ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.,2016
14209,M-100,INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS,2016
14210,M-101,INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL,2016
14211,M-102,"INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, ""INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY.""",2016
14212,M-103,"SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING",2016
14213,M-104,INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY,2016
14214,M-105,"NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE",2016
14215,M-106,ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT,2016
14216,M-107,"INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED ""STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY"".",2016
14217,M-108,CHANGES ARE BASED ON RESULTS FROM STUDY CV181057,2016
14218,M-109,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2016
14219,M-110,CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL,2016
14220,M-111,LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS,2016
14221,M-112,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS,2016
14222,M-113,LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS,2016
14223,M-114,CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR),2016
14224,M-115,"REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES",2016
14225,M-116,LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008,2016
14226,M-117,ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL,2016
14227,M-118,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36,2016
14228,M-119,LABELING CHANGES REGARDING MISSED DOSES,2016
14229,M-120,CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS,2016
14230,M-121,LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43,2016
14231,M-122,LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL,2016
14232,M-123,UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY,2016
14233,M-124,LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS,2016
14234,M-125,LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE,2016
14235,M-126,"UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086",2016
14236,M-127,REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004,2016
14237,M-128,CLINICAL TRIAL STUDY RESULTS,2016
14238,M-129,RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE,2016
14239,M-130,ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT,2016
14240,M-131,INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS,2016
14241,M-132,REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS,2016
14242,M-133,INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY,2016
14243,M-134,ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING,2016
14244,M-135,ADDITION OF INFORMATION TO THE CLINICAL STUDIES -RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT,2016
14245,M-136,ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS,2016
14246,M-137,LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER,2016
14247,M-138,INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER,2016
14248,M-139,INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA,2016
14249,M-140,"INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION",2016
14250,M-141,REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17),2016
14251,M-142,ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY,2016
14252,M-143,INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER,2016
14253,M-144,INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE,2016
14254,M-145,ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING,2016
14255,M-146,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS,2016
14256,M-147,OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES,2016
14257,M-148,LABELING CHANGES BASED ON STUDY H80-EW-GWDM,2016
14258,M-149,INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD,2016
14259,M-150,ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE,2016
14260,M-151,REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE,2016
14261,M-152,INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION,2016
14262,M-153,ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN,2016
14263,M-154,UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.,2016
14264,M-155,ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT,2016
14265,M-156,UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.,2016
14266,M-157,INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLITFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA,2016
14267,M-158,UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS,2016
14268,M-159,ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY,2016
14269,M-160,"UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT",2016
14270,M-161,"UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN",2016
14271,M-162,INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE,2016
14272,M-163,INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC),2016
14273,M-164,"REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED ""PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA""",2016
14274,M-165,"PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, ""A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)""",2016
14275,M-166,UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) -EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) -RESISTANT SUBJECTS,2016
14276,M-167,"APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED ""BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH"".",2016
14277,M-168,INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY),2016
14278,M-169,UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.,2016
